role,name,affiliation,address,trial_id,processed_name,first_name,gender,gender_probability,gender_sample_count,Rank,Title,Status,Study Results,Conditions,Interventions,Sponsor/Collaborators,Other IDs,First Posted,Locations,URL
Principal Investigator,"Austin Pantel, MD",Instructor of Radiology,,NCT03863457,austin pantel,austin,male,0.98,4612,1,[18F] F-GLN by PET/CT in Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Fluoroglutamine [18F]F-GLN,University of Pennsylvania,831804,"March 5, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03863457
Principal Investigator,"Rachel Freedman, MD, MPH",Dana-Farber Cancer Institute,,NCT03865654,rachel freedman,rachel,female,0.98,28052,2,Individualizing Surveillance Mammography for Older Breast Cancer Survivors,"Active, not recruiting",No Results Available,Breast Cancer,Other: Communication Tool,Dana-Farber Cancer Institute|National Institutes of Health (NIH)|National Cancer Institute (NCI),19-001|1R21CA227615-01A1,"March 7, 2019","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03865654
Principal Investigator,"Rachel A Freedman, MD, MPH",Dana-Farber Cancer Institute,,NCT03818087,rachel a freedman,rachel,female,0.98,28052,3,Elevate! : An Elderly Breast Cancer Cohort Study,Recruiting,No Results Available,Breast Cancer,Behavioral: Observational cohort,Dana-Farber Cancer Institute|Susan G. Komen Breast Cancer Foundation,18-634,"January 28, 2019","Brigham and Women Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03818087
Principal Investigator,"Rachel Freedman, MD, MPH",Dana-Farber Cancer Institute,,NCT03858322,rachel freedman,rachel,female,0.98,28052,305,'ADVANCE' (A Pilot Trial),Recruiting,No Results Available,Breast Cancer,Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Carboplatin,Dana-Farber Cancer Institute|Mayo Clinic,19-031,"February 28, 2019","City of Hope National Medical Center, Duarte, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center, Milford, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03858322
Principal Investigator,"Ann H. Partridge, MD",Dana-Farber Cancer Institute,,NCT03913936,ann h. partridge,ann,female,0.97,28026,4,"Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot","Active, not recruiting",No Results Available,Breast Cancer,Other: YES portal,Dana-Farber Cancer Institute|Breast Cancer Research Foundation,18-641,"April 12, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03913936
Principal Investigator,"Aditya Bardia, MD, MPH",Massachusetts General Hospital,,NCT04039230,aditya bardia,aditya,male,0.98,3231,5,Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.,Recruiting,No Results Available,Breast Cancer,Drug: Talazoparib|Drug: Sacituzumab Govitecan,Massachusetts General Hospital|Pfizer,19-239,"July 31, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04039230
Principal Investigator,"Aditya Bardia, MD",Massachusetts General Hospital,,NCT03959891,aditya bardia,aditya,male,0.98,3231,7,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",Recruiting,No Results Available,Breast Cancer,Drug: Ipatasertib|Drug: Fulvestrant|Drug: Aromatase Inhibitor|Drug: Palbociclib,"Massachusetts General Hospital|Genentech, Inc.",19-086,"May 22, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03959891
Principal Investigator,"Neelima Vidula, MD",Massachusetts General Hospital,,NCT03990896,neelima vidula,neelima,female,0.99,67,6,"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",Recruiting,No Results Available,Breast Cancer,Drug: Talazoparib,Massachusetts General Hospital|Pfizer,19-188,"June 19, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03990896
Principal Investigator,"Alphonse G. Taghian, MD",Dana-Farber Cancer Institute,,NCT03861975,alphonse g. taghian,alphonse,male,0.97,2546,9,Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening,Recruiting,No Results Available,Breast Cancer,Other: Breast Cancer-Related Lymphedema Measurements,Massachusetts General Hospital|Heinz Family Foundation,18-181,"March 5, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03861975
Study Chair,Peng Yuan,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT04033172,peng yuan,peng,male,0.84,1286,11,Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ),Recruiting,No Results Available,Breast Cancer|HER2-positive Breast Cancer,Drug: Pyrotinib Plus Fulvestrant,Chinese Academy of Medical Sciences,NCC2018M-042,"July 25, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04033172
Principal Investigator,Jian Yue,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT04033172,jian yue,jian,male,0.9,1562,11,Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ),Recruiting,No Results Available,Breast Cancer|HER2-positive Breast Cancer,Drug: Pyrotinib Plus Fulvestrant,Chinese Academy of Medical Sciences,NCC2018M-042,"July 25, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04033172
Study Chair,Peng Yuan,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT04194684,peng yuan,peng,male,0.84,1286,92,Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: nab-paclitaxel,Chinese Academy of Medical Sciences,NCC2129,"December 11, 2019",,https://ClinicalTrials.gov/show/NCT04194684
Principal Investigator,peng yuan,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT03933319,peng yuan,peng,male,0.84,1286,272,Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer,Recruiting,No Results Available,HER2-positive Breast Cancer,Drug: pegylated liposomal doxorubicin,"Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-DMS-BC-11,"May 1, 2019","Peng Yuan, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03933319
Principal Investigator,Peng Yuan,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT03939871,peng yuan,peng,male,0.84,1286,299,A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer,Recruiting,No Results Available,Hormone Receptor Positive Advanced Breast Cancer,Drug: fluvestrant + oral vinorelbine,Chinese Academy of Medical Sciences,NCC1564,"May 7, 2019","National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03939871
Study Chair,"Peng Yuan, M.D.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT03933982,peng yuan,peng,male,0.84,1286,310,A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer|Brain Metastases,Drug: Pyrotinib Plus Vinorelbine,Chinese Academy of Medical Sciences,NCC1865,"May 1, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China",https://ClinicalTrials.gov/show/NCT03933982
Principal Investigator,Peng Yuan,Chinese Academy of Medical Sciences,,NCT04002284,peng yuan,peng,male,0.84,1286,463,Anlotinib in Metastatic HER2 Negative Breast Cancer,Recruiting,No Results Available,Breast Neoplasm|Antineoplastic Agents|Anlotinib,Drug: Anlotinib Hydrochloride,Peng Yuan|Chinese Academy of Medical Sciences,NCC1692,"June 28, 2019","National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04002284
Study Director,"Jian Huang, chief doctor",Zhejiang Cancer Hospital,,NCT03876587,jian huang,jian,male,0.9,1562,387,Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Drug: Pyrotinib Maleate combine with Docetaxel,"Zhejiang Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd.",HR-BLTN-001,"March 15, 2019","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT03876587
Study Director,"Fan zhimin, Doctor",First Affiliated Hospital of Jilin University,,NCT03959397,fan zhimin,fan,male,0.56,2373,13,Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer Stage,Drug: nab-paclitaxel,Jilin University,CSPC-KAL-BC-12,"May 22, 2019","the first hospital of Jilin University, Jilin, Changchun, China",https://ClinicalTrials.gov/show/NCT03959397
Principal Investigator,"Patrick Dillon, MD",University of Virginia,,NCT04038489,patrick dillon,patrick,male,0.99,153288,14,"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer","Active, not recruiting",No Results Available,Breast Cancer|Estrogen Receptor-positive Breast Cancer,Drug: Aspirin|Drug: Tamoxifen Pill|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel,University of Virginia,21822,"July 30, 2019","University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT04038489
Principal Investigator,Dr Patrick Morris,Beaumont Hospital,,NCT03843346,patrick morris,patrick,male,0.99,153288,250,"The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer",Recruiting,No Results Available,Breast Cancer,,Cancer Trials Ireland,CTRIAL-IE 15-34,"February 18, 2019","Letterkenny University Hospital, Letterkenny, Co. Donegal, Ireland|St Vincent's University Hospital, Dublin, Dublin 4, Ireland|Mater Misericordiae University Hospital & Mater Private Hospital, Dublin, Dublin 7, Ireland|Beaumont Hospital, Dublin, Dublin 9, Ireland|Bon Secour Cork, Cork, Ireland|Cork University Hospital, Cork, Ireland|St James' Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|University Hospital Limerick, Limerick, Ireland|University Hospital Waterford, Waterford, Ireland",https://ClinicalTrials.gov/show/NCT03843346
Study Director,Matthew Dronsfield,Hospital Director- Mediclinic City Hospital,,NCT03879174,matthew dronsfield,matthew,male,1.0,35521,15,Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation,Not yet recruiting,No Results Available,Breast Cancer Female,Drug: Pembrolizumab + Tamoxifen,Mediclinic Middle East,AN.MCME.CR.12|MISP # 55574,"March 18, 2019","Mediclinic City Hospital, Dubai, United Arab Emirates",https://ClinicalTrials.gov/show/NCT03879174
Principal Investigator,Shaheenah Dawood,Consultant Oncologist,,NCT03879174,shaheenah dawood,shaheenah,female,1.0,2,15,Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation,Not yet recruiting,No Results Available,Breast Cancer Female,Drug: Pembrolizumab + Tamoxifen,Mediclinic Middle East,AN.MCME.CR.12|MISP # 55574,"March 18, 2019","Mediclinic City Hospital, Dubai, United Arab Emirates",https://ClinicalTrials.gov/show/NCT03879174
Principal Investigator,Matthew P Goetz,Mayo Clinic,,NCT03941730,matthew p goetz,matthew,male,1.0,35521,533,"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer",Recruiting,No Results Available,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma,Biological: Therapeutic Estradiol,Mayo Clinic|National Cancer Institute (NCI),MC1831|NCI-2019-02285|P30CA015083,"May 8, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03941730
Principal Investigator,"Matthew P Goetz, M.D.",Mayo Clinic,,NCT03979508,matthew p goetz,matthew,male,1.0,35521,569,A Breast Cancer Genome Guided Therapy Study,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Fibrocystic Change|Ductal Breast Carcinoma In Situ|Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Lobular Breast Carcinoma In Situ|Progesterone Receptor Negative|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,Drug: Abemaciclib|Procedure: Therapeutic Conventional Surgery,Mayo Clinic|National Cancer Institute (NCI),MC1734|NCI-2019-03567|P30CA015083,"June 7, 2019","Mayo Clinic Arizona, Phoenix, Arizona, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03979508
Principal Investigator,"Judy C. Boughey, M.D.",Mayo Clinic,,NCT03979508,judy c. boughey,judy,female,0.95,6014,569,A Breast Cancer Genome Guided Therapy Study,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Fibrocystic Change|Ductal Breast Carcinoma In Situ|Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Lobular Breast Carcinoma In Situ|Progesterone Receptor Negative|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,Drug: Abemaciclib|Procedure: Therapeutic Conventional Surgery,Mayo Clinic|National Cancer Institute (NCI),MC1734|NCI-2019-03567|P30CA015083,"June 7, 2019","Mayo Clinic Arizona, Phoenix, Arizona, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03979508
Principal Investigator,"Vladimir I Chernov, MD, Prof.",TomskNMRC,,NCT03991260,vladimir i chernov,vladimir,male,0.99,24429,16,99mTc-ADAPT6-based HER2 Imaging in Breast Cancer,Enrolling by invitation,No Results Available,Breast Cancer,Diagnostic Test: SPECT,Tomsk National Research Medical Center of the Russian Academy of Sciences|KTH Royal Institute of Technology|Uppsala University,99mTc-ADAPT6|99mTc-ADAPT6 [TomskNRMC],"June 19, 2019","TomskNRMC, Tomsk, Russian Federation",https://ClinicalTrials.gov/show/NCT03991260
Principal Investigator,"Budhi S Yadav, MD","PGIMER, Chandigarh, India",,NCT04075058,budhi s yadav,budhi,male,0.97,146,17,Hypofractionated Radiation Therapy in Patients With Breast Cancer,Enrolling by invitation,No Results Available,Breast Cancer,Radiation: Hypofractionated Radiation therapy,Postgraduate Institute of Medical Education and Research,HRBC,"August 30, 2019","Dr Budhi Singh Yadav, Chandigarh, N/A = Not Applicable, India",https://ClinicalTrials.gov/show/NCT04075058
Principal Investigator,"Budhi S Yadav, MD",Postgraduate Institute of Medical Education & Research,,NCT04072718,budhi s yadav,budhi,male,0.97,146,134,Simultaneous Integrated Boost With Volumetric Arc Radiotherapy in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Radiation: Radiotherapy,Postgraduate Institute of Medical Education and Research,INT/IEC/2017/127,"August 28, 2019","Dr Budhi Singh Yadav, Chandigarh, India",https://ClinicalTrials.gov/show/NCT04072718
Principal Investigator,"Mehran Habibi, MD",Johns Hopkins Bayview,,NCT04129216,mehran habibi,mehran,male,0.98,2033,18,The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Tamoxifen Citrate|Drug: Letrozole|Drug: Exemestane|Diagnostic Test: Blueprint|Diagnostic Test: Mammaprint,Johns Hopkins University|Agendia,IRB00130428,"October 16, 2019","Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04129216
Principal Investigator,"Luis Fontana, Ph.D.",Universidad de Granada,,NCT03885648,luis fontana,luis,male,0.99,176693,20,Breast Cancer and Its Relationship With the Microbiota,Recruiting,No Results Available,Breast Cancer,,Universidad de Granada,PI-0538-2017,"March 21, 2019","Unit of Mammary Pathology, General Surgery Service, University Hospital Campus de la Salud, Granada, Spain",https://ClinicalTrials.gov/show/NCT03885648
Principal Investigator,"Jinsong Lu, MD","Renji Hospital, School of Medicine, Shanghai Jiao Tong University",,NCT03982485,jinsong lu,jinsong,male,0.91,22,22,Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Apatinib|Drug: Paclitaxel|Drug: Cisplatin|Procedure: Surgery,RenJi Hospital,SHPD005,"June 11, 2019","Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT03982485
Principal Investigator,"Xuefei Wang, M.D.",PUMCH,,NCT03971019,xuefei wang,xuefei,female,0.61,28,23,Survival Benefits of Statins in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer Female,Drug: statins|Behavioral: Dietary intervention group (control group),Peking Union Medical College Hospital,PUMCH-SBSBC,"June 3, 2019","PUMCH, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03971019
Principal Investigator,Jenny Chang,Houston Methodist Cancer Center,,NCT04095689,jenny chang,jenny,female,0.98,74278,26,TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Docetaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Pembrolizumab|Drug: IL-12 gene therapy|Drug: L-NMMA,The Methodist Hospital System|Merck Sharp & Dohme Corp.,Merck IIS,"September 19, 2019","Houston Methodist Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04095689
Principal Investigator,"Jenny Chang, M.D.",Houston Methodist Cancer Center,,NCT03820141,jenny chang,jenny,female,0.98,74278,142,Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Durvalumab|Drug: Trastuzumab|Drug: Pertuzumab,"Jenny C. Chang, MD|AstraZeneca|The Methodist Hospital System",Pro00020917,"January 29, 2019","Houston Methodist Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03820141
Principal Investigator,Daniel Rea,University of Birmingham,,NCT04118192,daniel rea,daniel,male,0.99,317409,28,NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Tumour bed core biopsy,University of Birmingham|Roche Pharma AG|Cancer Research UK,RG_16-108,"October 8, 2019","Bailsdon Hospital, Basildon, Essex, United Kingdom|Blackpool Teaching Hospitals NHS Trust, Blackpool, United Kingdom|University Hospital of Llandough, Cardiff, United Kingdom|Cheltenham General hospital, Cheltenham, United Kingdom|Borders General Hospital, Melrose, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Poole Hospital, Poole, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Arrowe Park Hospital, Upton, United Kingdom",https://ClinicalTrials.gov/show/NCT04118192
Principal Investigator,"Daniel J Lenihan, M.D., FACC",Washington University School of Medicine,,NCT03862131,daniel j lenihan,daniel,male,0.99,317409,806,PROactive Evaluation of Function to Avoid CardioToxicity,Recruiting,No Results Available,Cardiotoxicity|Breast Cancer|Lymphoma|Sarcoma|Leukemia|Myeloma|Lung Cancer,Device: MyoStrain®,Washington University School of Medicine|Myocardial Solutions,201809177,"March 5, 2019","Yale, New Haven, Connecticut, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Texas Southwestern, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT03862131
Study Director,"Dr. Mikhail Khazan, MD",Ichnos Sciences,,NCT03983395,mikhail khazan,mikhail,male,0.99,3514,30,Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer,"Biological: ISB 1302 250 ng/kg|Biological: ISB 1302 325 ng/kg|Biological: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Biological: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Biological: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Biological: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|Biological: ISB 1302 escalating doses,1200 ng/kg D15,22|Biological: ISB 1302 at the MTD and/or RP2D dose",Ichnos Sciences SA|Glenmark Pharmaceuticals S.A.,ISB 1302-103|IND Number 131316,"June 12, 2019","Glenmark Investigational Site 1, Gilbert, Arizona, United States|Glenmark Investigational Site 5, Los Angeles, California, United States|Glenmark Investigational Site 4, Louisville, Kentucky, United States|Glenmark Investigational Site 2, Detroit, Michigan, United States|Glenmark Investigational Site 3, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03983395
Principal Investigator,"Michael R Speicher, MD",Medical University of Graz,,NCT03992521,michael r speicher,michael,male,0.99,245870,31,Breast Cancer Liquid Biopsy Stratification,"Active, not recruiting",No Results Available,Breast Cancer,Genetic: Nucleosome positioning,Medical University of Graz,BreastctDNA01,"June 20, 2019","Medical University of Graz, Graz, Austria",https://ClinicalTrials.gov/show/NCT03992521
Principal Investigator,"Michael Douek, MD",Guy's and St Thomas' NHS Foundation Trust,,NCT03880097,michael douek,michael,male,0.99,245870,125,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Research Biopsy,"University College, London",17/0765,"March 19, 2019",,https://ClinicalTrials.gov/show/NCT03880097
Principal Investigator,"Neill Patani, MD",University College London Hospitals,,NCT03880097,neill patani,neill,male,0.97,262,125,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Research Biopsy,"University College, London",17/0765,"March 19, 2019",,https://ClinicalTrials.gov/show/NCT03880097
Principal Investigator,"Jayant Vaidya, MD",The Whittington Hospital,,NCT03880097,jayant vaidya,jayant,male,0.99,320,125,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Research Biopsy,"University College, London",17/0765,"March 19, 2019",,https://ClinicalTrials.gov/show/NCT03880097
Principal Investigator,"Amna Sherri, MD",Royal Free London NHS Foundation Trust,,NCT03880097,amna sherri,amna,female,0.97,1115,125,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Research Biopsy,"University College, London",17/0765,"March 19, 2019",,https://ClinicalTrials.gov/show/NCT03880097
Principal Investigator,"Laura Johnson, MD",Barts & The London NHS Trust,,NCT03880097,laura johnson,laura,female,0.98,288403,125,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Research Biopsy,"University College, London",17/0765,"March 19, 2019",,https://ClinicalTrials.gov/show/NCT03880097
Principal Investigator,"Robert Price, MD",King's College Hospital NHS Trust,,NCT03880097,robert price,robert,male,0.99,177418,125,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Research Biopsy,"University College, London",17/0765,"March 19, 2019",,https://ClinicalTrials.gov/show/NCT03880097
Principal Investigator,"Michael Hurwitz, MD",Yale University,,NCT04111510,michael hurwitz,michael,male,0.99,245870,276,Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer,Recruiting,No Results Available,Metastatic Triple Negative Breast Cancer,Drug: Tumor infiltrating lymphocytes (TIL) LN-145,"Yale University|Iovance Biotherapeutics, Inc.",2000025837,"October 1, 2019","Yale School of Medicine, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04111510
Principal Investigator,"Michael H Antoni, Ph.D",University of Miami,,NCT03955991,michael h antoni,michael,male,0.99,245870,513,VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer),Recruiting,No Results Available,Stress,Behavioral: R-CBSM|Biological: Influenza vaccine,University of Miami|Florida Department of Health,20160525,"May 20, 2019","Flipse Building, Coral Gables, Florida, United States",https://ClinicalTrials.gov/show/NCT03955991
Study Chair,"Michael Lock, MD",London Health Sciences Centre/London Regional Cancer Program,,NCT03978663,michael lock,michael,male,0.99,245870,546,Three Fraction Radiation to Induce Immuno-Oncologic Response,Not yet recruiting,No Results Available,High-Risk Cancer|Locally Advanced Breast Cancer,Radiation: Neoadjuvant radiotherapy,Lawson Health Research Institute,112626,"June 7, 2019","London Regional Cancer Program, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03978663
Principal Investigator,"Muriel Brackstone, MD PhD",London Health Sciences Centre/Lawson Health Research Institute,,NCT03978663,muriel brackstone,muriel,female,0.98,14732,546,Three Fraction Radiation to Induce Immuno-Oncologic Response,Not yet recruiting,No Results Available,High-Risk Cancer|Locally Advanced Breast Cancer,Radiation: Neoadjuvant radiotherapy,Lawson Health Research Institute,112626,"June 7, 2019","London Regional Cancer Program, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03978663
Study Chair,"Brian Yaremko, MD",London Health Sciences Centre/London Regional Cancer Program,,NCT03978663,brian yaremko,brian,male,0.99,51483,546,Three Fraction Radiation to Induce Immuno-Oncologic Response,Not yet recruiting,No Results Available,High-Risk Cancer|Locally Advanced Breast Cancer,Radiation: Neoadjuvant radiotherapy,Lawson Health Research Institute,112626,"June 7, 2019","London Regional Cancer Program, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03978663
Principal Investigator,"Michael Knopp, MD",Ohio State University Comprehensive Cancer Center,,NCT04063410,michael knopp,michael,male,0.99,245870,739,Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy,Not yet recruiting,No Results Available,Mammoplasty Patient,Procedure: Angiography|Procedure: MRI-Based Angiogram|Other: Quality-of-Life Assessment,Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),OSU-18094|NCI-2018-03417|P30CA016058,"August 21, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04063410
Study Director,"Michael Schmitt, MD, PhD","Seattle Genetics, Inc.",,NCT03957096,michael schmitt,michael,male,0.99,245870,797,A Safety Study of SGN-CD47M in Patients With Solid Tumors,Recruiting,No Results Available,Soft Tissue Sarcoma|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|Non-small Cell Lung Carcinoma|Breast Carcinoma|Ovarian Carcinoma|Exocrine Pancreatic Carcinoma|Gastric Carcinoma|Melanoma,Drug: SGN-CD47M,"Seattle Genetics, Inc.",SGN47M-001,"May 21, 2019","Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT03957096
Study Chair,"Jin Zhang, Pro.",Tianjin Medical University Cancer Institute and Hospital,,NCT03983096,jin zhang,jin,male,0.7,7587,32,Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.,Not yet recruiting,No Results Available,Breast Cancer,,"Tianjin Medical University Cancer Institute and Hospital|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-DMS-BC-13,"June 12, 2019","Jin Zhang, Tianjin, China",https://ClinicalTrials.gov/show/NCT03983096
Principal Investigator,Vasco Fonseca,"Hospital S Francisco Xavier - Ocidental Lisbon Hospital Center, Lisbon, Portugal",,NCT03831308,vasco fonseca,vasco,male,0.98,5355,33,Evaluating and Following Breast Cancer Patients in a Better Way,Not yet recruiting,No Results Available,Breast Cancer Female,Diagnostic Test: clinical and physical assessment,Centro Hospitalar Lisboa Ocidental|University of Lisbon,CentroHLO_EFBreastCancer,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT03831308
Study Chair,"Pedro Sarmento, PhD",Faculty of Human Motricity - University of Lisbon,,NCT03831308,pedro sarmento,pedro,male,0.99,165413,33,Evaluating and Following Breast Cancer Patients in a Better Way,Not yet recruiting,No Results Available,Breast Cancer Female,Diagnostic Test: clinical and physical assessment,Centro Hospitalar Lisboa Ocidental|University of Lisbon,CentroHLO_EFBreastCancer,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT03831308
Study Director,"ahmed a berry, PhD","Faculty of Medicine, Beni Suef University",,NCT04143282,ahmed a berry,ahmed,male,0.98,139051,34,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,Completed,No Results Available,Metastatic Breast Cancer,Drug: Metformin plus chemotherapy|Drug: Chemotherapy,Hager salah el din|Beni-Suef University,FWA00015574/6-01-2019/korany,"October 29, 2019","Beni-Seuf University Hospital, Banī Suwayf, Egypt",https://ClinicalTrials.gov/show/NCT04143282
Study Director,"ahmed h shaaban, MD","Faculty of Medicine, Beni Suef University",,NCT04143282,ahmed h shaaban,ahmed,male,0.98,139051,34,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,Completed,No Results Available,Metastatic Breast Cancer,Drug: Metformin plus chemotherapy|Drug: Chemotherapy,Hager salah el din|Beni-Suef University,FWA00015574/6-01-2019/korany,"October 29, 2019","Beni-Seuf University Hospital, Banī Suwayf, Egypt",https://ClinicalTrials.gov/show/NCT04143282
Study Director,"hoda m rabea, PhD","Faculty of Medicine, Beni Suef University",,NCT04143282,hoda m rabea,hoda,female,0.94,2444,34,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,Completed,No Results Available,Metastatic Breast Cancer,Drug: Metformin plus chemotherapy|Drug: Chemotherapy,Hager salah el din|Beni-Suef University,FWA00015574/6-01-2019/korany,"October 29, 2019","Beni-Seuf University Hospital, Banī Suwayf, Egypt",https://ClinicalTrials.gov/show/NCT04143282
Study Director,"Ahmed T. Awad, MD","professor of surgical oncology,Alexandria university",,NCT03900299,ahmed t. awad,ahmed,male,0.98,139051,110,Evaluating New Surgical Technique in Management of Female Patients With Operable Multifocal Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Procedure: oncoplastic breast surgery,Alexandria University,multifocal breast cancer2018,"April 3, 2019","Faculty of medicine ,Alexandria university, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT03900299
Principal Investigator,"Mostafa M. Elsayed, Msc","Surgical oncology registrar,Alexandria university",,NCT03900299,mostafa m. elsayed,mostafa,male,0.98,14950,110,Evaluating New Surgical Technique in Management of Female Patients With Operable Multifocal Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Procedure: oncoplastic breast surgery,Alexandria University,multifocal breast cancer2018,"April 3, 2019","Faculty of medicine ,Alexandria university, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT03900299
Principal Investigator,"Ahmed AH Abdellatif, PhD",Qassim University,,NCT04138342,ahmed ah abdellatif,ahmed,male,0.98,139051,467,Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer,Recruiting,No Results Available,Breast Cancer|Skin Cancer|Skin Diseases,Drug: Quantum dots coated with veldoreotide|Drug: Topical approved placebo,Al-Azhar University,Qassim QDs-VELD,"October 24, 2019","Assiut Clinic, Assiut, Egypt|Buraidah Clinic, Buraidah, Al Qassim, Saudi Arabia|Faculty of Pharmacy, Buraidah, Qassim, Saudi Arabia|Pharmaceutics dept., Faculty of Pharmacy, Qassim University, Buraidah, Qassim, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04138342
Study Chair,Gilles Romieu,Institut du Cancer de Montpellier,,NCT04109326,gilles romieu,gilles,male,0.99,26205,35,Effect of a Program of Physical Activity and Nutritional Therapeutic Education in Breast Cancer Patients,Completed,No Results Available,Breast Cancer,Other: APAD,Institut du Cancer de Montpellier - Val d'Aurelle,VA2012/39|2012-A01648-35,"September 30, 2019","Institut Sainte Catherine, Avignon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|CH Ambroise Paré, Marseille, France|ICM, Montpellier, France|CH Montélimar, Montélimar, France|Centre Eugène Marquis, Rennes, France|Institut de Cancéologie de l'Ouest, Saint-Herblain, France",https://ClinicalTrials.gov/show/NCT04109326
Principal Investigator,Gilles Berclaz,Brustzentrum Bern,,NCT03902977,gilles berclaz,gilles,male,0.99,26205,445,Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection,Recruiting,No Results Available,Breast Cancer Female,Procedure: quilting|Procedure: conventional suture,"Gilles Berclaz, MD PD|University of Bern|StiftungLindenhof|Brustzentrum Bern der Lindenhofgruppe",BZ01/17|17-17-F,"April 4, 2019","Brustzentrum Bern, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT03902977
Principal Investigator,"Gilles FREYER, Pr",Centre Hospitalier Lyon Sud,,NCT04158362,gilles freyer,gilles,male,0.99,26205,548,Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer,Suspended,No Results Available,Cancer Metastatic,Drug: Paclitaxel injection|Drug: Capecitabine tablets|Drug: Letrozole 2.5mg|Drug: Anastrozole 1mg|Drug: Fulvestrant Prefilled Syringe|Drug: Abemaciclib,UNICANCER,UC-0140/1901|2019-000260-14,"November 8, 2019","Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Eugène Marquis, Rennes, France",https://ClinicalTrials.gov/show/NCT04158362
Principal Investigator,"Solveig Hofvind, PhD",Cancer Registry of Norway,,NCT03877029,solveig hofvind,solveig,female,0.97,927,37,Long-term Effects of Breast Cancer Treatment,Not yet recruiting,No Results Available,Breast Cancer,,Cancer Registry of Norway|Extrastiftelsen,2019/FO244363,"March 15, 2019",,https://ClinicalTrials.gov/show/NCT03877029
Principal Investigator,"Solveig Hofvind, PhD",Cancer Registry of Norway,,NCT03852953,solveig hofvind,solveig,female,0.97,927,632,Under- and Overdiagnosis in BreastScreen Norway,"Active, not recruiting",No Results Available,Breast Cancer,Other: Under- or overdiagnosed cancer|Other: Screening,Cancer Registry of Norway|Extrastiftelsen,17/222|2018/FO201362,"February 25, 2019","Cancer Registry of Norway, Oslo, Norway",https://ClinicalTrials.gov/show/NCT03852953
Principal Investigator,"Viviana E Galimberti, MD",IEO,,NCT03920488,viviana e galimberti,viviana,female,0.99,11961,38,Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer,Recruiting,No Results Available,Triple Negative Breast Cancer,,European Institute of Oncology,IEO 0761/,"April 19, 2019","Istituto Europeo di Oncologia, Milan, Italy",https://ClinicalTrials.gov/show/NCT03920488
Principal Investigator,"Lisa Mullen, MD",JHU School of Medicine,,NCT03863522,lisa mullen,lisa,female,0.98,102796,39,Automated Method for Breast Cancer Detection,Recruiting,No Results Available,Breast Cancer Diagnosis,Procedure: Fine needle aspiration|Device: Cancer Detection cartridge,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,J18138|IRB00172441,"March 5, 2019","Johns Hopkins Hospital Outpatient Center, Baltimore, Maryland, United States|Johns Hopkins Medical Imaging at Green spring Station, Lutherville-Timonium, Maryland, United States",https://ClinicalTrials.gov/show/NCT03863522
Principal Investigator,"Lisa D Yee, MD",City of Hope Medical Center,,NCT03865992,lisa d yee,lisa,female,0.98,102796,317,Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease,Recruiting,No Results Available,Breast Cancer|Joint Pain,Dietary Supplement: Curcumin|Other: Placebo|Other: Nanoemulsion|Other: Quality-of-Life Assessment|Behavioral: Questionnaire,City of Hope Medical Center|National Cancer Institute (NCI),18432|NCI-2018-03787|UG1CA189823,"March 7, 2019","City of Hope Medical Center, Duarte, California, United States|City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT03865992
Principal Investigator,"Lisa J Taylor-Swanson, PhD LAc","Associate Professor of College of Nursing, Licensed Acupunturist",,NCT04067544,lisa j taylor-swanson,lisa,female,0.98,102796,702,Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women,Recruiting,No Results Available,Chemotherapy-induced Peripheral Neuropathy|Breast Cancer Female|Gynecologic Cancer,Device: Acupuncture,University of Utah,107709,"August 26, 2019","Huntsman Cancer Institute, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04067544
Principal Investigator,"Weichuan Yu, Ph.D","Department of Electronic and computer engineering, HKUST",,NCT03941639,weichuan yu,weichuan,male,1.0,2,40,Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment,Recruiting,No Results Available,Breast Cancer,,"Chinese University of Hong Kong|Department of Electronic and computer engineering, HKUST|Department of clinical oncology, CUHK|Department of Anatomical and Cellular Pathology,PWH|Department of Surgery, North District Hospital",2019.089,"May 8, 2019","The Chinese University of Hong Kong, Prince of Wale Hospital, Hong Kong, Shatin, Hong Kong",https://ClinicalTrials.gov/show/NCT03941639
Principal Investigator,"Renske Altena, MD, PhD",Karolinska University Hospital,,NCT03894007,renske altena,renske,female,0.99,460,43,Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer,Recruiting,No Results Available,Early-stage Breast Cancer|HER2-positive Breast Cancer,Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Atezolizumab|Drug: Trastuzumab emtansine,Renske Altena|Karolinska University Hospital,PREDIX II HER2|2018-004457-24,"March 28, 2019","Sahlgrenska universitetssjukhuset, Göteborg, Sweden|Skånes universitetssjukhus, Malmö, Sweden|Karolinska universitetssjukhuset, Stockholm, Sweden|Länssjukhuset Sundsvall, Sundsvall, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Örebro universitetssjukhus, Örebro, Sweden",https://ClinicalTrials.gov/show/NCT03894007
Study Director,"Jonas Bergh, MD, PhD",Karolinska Institutet,,NCT03894007,jonas bergh,jonas,male,0.99,25038,43,Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer,Recruiting,No Results Available,Early-stage Breast Cancer|HER2-positive Breast Cancer,Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Atezolizumab|Drug: Trastuzumab emtansine,Renske Altena|Karolinska University Hospital,PREDIX II HER2|2018-004457-24,"March 28, 2019","Sahlgrenska universitetssjukhuset, Göteborg, Sweden|Skånes universitetssjukhus, Malmö, Sweden|Karolinska universitetssjukhuset, Stockholm, Sweden|Länssjukhuset Sundsvall, Sundsvall, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Örebro universitetssjukhus, Örebro, Sweden",https://ClinicalTrials.gov/show/NCT03894007
Study Director,Ke Chen,"Suzhou Kintor Pharmaceuticals,inc",,NCT04103853,ke chen,ke,male,0.8,1541,44,"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","Active, not recruiting",No Results Available,Metastatic Breast Cancer,Drug: Proxalutamide,"Suzhou Kintor Pharmaceutical Inc,|Beijing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Ruijin Hospital|The First Affiliated Hospital with Nanjing Medical University|Hebei Medical University Fourth Hospital|Hunan Cancer Hospital",GT0918-CN-2001,"September 26, 2019","Beijing Cancer Hospital, Beijing, Beijing, China|Sun-Yat-sen University Cancer center, Guangzhou, Fujian, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",https://ClinicalTrials.gov/show/NCT04103853
Principal Investigator,"Alessandra Franzetti Pellanda, MD",Clinica Luganese Moncucco,,NCT04002570,alessandra franzetti pellanda,alessandra,female,0.99,47882,47,Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Other: blood samples collection,"Clinica Luganese Moncucco|Curzio Rüegg, MD, Head of Department, University of Fribourg|Swiss National Science Foundation|Tsoutsou Pelagia MD, Head of Radation Therapy Department",CirculatingCellsBreast-RT,"June 28, 2019","Clinica Luganese Moncucco, Lugano, Ticino, Switzerland",https://ClinicalTrials.gov/show/NCT04002570
Principal Investigator,"Olga Husson, PhD","Institute of Cancer Research, United Kingdom",,NCT03866655,olga husson,olga,female,0.98,80307,48,Evaluating a Digital Tool for Supporting Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer,Device: OWise,Royal Marsden NHS Foundation Trust|Innovate UK,CCR4965,"March 7, 2019",,https://ClinicalTrials.gov/show/NCT03866655
Principal Investigator,"Christopher Riedle, MD, PhD",Memorial Sloan Kettering Cancer Center,,NCT04054986,christopher riedle,christopher,male,0.99,53539,50,Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: F-Var3 PET/CT|Other: Blood draw,Memorial Sloan Kettering Cancer Center,19-147,"August 13, 2019","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04054986
Principal Investigator,"Jody Hayes, MD",UT Southwestern Medical Center,,NCT03990012,jody hayes,jody,male,0.53,2748,51,Infrared Imaging for Breast Cancer Modeling,"Active, not recruiting",No Results Available,Breast Cancer,Procedure: IR Imaging|Procedure: 3D Scanning,University of Texas Southwestern Medical Center,STU-2018-0370,"June 18, 2019","Parkland Memorial Hospital, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT03990012
Principal Investigator,"Mario CAMPONE, MD, PhD",Institut de Cancerologie de l'Ouest,,NCT03958136,mario campone,mario,male,0.99,168958,52,Clinico-biological Data Collection Study of Metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer,"Procedure: Metastasis biopsy|Biological: Biomarkers blood, urine and microbiota samples|Behavioral: Patient Reported Outcome (PRO)",Institut Cancerologie de l'Ouest|European Regional Development Fund|AstraZeneca|Novartis|Eli Lilly and Company,ICO-N-2017-12,"May 21, 2019","Institut de Cacerologie de l'ouest - site Paul Papin, Angers, France|Institut de cancerologie de l'Ouest, Saint Herblain, France",https://ClinicalTrials.gov/show/NCT03958136
Study Chair,"Ching-Hung Lin, Ph.D",National Taiwan University Hospital,,NCT04011085,ching-hung lin,ching-hung,male,1.0,2,58,Tw HER2 Positive Breast Cancer Productivity & Utility Study,Recruiting,No Results Available,HER2-positive Breast Cancer,,Taiwan Epidemiology Association,ML40952,"July 8, 2019","National Taiwan University hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04011085
Study Chair,"Liang-Chih Liu, Ph.D",China Medical University Hospital,,NCT04011085,liang-chih liu,liang-chih,male,1.0,1,58,Tw HER2 Positive Breast Cancer Productivity & Utility Study,Recruiting,No Results Available,HER2-positive Breast Cancer,,Taiwan Epidemiology Association,ML40952,"July 8, 2019","National Taiwan University hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04011085
Study Chair,"Ming-Feng Hou, M.D.",Kaohsiung Medical University,,NCT04011085,ming-feng hou,ming-feng,male,1.0,1,58,Tw HER2 Positive Breast Cancer Productivity & Utility Study,Recruiting,No Results Available,HER2-positive Breast Cancer,,Taiwan Epidemiology Association,ML40952,"July 8, 2019","National Taiwan University hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04011085
Principal Investigator,"Anne-Sophie HAMY-PETIT, MD",Institut Curie,,NCT03884413,anne-sophie hamy-petit,anne-sophie,female,0.97,4583,59,"FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France",Recruiting,No Results Available,Breast Cancer Female,Other: questionnaires,Institut Curie|seintinelles network,IC 2016-07,"March 21, 2019","Seintinelles.Com, Paris, France",https://ClinicalTrials.gov/show/NCT03884413
Principal Investigator,"Heather McArthur, MD, MPH",Cedars-Sinai,,NCT03872505,heather mcarthur,heather,female,0.98,6049,60,"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer",Not yet recruiting,No Results Available,Breast Cancer|Triple Negative Breast Cancer,Drug: Durvalumab|Radiation: Radiation Therapy|Drug: Carboplatin|Drug: Paclitaxel,Cedars-Sinai Medical Center|AstraZeneca,IIT2018-17-McArthur-TCDRT,"March 13, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT03872505
Principal Investigator,Heather Greenlee,Fred Hutch/University of Washington Cancer Consortium,,NCT04200482,heather greenlee,heather,female,0.98,6049,481,Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors,Suspended,No Results Available,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Behavioral: One Diet and Physical Activity Class|Other: Electronic (e) Health (eHealth) Communication Intervention|Behavioral: Six Diet and Physical Activity In-Person Group Classes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|Breast Cancer Research Foundation,RG1006427|NCI-2019-07643|P30CA015704,"December 16, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04200482
Principal Investigator,Nancy E Davidson,Fred Hutch/University of Washington Cancer Consortium,,NCT04200482,nancy e davidson,nancy,female,0.98,42623,481,Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors,Suspended,No Results Available,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Behavioral: One Diet and Physical Activity Class|Other: Electronic (e) Health (eHealth) Communication Intervention|Behavioral: Six Diet and Physical Activity In-Person Group Classes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|Breast Cancer Research Foundation,RG1006427|NCI-2019-07643|P30CA015704,"December 16, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04200482
Principal Investigator,Heather S Jim,University of Rochester NCORP Research Base,,NCT03996265,heather s jim,heather,female,0.98,6049,619,Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Cancer Fatigue|Cancer Survivor|Complete Remission|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Drug: Bupropion Hydrochloride Controlled-release|Other: Placebo|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,Gary Morrow|National Cancer Institute (NCI)|University of Rochester,URCC-18007|NCI-2019-01528|R01CA214647|UG1CA189961,"June 24, 2019","Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours DePaul Medical Center, Norfolk, Virginia, United States|Bon Secours Maryview Medical Center, Portsmouth, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Health Center at Harbour View, Suffolk, Virginia, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03996265
Principal Investigator,"Joanna D Davies, PhD",San Diego Biomedical Research Institute,,NCT04208074,joanna d davies,joanna,female,0.98,72381,61,Exercise Study for Breast Cancer Survivors,"Active, not recruiting",No Results Available,Breast Cancer,Other: Exercise Intervention,San Diego Biomedical Research Institute|California Breast Cancer Research Program|Arizona State University|Tri-City Wellness & Fitness Center|We Support U,25IB-0023,"December 23, 2019","Aditi Narsale, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04208074
Principal Investigator,"Joanna J Arch, PhD","University of Colorado, Boulder",,NCT03980093,joanna j arch,joanna,female,0.98,72381,136,The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,"Active, not recruiting",No Results Available,Breast Cancer,Behavioral: Education|Behavioral: Values,"University of Colorado, Boulder|National Cancer Institute (NCI)",18-0234,"June 10, 2019","Rocky Mountain Cancer Centers, Greenwood Village, Colorado, United States",https://ClinicalTrials.gov/show/NCT03980093
Study Director,Novartis Pharmaceuticals,Novartis Pharmaceuticals,,NCT03822468,novartis pharmaceuticals,novartis,male,1.0,4,63,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Recruiting,No Results Available,Breast Cancer,Drug: Ribociclib|Drug: Letrozole or Anastrozole|Drug: Goserelin,Novartis Pharmaceuticals|Novartis,CLEE011A2207|2018-004234-15,"January 30, 2019","Southern Cancer Center PC, Mobile, Alabama, United States|Marin Cancer Care, Greenbrae, California, United States|Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50), Greenwood Village, Colorado, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States|Weinberg Cancer Institute at Franklin Square Hospital, Baltimore, Maryland, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Las Vegas, Nevada, United States|New York Oncology Hematology SC, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine CFTY720D2306, New York, New York, United States|US Oncology Central Monitoring Regulatory - 2, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, San Juan, Argentina|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Florianopolis, Santa Catarina, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Jose Do Rico Preto, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Valledupar, Cesar, Colombia|Novartis Investigative Site, Ibague, Tolima, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Muenchen, Bavaria, Germany|Novartis Investigative Site, Langen, Hessen, Germany|Novartis Investigative Site, Velbert, Nordhein-Westfalen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Tamil Nadu, Chennai, India|Novartis Investigative Site, Raipur, Chhattisgarh, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Bhubaneshwar, Orissa, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lisbon, Portugal|Novartis Investigative Site, Loures, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand",https://ClinicalTrials.gov/show/NCT03822468
Study Director,Novartis Pharmaceuticals,Novartis Pharmaceuticals,,NCT03839823,novartis pharmaceuticals,novartis,male,1.0,4,99,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer,Combination Product: Docetaxel / Capecitabine|Combination Product: Capecitabine / Vinorelbine|Combination Product: Paclitaxel / Gemcitabine|Drug: Ribociclib|Drug: Letrozole OR Anastrozole|Drug: Goserelin,Novartis Pharmaceuticals|Novartis,CLEE011A3201C,"February 15, 2019","Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Giza, Egypt|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Cankaya Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kecioren Ankara, Turkey|Novartis Investigative Site, Malatya, Turkey|Novartis Investigative Site, Hanoi, Vietnam",https://ClinicalTrials.gov/show/NCT03839823
Study Director,Novartis Pharmaceuticals,Novartis Pharmaceuticals,,NCT04208178,novartis pharmaceuticals,novartis,male,1.0,4,286,Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation,Not yet recruiting,No Results Available,Advanced HER2+Breast Cancer,Drug: Alpelisib|Drug: Alpelisib matching Placebo|Drug: Trastuzumab|Drug: Pertuzumab,Novartis Pharmaceuticals|Novartis,CBYL719G12301|2019-002741-37,"December 23, 2019",,https://ClinicalTrials.gov/show/NCT04208178
Principal Investigator,"Ivana L Ribeiro, PhD",Catholic University of Maule,,NCT04116281,ivana l ribeiro,ivana,female,0.99,38850,64,Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery,Recruiting,No Results Available,Breast Cancer,Other: Rehabilitation after breast cancer surgery,Universidade Federal de Sao Carlos,154/2019,"October 4, 2019","Catholic University of Maule, Talca, Maule, Chile",https://ClinicalTrials.gov/show/NCT04116281
Study Director,"Adam Ostrowski, MD Medical Director",Immunicom Inc,,NCT04004910,adam ostrowski,adam,male,0.98,116396,66,Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC),Recruiting,No Results Available,Advanced Triple Negative Breast Cancer,"Other: Plasma soluble TNF receptor pulldown|Other: Plasma soluble TNF receptor pulldown + chemotherapy|Drug: Chemotherapy Drugs, Cancer",Immunicom Inc,CP7-005,"July 2, 2019","Katedra i Klinika Onkologii UJ CM, Kraków, Małopolskie, Poland",https://ClinicalTrials.gov/show/NCT04004910
Principal Investigator,"Adam H Buchanan, MS, LGC",Geisinger - Genomic Medicine Institute,,NCT03832985,adam h buchanan,adam,male,0.98,116396,823,Pediatric Reporting of Adult-Onset Genomic Results,Recruiting,No Results Available,Hereditary Breast and Ovarian Cancer Syndrome|Lynch Syndrome|Familial Hypercholesterolemia,Genetic: Receive an adult-onset result|Genetic: Receive a pediatric-onset result|Genetic: Control - No Result,Geisinger Clinic|National Human Genome Research Institute (NHGRI),2018-0419|1R01HG009671-01A1,"February 6, 2019","Geisinger, Danville, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03832985
Principal Investigator,"ZhiMin Shao, MD, PhD",Fudan University,,NCT04193059,zhimin shao,zhimin,male,0.81,37,67,Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Paclitaxel|Drug: Carboplatin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Docetaxel,Fudan University,2018-68-1461,"December 10, 2019","Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04193059
Study Chair,Zhimin Shao,Fudan University,,NCT03980054,zhimin shao,zhimin,male,0.81,37,173,A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: Pyrotinib|Drug: Placebo,"Jiangsu HengRui Medicine Co., Ltd.",HR-BLTN-III-EBC,"June 10, 2019",,https://ClinicalTrials.gov/show/NCT03980054
Principal Investigator,"Zhimin Shao, MD, PhD",Fudan University,,NCT03926091,zhimin shao,zhimin,male,0.81,37,183,Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Docetaxel|Drug: Cyclophosphamide,Fudan University,CLOVER,"April 24, 2019","Chongqing Cancer Hospital, Chongqing, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Sun Yet-Sen Memorial Hospital, Sun Yet-Sen University, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Bethune Hospital of Jilin University (The First Hospital of Jilin University), Changchun, Jilin, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|OB/GYN Hospital of Fudan University, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, ZheJiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT03926091
Principal Investigator,"zhimin shao, doctor",Fudan University affiliated cancer hospital,,NCT03949634,zhimin shao,zhimin,male,0.81,37,220,Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD),Recruiting,No Results Available,Early Breast Cancer,Drug: PLD|Drug: CTX|Drug: Docetaxel|Drug: Paclitaxel|Drug: Doxorubicin,Fudan University,CSPC -DMS- BC-08,"May 14, 2019","Fudan University affiliated cancer hospital, Shanghai, China",https://ClinicalTrials.gov/show/NCT03949634
Principal Investigator,Zhimin Shao,Fudan University,,NCT03799679,zhimin shao,zhimin,male,0.81,37,260,Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Chemotherapeutic Agent,Fudan University,1808189-7,"January 10, 2019","Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT03799679
Principal Investigator,"zhimin shao, MD,PHD",Fudan University,,NCT04129996,zhimin shao,zhimin,male,0.81,37,269,A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS),Recruiting,No Results Available,Triple-Negative Breast Cancer,Drug: camrelizumab in combination with nab-paclitaxel and famitinib,Fudan University,SCHBCC-N025,"October 17, 2019","Zhi-Ming Shao, Shanghai, China",https://ClinicalTrials.gov/show/NCT04129996
Principal Investigator,Zhimin Shao,Fudan University,,NCT03799692,zhimin shao,zhimin,male,0.81,37,279,Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer,Recruiting,No Results Available,HER-2 Negative Breast Cancer,Drug: Chemotherapy,Fudan University,1808189-8,"January 10, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, China",https://ClinicalTrials.gov/show/NCT03799692
Principal Investigator,"Zhimin U Shao, Professor",Fudan University,,NCT03805399,zhimin u shao,zhimin,male,0.81,37,458,FUSCC Refractory TNBC Umbrella (FUTURE),Recruiting,No Results Available,Triple-negative Breast Cancer,Drug: Pyrotinib with Capecitabine|Drug: AR inhibitor with CDK4/6 inhibitor|Drug: anti PD-1 with nab-paclitaxel|Drug: PARP inhibitor included therapy|Drug: BLIS with anti-VEGFR included therapy|Drug: MES with anti-VEGFR included therapy|Drug: mTOR inhibitor with nab-paclitaxel,Fudan University,1807188-16,"January 15, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT03805399
Principal Investigator,"Zhimin Shao, Doctor",Fudan University Shanghai Cancer Centre,,NCT04174599,zhimin shao,zhimin,male,0.81,37,623,Trial to Compare the Efficacy and Safety of F-627 and GRAN®,Completed,No Results Available,Breast Cancer,Biological: F-627,Generon (Shanghai) Corporation Ltd.,SP11631,"November 22, 2019","Peking University Cancer Hospital, Peking, Beijing, China",https://ClinicalTrials.gov/show/NCT04174599
Principal Investigator,"Jami Fukui, MD",University of Hawaii Cancer Research Center,,NCT04013568,jami fukui,jami,male,0.6,1076,69,Exercise Programming in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Other: Exercise,University of Hawaii,Fukui-2019-1,"July 9, 2019","University of Hawaii Cancer Center, Honolulu, Hawaii, United States",https://ClinicalTrials.gov/show/NCT04013568
Principal Investigator,"Woo Kyung Moon, MD PhD",Professor,,NCT03835897,woo kyung moon,woo,male,0.82,1372,70,Breast Cancer Screening With Diffusion-weighted MRI in Women at High Risk for Breast Cancer,Recruiting,No Results Available,Breast Cancer,,Seoul National University Hospital,Breast Screening with DWI,"February 11, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT03835897
Study Chair,"Hans Wildiers, prof. dr.",UZ Gasthuisberg,,NCT03956654,hans wildiers,hans,male,0.97,37182,71,A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer,Recruiting,No Results Available,Breast Cancer,Drug: Ribociclib,Universitaire Ziekenhuizen Leuven,s61033,"May 21, 2019","UZ Gasthuisberg Leuven, Leuven, Belgium",https://ClinicalTrials.gov/show/NCT03956654
Principal Investigator,"Hans Tesch, Prof. Dr. med.",Onkologie Bethanien Frankfurt,,NCT04030728,hans tesch,hans,male,0.97,37182,74,Implementing Patients´ Competence in Oral Breast Cancer Therapy,Not yet recruiting,No Results Available,Metastatic Breast Cancer|Advanced Breast Cancer,,Onco Medical Consult GmbH|Eli Lilly and Company|Institut fuer Frauengesundheit,OMC2018/01,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT04030728
Principal Investigator,"Manfred Welslau, Dr. med.",Onkologie Aschaffenburg,,NCT04030728,manfred welslau,manfred,male,0.99,9222,74,Implementing Patients´ Competence in Oral Breast Cancer Therapy,Not yet recruiting,No Results Available,Metastatic Breast Cancer|Advanced Breast Cancer,,Onco Medical Consult GmbH|Eli Lilly and Company|Institut fuer Frauengesundheit,OMC2018/01,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT04030728
Principal Investigator,"Javier Cortés, PhD",MedSIR,,NCT03795012,javier cortés,javier,male,0.99,106497,73,Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Drug: Eribulin,MedSIR,MedOPP167,"January 7, 2019","Hospital de Jaén, Jaen, Jaén, Spain|Hospital Quiron Dexeus, Barcelona, Please Select, Spain|Institut Català d'Oncologia, Girona, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz,, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Dr Peset, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT03795012
Principal Investigator,Sarah Tevis,"University of Colorado, Denver",,NCT03995082,sarah tevis,sarah,female,0.98,174584,75,Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey,Not yet recruiting,No Results Available,Breast Cancer,Other: Patient Reported Outcome Measure Survey result feedback,"University of Colorado, Denver|National Cancer Institute (NCI)",18-2562.cc|P30CA046934,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03995082
Study Chair,"Lorenzo Livi, MD,Prof","University of Florence, Florence, Italy",,NCT04134598,lorenzo livi,lorenzo,male,0.99,55168,76,ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years With Luminal-A Early Stage Breast Cancer (EUROPA),Not yet recruiting,No Results Available,Breast Cancer,"Radiation: Partial Breast Irradiation (PBI)|Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen",Azienda Ospedaliero-Universitaria Careggi|Institut Curie|University of Florence,EUROPA,"October 22, 2019",,https://ClinicalTrials.gov/show/NCT04134598
Study Chair,"Philip M Poortmans, MD,PhD,Prof","Institut Curie, Paris, France",,NCT04134598,philip m poortmans,philip,male,0.99,21882,76,ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years With Luminal-A Early Stage Breast Cancer (EUROPA),Not yet recruiting,No Results Available,Breast Cancer,"Radiation: Partial Breast Irradiation (PBI)|Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen",Azienda Ospedaliero-Universitaria Careggi|Institut Curie|University of Florence,EUROPA,"October 22, 2019",,https://ClinicalTrials.gov/show/NCT04134598
Principal Investigator,"Icro Meattini, MD,Prof","University of Florence, Florence, Italy",,NCT04134598,icro meattini,icro,male,0.67,3,76,ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years With Luminal-A Early Stage Breast Cancer (EUROPA),Not yet recruiting,No Results Available,Breast Cancer,"Radiation: Partial Breast Irradiation (PBI)|Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen",Azienda Ospedaliero-Universitaria Careggi|Institut Curie|University of Florence,EUROPA,"October 22, 2019",,https://ClinicalTrials.gov/show/NCT04134598
Study Chair,"Lorenzo Livi, MD","Radiation Oncology Unit, AOU Careggi",,NCT04161833,lorenzo livi,lorenzo,male,0.99,55168,705,Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA),Completed,No Results Available,Breast Cancer|Hormone Receptor Positive Tumor|Arthralgia,Dietary Supplement: OPERA,Azienda Ospedaliero-Universitaria Careggi,OPERA2,"November 13, 2019","Azienda Ospedaliero Universitaria Careggi, Florence, Italy",https://ClinicalTrials.gov/show/NCT04161833
Principal Investigator,"Isacco Desideri, MD","Radiation Oncology Unit, AOU Careggi",,NCT04161833,isacco desideri,isacco,male,0.99,193,705,Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA),Completed,No Results Available,Breast Cancer|Hormone Receptor Positive Tumor|Arthralgia,Dietary Supplement: OPERA,Azienda Ospedaliero-Universitaria Careggi,OPERA2,"November 13, 2019","Azienda Ospedaliero Universitaria Careggi, Florence, Italy",https://ClinicalTrials.gov/show/NCT04161833
Principal Investigator,"Silvia Formenti, M.D.",Weill Cornell Medicine - New York Presbyterian Hospital,,NCT03804944,silvia formenti,silvia,female,0.99,120107,77,Converting HR+ Breast Cancer Into an Individualized Vaccine,"Active, not recruiting",No Results Available,Breast Cancer,Radiation: Focal Radiation therapy|Drug: Pembrolizumab (200mg IV for 30 minutes|Biological: CDX-301,Weill Medical College of Cornell University,1808019498,"January 15, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States|Icahn School of Medicine at Mt Sinai, New York, New York, United States|Weill Cornell Medicine New York Presbyterian Hospital, New York, New York, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Houston Methodist Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03804944
Principal Investigator,"Silvia Formenti, M.D.",Weill Cornell Medicine,,NCT04175210,silvia formenti,silvia,female,0.99,120107,622,Prospective Randomized Study of Accelerated Radiation Therapy (PRART),Recruiting,No Results Available,Breast Cancer,Radiation: Radiation therapy - 3 weeks|Radiation: Radiation therapy - 2 weeks,Weill Medical College of Cornell University,19-07020533,"November 22, 2019","New York Presbyterian Hospital at Lower Manhattan Cancer Center, New York, New York, United States|Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States|New York Presbyterian Hospital - Queens, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04175210
Principal Investigator,"Isabelle THOMASSIN-NAGGARA, PU-PH",Assistance Publique - Hôpitaux de Paris,,NCT04020523,isabelle thomassin-naggara,isabelle,female,0.99,89728,80,Advanced MR Techniques for Breast Cancer Detection,Not yet recruiting,No Results Available,Breast Cancer,Other: MRI sequence,Assistance Publique - Hôpitaux de Paris|GE Healthcare,K180603J|2018-A01647-48,"July 16, 2019","Service de Radiologie Hôpital Tenon (APHP), Paris, France",https://ClinicalTrials.gov/show/NCT04020523
Principal Investigator,"Isabelle DESMOULINS, MD",Georges François Leclerc Centre,,NCT04176809,isabelle desmoulins,isabelle,female,0.99,89728,164,Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer (COMPLIANCE),Not yet recruiting,No Results Available,Breast Cancer,Other: Routine Assessment of HRQoL coupled with Therapeutic Information,Centre Georges Francois Leclerc,2019-A01323-54,"November 25, 2019",,https://ClinicalTrials.gov/show/NCT04176809
Principal Investigator,"Carlos A Parra-Lopez, MD PhD",Full Professor School of Medicine. Microbiology Department.,,NCT04105582,carlos a parra-lopez,carlos,male,0.99,236888,81,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Recruiting,No Results Available,Breast Cancer|Triple Negative Breast Cancer,Biological: Neo-antigen pulsed Dendritic cell,Universidad Nacional de Colombia|Fundación Salud de los Andes,TEBICA002,"September 26, 2019","Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04105582
Principal Investigator,Carlos H Barcenas,M.D. Anderson Cancer Center,,NCT03872388,carlos h barcenas,carlos,male,0.99,236888,561,Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy,Recruiting,No Results Available,Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Inflammatory Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma,Drug: Atorvastatin|Drug: Capecitabine,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2018-0550|NCI-2019-00004|P30CA016672,"March 13, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03872388
Principal Investigator,"Carlos Peña Gil, MD, PhD","Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV",,NCT03964142,carlos peña gil,carlos,male,0.99,236888,647,Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity,Recruiting,No Results Available,Cardiotoxicity|Cardiac Rehabilitation,Other: Cardiac rehabilitation,Hospital Clinico Universitario de Santiago|Instituto de Salud Carlos III,PI17/01687,"May 28, 2019","Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT03964142
Study Director,"José Ramón González Juanatey, MD, PhD","Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV",,NCT03964142,josé ramón gonzález juanatey,josé,male,0.97,2086,647,Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity,Recruiting,No Results Available,Cardiotoxicity|Cardiac Rehabilitation,Other: Cardiac rehabilitation,Hospital Clinico Universitario de Santiago|Instituto de Salud Carlos III,PI17/01687,"May 28, 2019","Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT03964142
Principal Investigator,"Amparo Martínez Monzonís, MD, PhD","Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV",,NCT03964142,amparo martínez monzonís,amparo,female,0.98,9043,647,Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity,Recruiting,No Results Available,Cardiotoxicity|Cardiac Rehabilitation,Other: Cardiac rehabilitation,Hospital Clinico Universitario de Santiago|Instituto de Salud Carlos III,PI17/01687,"May 28, 2019","Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT03964142
Study Chair,"Fengxi Su, MD",Sun Yat-sen Menorial Hospital,,NCT04076111,fengxi su,fengxi,male,1.0,1,82,Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China,Not yet recruiting,No Results Available,Breast Cancer,,Fengxi Su|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,BCSCO003,"September 3, 2019","Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Cancer Hospital OF Shantou University Medical College, Shantou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China",https://ClinicalTrials.gov/show/NCT04076111
Study Chair,"Qiang liu, MD",Sun Yat-sen Menorial Hospital,,NCT04076111,qiang liu,qiang,male,0.96,509,82,Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China,Not yet recruiting,No Results Available,Breast Cancer,,Fengxi Su|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,BCSCO003,"September 3, 2019","Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Cancer Hospital OF Shantou University Medical College, Shantou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China",https://ClinicalTrials.gov/show/NCT04076111
Study Director,"Musheng Zeng, MD",Sun Yat-sen University,,NCT04076111,musheng zeng,musheng,male,1.0,4,82,Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China,Not yet recruiting,No Results Available,Breast Cancer,,Fengxi Su|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,BCSCO003,"September 3, 2019","Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Cancer Hospital OF Shantou University Medical College, Shantou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China",https://ClinicalTrials.gov/show/NCT04076111
Study Director,"Qianjun Chen, MD",Guuangdong Province Hospital of Chinese Medicine,,NCT04076111,qianjun chen,qianjun,female,0.5,2,82,Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China,Not yet recruiting,No Results Available,Breast Cancer,,Fengxi Su|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,BCSCO003,"September 3, 2019","Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Cancer Hospital OF Shantou University Medical College, Shantou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China",https://ClinicalTrials.gov/show/NCT04076111
Study Chair,"Qiang Sun, M.D.",Peking Union Medical College Hospital,,NCT03910712,qiang sun,qiang,male,0.96,509,652,Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC,Not yet recruiting,No Results Available,Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor,Drug: Pyrotinib|Drug: Trastuzumab|Drug: Aromatase inhibitor,Peking Union Medical College Hospital,BREAST-Pyrotinib,"April 10, 2019",,https://ClinicalTrials.gov/show/NCT03910712
Principal Investigator,"Nur Aishah Taib, MBBS",University of Malaya,,NCT03847623,nur aishah taib,nur,female,0.9,24229,83,Effect of Preoperative Curcumin in Breast Cancer Patients,"Active, not recruiting",No Results Available,Breast Cancer,Dietary Supplement: Curcumin|Other: Placebo,University of Malaya,20149-582,"February 20, 2019","University of Malaya Medical Center, Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT03847623
Principal Investigator,"Nur Aishah Taib, MBBS",University of Malaya,,NCT03855423,nur aishah taib,nur,female,0.9,24229,193,"Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer",Recruiting,No Results Available,Breast Cancer Female,Dietary Supplement: Tocotrienol-rich Fraction (TRF),Nur Aishah Mohd Taib|Malaysia Palm Oil Board|University of Malaya,853.4,"February 26, 2019","University of Malaya Medical Center, Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT03855423
Principal Investigator,"JEEHYUN KIM, MD,PhD",Seoul National University Bundang Hospital,,NCT04061863,jeehyun kim,jeehyun,female,0.85,62,84,Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Nivolumab,Seoul National University Hospital|Seoul National University Bundang Hospital|Korean Cancer Study Group (KCSG)|Eisai Korea Inc.|Ono pharmaceutical Korea,KCSG BR18-16,"August 20, 2019","Seoul National University Bundang Hospital, Seongnam, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04061863
Principal Investigator,"William Carson, MD",Ohio State Comprehensive Cancer Center,,NCT04022616,william carson,william,male,0.99,64097,86,Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Other: Specimen collection,Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),OSU-09142,"July 17, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04022616
Study Chair,"WILLIAM JACOT, MD",Institut régional du cancer de Montpellier,,NCT04091178,william jacot,william,male,0.99,64097,234,Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer,Completed,No Results Available,Breast Cancer,Dietary Supplement: VITAMIN D,Institut du Cancer de Montpellier - Val d'Aurelle,ICM2013/06,"September 16, 2019","Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France",https://ClinicalTrials.gov/show/NCT04091178
Principal Investigator,"William T. Tran, MRT(T), PhD",Sunnybrook Health Sciences Centre,,NCT04021069,william t. tran,william,male,0.99,64097,396,Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer|Invasive Ductal Breast Carcinoma|Invasive Lobular Breast Carcinoma,"Diagnostic Test: Radiomic, pathomic, and clinical markers",Sunnybrook Health Sciences Centre,270-2018,"July 16, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04021069
Principal Investigator,"Kasia Jerzak, M.Sc., MD",Sunnybrook Health Sciences Centre,,NCT04021069,kasia jerzak,kasia,female,0.98,80027,396,Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer|Invasive Ductal Breast Carcinoma|Invasive Lobular Breast Carcinoma,"Diagnostic Test: Radiomic, pathomic, and clinical markers",Sunnybrook Health Sciences Centre,270-2018,"July 16, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04021069
Principal Investigator,"Fang-I Lu, MD, FRCPC",Sunnybrook Health Sciences Centre,,NCT04021069,fang-i lu,fang-i,female,1.0,1,396,Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer|Invasive Ductal Breast Carcinoma|Invasive Lobular Breast Carcinoma,"Diagnostic Test: Radiomic, pathomic, and clinical markers",Sunnybrook Health Sciences Centre,270-2018,"July 16, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04021069
Principal Investigator,William Gwin,Fred Hutch/University of Washington Cancer Consortium,,NCT04120246,william gwin,william,male,0.99,64097,491,Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer,Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Refractory Breast Carcinoma,Drug: Alpha-tocopheryloxyacetic Acid|Biological: Trastuzumab,"University of Washington|National Cancer Institute (NCI)|Veana Therapeutics, Inc.",RG1004302|NCI-2019-06457|P30CA015704,"October 9, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04120246
Principal Investigator,"Xavier DURANDO, Pr",Centre Jean Perrin,,NCT04068623,xavier durando,xavier,male,0.99,36056,90,Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients,Recruiting,No Results Available,Triple Negative Breast Cancer,Other: Blood sample,Centre Jean Perrin,2019-A01861-56,"August 28, 2019","Centre Jean PERRIN, Clermont-Ferrand, Please Select, France",https://ClinicalTrials.gov/show/NCT04068623
Principal Investigator,"Xavier DURANDO, Professor",Centre Jean Perrin,,NCT04133077,xavier durando,xavier,male,0.99,36056,203,Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer Female,Biological: blood samples collection,Centre Jean Perrin,2020-A00398-31,"October 21, 2019",,https://ClinicalTrials.gov/show/NCT04133077
Principal Investigator,"Adamantia Nikolaidi, MD","Oncology Department, MITERA Hospital",,NCT04033965,adamantia nikolaidi,adamantia,female,0.97,68,91,"Corellation of Mutations, TILs and Age in Breast Cancer",Completed,No Results Available,Breast Cancer,"Genetic: Corellation of Mutations, TILs and Age in Breast Cancer",Hellenic Cooperative Oncology Group,HE10/mut,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT04033965
Study Chair,David Cescon,"University Health Network, PMH, Toronto ON",,NCT04176848,david cescon,david,male,0.99,501011,94,CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: CFI-400945|Drug: Durvalumab,"Canadian Cancer Trials Group|AstraZeneca|University Health Network, Toronto",I239,"November 25, 2019",,https://ClinicalTrials.gov/show/NCT04176848
Study Chair,Andrew Robinson,"Cancer Centre of Southeastern Ontario at Kingston, ON",,NCT04176848,andrew robinson,andrew,male,0.99,60301,94,CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: CFI-400945|Drug: Durvalumab,"Canadian Cancer Trials Group|AstraZeneca|University Health Network, Toronto",I239,"November 25, 2019",,https://ClinicalTrials.gov/show/NCT04176848
Principal Investigator,"David Lalush, PhD",UNC Biomedical Engineering,,NCT04149353,david lalush,david,male,0.99,501011,417,PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo,Terminated,Has Results,Breast Cancer,Diagnostic Test: PET/MR,UNC Lineberger Comprehensive Cancer Center,LCCC 1716,"November 4, 2019","UNC- Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04149353
Principal Investigator,"Andrew Karellas, PhD",University of Arizona,,NCT03954431,andrew karellas,andrew,male,0.99,60301,611,High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT),Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Contrast-media enhanced breast CT(CE-BCT)|Drug: Iodinated Contrast Agent,University of Arizona|National Institutes of Health (NIH)|National Cancer Institute (NCI),1903399639|R01CA199044,"May 17, 2019","University of Arizona, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT03954431
Principal Investigator,"Srinivasan Vedantham, PhD",University of Arizona,,NCT03954431,srinivasan vedantham,srinivasan,male,0.98,307,611,High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT),Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Contrast-media enhanced breast CT(CE-BCT)|Drug: Iodinated Contrast Agent,University of Arizona|National Institutes of Health (NIH)|National Cancer Institute (NCI),1903399639|R01CA199044,"May 17, 2019","University of Arizona, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT03954431
Principal Investigator,"Tae H Kim, Ph.D","National Cancer Center, Korea",,NCT04203849,tae h kim,tae,male,0.86,2498,96,Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy,Enrolling by invitation,No Results Available,Breast Cancer,,"National Cancer Center, Korea",NCC2019-0142,"December 18, 2019","National Cancer Center Korea, Goyang, Gyeonggi, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04203849
Principal Investigator,"Jinhua Zhao, PhD",Shanghai General Hospital Nuclear Medicine Dept,,NCT04040686,jinhua zhao,jinhua,female,0.72,113,97,HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT,Recruiting,No Results Available,Breast Cancer,Drug: 99m-Tc-NM-02 Injection,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|NanoMab",2019/52,"August 1, 2019","Shanghai General Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04040686
Principal Investigator,"Desiree van den Bongard, MD PhD",UMC Utrecht,,NCT03863301,desiree van den bongard,desiree,female,0.98,8021,100,MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer,Recruiting,No Results Available,Breast Cancer,Radiation: MR-guided single dose preoperative PBI,UMC Utrecht,NL63209 041 18,"March 5, 2019","UMC Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT03863301
Study Director,"Mieke Ptaszynski, MD",Zeno Alpha Inc.,,NCT04176757,mieke ptaszynski,mieke,female,0.99,3205,101,A Study of ZN-c5 in Participants With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: ZN-c5,Zeno Alpha Inc.,ZN-c5-002,"November 25, 2019","Site 3, Tucson, Arizona, United States|Site 2, New York, New York, United States|Site 4, Nashville, Tennessee, United States|Site 1, Houston, Texas, United States|Site 5, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04176757
Study Director,"Mieke Ptaszynski, MD",K-Group Beta,,NCT04158336,mieke ptaszynski,mieke,female,0.99,3205,775,A Study of ZN-c3 in Participants With Solid Tumors,Recruiting,No Results Available,Solid Tumor|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Triple Negative Breast Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Malignant Melanoma|Non Small Cell Lung Cancer|Urothelial Carcinoma,Drug: ZN-c3|Drug: Talazoparib|Drug: Pembrolizumab,K-Group Beta|IQVIA Biotech,ZN-c3-001,"November 8, 2019","Site 0102, Tucson, Arizona, United States|Site 0101, Detroit, Michigan, United States|Site 0103, Houston, Texas, United States|Site 0100, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04158336
Principal Investigator,"Asal Rahimi, MD",UT Southwestern Medical Center,,NCT04040569,asal rahimi,asal,female,0.89,1077,103,Dose Escalation Study of Single Fraction Early Stage Breast Cancer,Recruiting,No Results Available,Breast Cancer,Radiation: Radiomics on MRI,University of Texas Southwestern Medical Center,2019-1183,"July 31, 2019","University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04040569
Study Director,"Maged W Helmy, PhD","Professor of Pharmacology, Faculty of pharmacy, Damanhour University",,NCT04166253,maged w helmy,maged,male,0.98,2119,105,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,Recruiting,No Results Available,Breast Cancer,Drug: Vitamin D,Damanhour University,919PP17,"November 18, 2019","Damnhour university, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04166253
Study Director,"Gehan A Khedr, PhD","Assistant Professor of Oncology, Faculty of Medicine, Alexandria University",,NCT04166253,gehan a khedr,gehan,female,0.75,122,105,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,Recruiting,No Results Available,Breast Cancer,Drug: Vitamin D,Damanhour University,919PP17,"November 18, 2019","Damnhour university, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04166253
Study Director,"Noha A El Bassiouny, PhD","Lecturer of Clinical Pharmacy, Faculty of Pharmacy, Damanhour University",,NCT04166253,noha a el bassiouny,noha,female,0.92,2376,105,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,Recruiting,No Results Available,Breast Cancer,Drug: Vitamin D,Damanhour University,919PP17,"November 18, 2019","Damnhour university, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04166253
Principal Investigator,"Mostafa A Mahmoud, PharmD",Clinical Pharmacy Specialist,,NCT04166253,mostafa a mahmoud,mostafa,male,0.98,14950,105,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,Recruiting,No Results Available,Breast Cancer,Drug: Vitamin D,Damanhour University,919PP17,"November 18, 2019","Damnhour university, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04166253
Study Chair,"Maged W Helmy, PhD","Professor in Pharmacology, Faculty of pharmacy, Damanhour University",,NCT04170465,maged w helmy,maged,male,0.98,2119,150,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Recruiting,No Results Available,Breast Cancer Female,Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen,Damanhour University|Alexandria University,919PP18,"November 20, 2019","Damanhour University, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04170465
Study Chair,"Noha A El-Bassiouny, PhD","Lecturer in Clinical Pharmacy, Faculty of Pharmacy, Damanhour University",,NCT04170465,noha a el-bassiouny,noha,female,0.92,2376,150,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Recruiting,No Results Available,Breast Cancer Female,Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen,Damanhour University|Alexandria University,919PP18,"November 20, 2019","Damanhour University, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04170465
Study Director,"Mahmoud M El-Mas, PhD","Professor in Pharmacology, Faculty of Pharmacy, Alexandria University",,NCT04170465,mahmoud m el-mas,mahmoud,male,0.98,21229,150,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Recruiting,No Results Available,Breast Cancer Female,Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen,Damanhour University|Alexandria University,919PP18,"November 20, 2019","Damanhour University, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04170465
Study Director,"Yasser M El-Kerm, PhD","Professor in Clinical Oncology, Medical Research Institute,Alexandria University",,NCT04170465,yasser m el-kerm,yasser,male,0.98,9171,150,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Recruiting,No Results Available,Breast Cancer Female,Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen,Damanhour University|Alexandria University,919PP18,"November 20, 2019","Damanhour University, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04170465
Study Chair,"Amira B Kassem, PhD","Lecturer in Clinical Pharmacy, Faculty of Pharmacy, Damanhour University",,NCT04170465,amira b kassem,amira,female,0.97,11084,150,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Recruiting,No Results Available,Breast Cancer Female,Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen,Damanhour University|Alexandria University,919PP18,"November 20, 2019","Damanhour University, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04170465
Principal Investigator,"Manar A Serageldin, Bachelor","Teaching assistant in Pharmacology, Faculty of Pharmacy, Alexandria University",,NCT04170465,manar a serageldin,manar,female,0.87,2183,150,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Recruiting,No Results Available,Breast Cancer Female,Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen,Damanhour University|Alexandria University,919PP18,"November 20, 2019","Damanhour University, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04170465
Principal Investigator,"Nancy DeMore, MD, FACS",Medical University of South Carolina,,NCT03980509,nancy demore,nancy,female,0.98,42623,106,"A ""Window Trial"" on Curcumin for Invasive Breast Cancer Primary Tumors",Recruiting,No Results Available,Breast Cancer,Drug: Curcumin,Medical University of South Carolina,103089,"June 10, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",https://ClinicalTrials.gov/show/NCT03980509
Principal Investigator,Qifeng Yang,"Qilu Hospital, Shandong University",,NCT03857932,qifeng yang,qifeng,male,0.78,18,107,Regularity of Lymphatic Drainage and Surgical Treatment of Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Participants receive SLNB as well as non SLNs resection,Shandong University,HECT004,"February 28, 2019","Qifeng Yang, Jinan, Shandong, China",https://ClinicalTrials.gov/show/NCT03857932
Principal Investigator,"Carla Prado, PhD",University of Alberta,,NCT03795493,carla prado,carla,female,0.98,72540,108,Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer,Enrolling by invitation,No Results Available,Breast Cancer,Behavioral: Short-term diet and exercise intervention,University of Alberta|Canadian Cancer Society Research Institute (CCSRI)|Canadian Institutes of Health Research (CIHR),HREBA.CC-18-0657,"January 7, 2019","University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT03795493
Principal Investigator,"Richard Thompson, PhD",University of Alberta,,NCT03795493,richard thompson,richard,male,0.99,101928,108,Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer,Enrolling by invitation,No Results Available,Breast Cancer,Behavioral: Short-term diet and exercise intervention,University of Alberta|Canadian Cancer Society Research Institute (CCSRI)|Canadian Institutes of Health Research (CIHR),HREBA.CC-18-0657,"January 7, 2019","University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT03795493
Principal Investigator,"Richard Greil, MD","IIIrd Medical Department, Private Medical University Hospital Salzburg",,NCT03870620,richard greil,richard,male,0.99,101928,290,Metastatic Breast Cancer in Austria,Recruiting,No Results Available,Breast Cancer|Breast Carcinoma|Breast Tumor,,Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche|Pfizer,AGMT_MBC-Registry,"March 12, 2019","BHS Linz, Linz, Oberösterreich, Austria|Kepler Universitätsklinikum, Linz, Oberösterreich, Austria|LKH Steyr, Steyr, Oberösterreich, Austria|Klinikum Wels Grieskirchen, Wels, Oberösterreich, Austria|LKH-Univ. Klinikum Graz, Graz, Steiermark, Austria|Universitätsklinik für Frauenheilkunde Innsbruck, Innsbruck, Tirol, Austria|BKH Kufstein, Kufstein, Tirol, Austria|LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Universitätsklinik für Innere Medizin III Salzburg, Salzburg, Austria|AKH Wien, Universitätsklinik für Frauenheilkunde, Wien, Austria",https://ClinicalTrials.gov/show/NCT03870620
Principal Investigator,"Richard Brull, MD,FRCPC",Women's College Hospital,,NCT03978780,richard brull,richard,male,0.99,101928,575,Serratus vs. Erector Spinae Fascial Plane Block for Breast and Axillary Surgery,Not yet recruiting,No Results Available,Breast Cancer|Nerve Block|Regional Anesthesia|Neuromuscular Blockade,Procedure: Serratus Block|Procedure: Erector spinae plane block,Women's College Hospital,Serratus vs. ESP block,"June 7, 2019","Women's College Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03978780
Principal Investigator,"Richard Crownover, MD",Principal Investigator,,NCT03799523,richard crownover,richard,male,0.99,101928,616,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,Recruiting,No Results Available,Breast Cancer,Other: Temporary skin markings|Other: Surface imaging,The University of Texas Health Science Center at San Antonio,CTMS# 18-0135|18-769H,"January 10, 2019","UT Health San Antonio Mays Cancer Center, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT03799523
Principal Investigator,"Folke Sjöberg, MD, Prof",CTC Clinical Trial Consultants,,NCT04080024,folke sjöberg,folke,male,0.92,120,109,A First-in-human Clinical Evaluation of SN132D in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: SN132D,Spago Nanomedical AB|CTC Clinical Trial Consultants AB|Antaros Medical AB,SN132D CSP final version 3.0|2018-002193-41,"September 6, 2019","Gothia Forum Clinical Trial Center, Gothenburg, Sweden|CTC Clinical Trial Consultants AB, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT04080024
Principal Investigator,"Dan Curiac, MD, PhD",Gothia Forum Clinical Trial Center,,NCT04080024,dan curiac,dan,male,0.95,55986,109,A First-in-human Clinical Evaluation of SN132D in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: SN132D,Spago Nanomedical AB|CTC Clinical Trial Consultants AB|Antaros Medical AB,SN132D CSP final version 3.0|2018-002193-41,"September 6, 2019","Gothia Forum Clinical Trial Center, Gothenburg, Sweden|CTC Clinical Trial Consultants AB, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT04080024
Study Director,"Elaine Caldeira de Oliveira Guirro, PhD",University of São Paulo,,NCT04076033,elaine caldeira de oliveira guirro,elaine,female,0.98,8901,111,Reliability and Reproducibility of Bandaging in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Other: functional compressive bandage,Elaine Caldeira de Oliveira Guirro|University of Sao Paulo,000001,"September 3, 2019","University of São Paulo, Ribeirão Preto, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04076033
Principal Investigator,"John Mackey, MD",Cross Cancer Institute,,NCT03831178,john mackey,john,male,0.99,218952,113,Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting,Recruiting,No Results Available,Breast Cancer,Dietary Supplement: Docosahexaenoic acid (DHA)|Drug: Placebo oral capsule,AHS Cancer Control Alberta|Canadian Institutes of Health Research (CIHR)|University of Alberta,IIT-0005,"February 5, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT03831178
Principal Investigator,John A Glaspy,UCLA / Jonsson Comprehensive Cancer Center,,NCT04185311,john a glaspy,john,male,0.99,218952,562,"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",Recruiting,No Results Available,"Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|HER2/Neu Negative|Invasive Ductal Carcinoma, Not Otherwise Specified|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma",Biological: Ipilimumab|Biological: Nivolumab|Biological: Talimogene Laherparepvec,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),18-000427|NCI-2018-01410|Glaspy BMS CA209-9ET Breast|P30CA016042,"December 4, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04185311
Principal Investigator,"Karen Wonders, PhD, FACSM",Maple Tree Cancer Alliance,,NCT04106609,karen wonders,karen,female,0.95,48557,114,Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,"Other: Supervised, individualized exercise oncology program|Other: Current standard of care",Karen Wonders|Kettering Health Network,Maple Tree Exercise,"September 27, 2019","Maple Tree Cancer Alliance, Dayton, Ohio, United States",https://ClinicalTrials.gov/show/NCT04106609
Principal Investigator,Karen M Basen-Engquist,M.D. Anderson Cancer Center,,NCT04125914,karen m basen-engquist,karen,female,0.95,48557,748,Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families,Recruiting,No Results Available,Hereditary Breast Carcinoma|Hereditary Ovarian Carcinoma|Lynch Syndrome|Mutation Carrier,Behavioral: Behavioral Dietary Intervention|Other: E-mail|Behavioral: Exercise Intervention|Other: Internet-Based Intervention|Other: Questionnaire Administration|Behavioral: Telephone-Based Intervention|Other: Text Message,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2016-0775|NCI-2019-02453|P30CA016672,"October 14, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04125914
Principal Investigator,"Raffaele LONGO, Dr",CHR Metz-Thionville,,NCT03898453,raffaele longo,raffaele,male,0.99,27499,115,EMDR Psychotherapy for Anxious-depressive Symptoms in Breast Cancer Patient,"Active, not recruiting",No Results Available,Breast Cancer Female,Behavioral: EMDR psychotherapy|Behavioral: support psychotherapy,"Centre Hospitalier Régional Metz-Thionville|University of Lorraine|Central Hospital, Nancy, France",2018-A01128-47,"April 2, 2019","CHR Metz-Thionville, Metz, France",https://ClinicalTrials.gov/show/NCT03898453
Principal Investigator,Anne Armstrong,The Christie NHS Foundation Trust,,NCT04188119,anne armstrong,anne,female,0.97,78727,116,A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: Avelumab|Drug: Aspirin|Drug: Lansoprazole,The Christie NHS Foundation Trust|University of Manchester,CFT / sp123|2018-004121-80|017NovCC107,"December 5, 2019",,https://ClinicalTrials.gov/show/NCT04188119
Principal Investigator,Anne Armstrong,The Christie NHS Foundation Trust,,NCT03794596,anne armstrong,anne,female,0.97,78727,149,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer",Withdrawn,No Results Available,Breast Cancer,Drug: Avelumab|Drug: Aspirin|Drug: Lansoprazole (Proton Pump Inhibitor),The Christie NHS Foundation Trust|University of Manchester,CFT/sp123|2018-004121-80|16_DOG02_289|017NovCC1079,"January 7, 2019",,https://ClinicalTrials.gov/show/NCT03794596
Principal Investigator,"Anne May, PhD",UMC Utrecht Julius Center,,NCT04120298,anne may,anne,female,0.97,78727,202,Effects of Exercise in Patients With Metastatic Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Behavioral: Supervised exercise,"UMC Utrecht|German Cancer Research Center|Australian Catholic University|Karolinska Institutet|The Netherlands Cancer Institute|Medical University of Gdansk|Fundación Onkologikoa Fundazioa|Europa Donna|German Sport University, Cologne|University Hospital Heidelberg|Nurogames GmbH, Cologne",19-524|NL69600.041.19,"October 9, 2019",,https://ClinicalTrials.gov/show/NCT04120298
Principal Investigator,"Anne Blaes, MD","University of Minnesota, Division of Hematology, Oncology and Transplantation",,NCT03946423,anne blaes,anne,female,0.97,78727,354,BAriaTric Surgery After Breast Cancer Treatment (BATS),Not yet recruiting,No Results Available,Early-stage Breast Cancer|Obesity,Procedure: Bariatric Surgery with Sleeve Gastrectomy|Behavioral: Lifestyle Intervention,"Masonic Cancer Center, University of Minnesota",2018LS148,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT03946423
Study Director,"Anne BREDART, PHD",Institut Curie,,NCT04118062,anne bredart,anne,female,0.97,78727,578,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR),Not yet recruiting,No Results Available,Metastatic Uveal Melanoma|Triple Negative Breast Cancer|Luminal B Breast Cancer|Pediatric Cancer,Behavioral: Questionnaires|Behavioral: Semi-structured individual interviews|Other: Focus Group|Other: DELPHI Consensus Method,Institut Curie,IC 2018-09,"October 7, 2019","Institut Curie, Paris, France",https://ClinicalTrials.gov/show/NCT04118062
Study Director,"Sylvie DOLBEAULT, PHD",Institut Curie,,NCT04118062,sylvie dolbeault,sylvie,female,0.98,65175,578,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR),Not yet recruiting,No Results Available,Metastatic Uveal Melanoma|Triple Negative Breast Cancer|Luminal B Breast Cancer|Pediatric Cancer,Behavioral: Questionnaires|Behavioral: Semi-structured individual interviews|Other: Focus Group|Other: DELPHI Consensus Method,Institut Curie,IC 2018-09,"October 7, 2019","Institut Curie, Paris, France",https://ClinicalTrials.gov/show/NCT04118062
Study Chair,"Elisabetta Munzone, MD",European Institute of Oncology,,NCT03820830,elisabetta munzone,elisabetta,female,0.99,12887,117,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,Recruiting,No Results Available,Breast Cancer Recurrent,Drug: Palbociclib 125mg|Drug: Standard endocrine therapy,International Breast Cancer Study Group|Pfizer,IBCSG 59-19|2018-003553-19|BIG 18-02|WI239003,"January 29, 2019","Medizinische Universität Graz (MUG), Graz, Austria|Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde, Innsbruck, Austria|Uniklinikum Salzburg, Salzburg, Austria|MUW - Universitätsklinik für Innere Medizin, Vienna, Austria|Institut Sainte Catherine, Avignon, France|Polyclinique Bordeaux Nord, Bordeaux, France|Centre Francois Baclesse, Caen, France|Cêntre Hospitaler de Cholet, Cholet, France|Centre Georges François Leclerc, Dijon, France|Centre Hospitalier Universitaire de Limoges, Limoges, France|ICM Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Institut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France|National Institute of Oncology, Budapest, Hungary|Cro Irccs, Aviano, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|PO Antonio Perrino Brindisi, Brindisi, Italy|Istituto scientifico Romagnolo per lo studio e la cura, Meldola, Italy|Istituto Europeo di Oncologia, Milan, Italy|AOU Maggiore Della Carita, University of Eastern Piedmont, Novara, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|Istituti Clinici Scientifici Maugeri, Pavia, Italy|Ospedale S. Stefano, Prato, Italy|U.O. Oncologia, Ospedale Infermi, Rimini, Italy|Hospital Universitario de Canarias, San Cristóbal de La Laguna, Tenerife, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Vall d´Hebrón, Barcelona, Spain|Instituto Catalan de Oncologia L´Hospitalet, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|HU Ramón y Cajal, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Instituto Valenciano de Oncología (IVO), Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Baden, Baden, Switzerland|Brustzentrum Basel Bethesda Spital, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Centre du Sein Fribourg, Fribourg, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Brust-Zentrum AG Zürich, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT03820830
Study Director,Wei Zhao,"Shiyao Group Ouyi Pharmaceutical Co., Ltd.",,NCT04060290,wei zhao,wei,male,0.72,5779,122,Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Other: Observational study,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",CSPC-KAL-AE-01,"August 19, 2019","Anhui Cancer Hospital, Hefei, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Inner Mongolia Autonomous Region Cancer Hospital, Hohhot, Inner Mongolia Autonomous Region, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China",https://ClinicalTrials.gov/show/NCT04060290
Principal Investigator,"Biyun Wang, Professor",Fudan University,,NCT03894410,biyun wang,biyun,female,1.0,6,123,Real World Study of Lapatinib Among Metastatic Breast Cancer Patients,"Active, not recruiting",No Results Available,Breast Cancer,,Fudan University,YOUNGBC-6,"March 28, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT03894410
Principal Investigator,"Biyun Wang, Professor",Fudan University,,NCT04001634,biyun wang,biyun,female,1.0,6,429,Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC,"Active, not recruiting",No Results Available,Breast Cancer,,Fudan University,YOUNGBC-8,"June 28, 2019","Biyun Wang, MD, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04001634
Principal Investigator,"Biyun Wang, Professor",Fudan University,,NCT04006626,biyun wang,biyun,female,1.0,6,432,18F-FES PET/CT's Additional Clinical Value in ER+ BC,Completed,No Results Available,Breast Cancer,,Fudan University,YOUNGBC-7,"July 5, 2019","Biyun Wang, MD, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04006626
Principal Investigator,"Leigh Leibel, MSc",Columbia University,,NCT04042870,leigh leibel,leigh,male,0.5,2515,124,Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors,Completed,No Results Available,Breast Cancer,Behavioral: Joint Loosening Yoga,"AshtaYoga, LLC|Columbia University|Swami Vivekananda Yoga Anusandhana Samsthana",AI Yoga Study on Facebook - 1,"August 2, 2019","Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04042870
Principal Investigator,"Laura M Kenny, MD FRCP PhD",Imperial College London,,NCT03827317,laura m kenny,laura,female,0.98,288403,181,HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Radiation: [18F]GE-226,Imperial College London|Medical Research Council|University of Cambridge,2015‐004027‐31,"February 1, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT03827317
Principal Investigator,"Laura Biganzoli, MD",Hospital of Prato,,NCT03944434,laura biganzoli,laura,female,0.98,288403,204,FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer,Recruiting,No Results Available,Breast Cancer,"Drug: Ribociclib|Drug: Aromatase Inhibitors, non steroideal|Drug: LHRH agonist",Fondazione Sandro Pitigliani|Novartis,FACILE,"May 9, 2019","Hospital of Prato, Prato, Please Select:, Italy",https://ClinicalTrials.gov/show/NCT03944434
Principal Investigator,"Laura Q Rogers, MD, MPH",University of Alabama at Birmingham,,NCT04088708,laura q rogers,laura,female,0.98,288403,471,"Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors",Recruiting,No Results Available,Breast Cancer|Gut Microbiome|Exercise|Fatigue,Other: Aerobic Exercise Training|Other: Attention Control,University of Alabama at Birmingham|National Cancer Institute (NCI),IRB-30000320|R01CA235598,"September 13, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04088708
Principal Investigator,"Laura Heacock, MD",New York Langone Medical Center,,NCT03927768,laura heacock,laura,female,0.98,288403,612,Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP),Recruiting,No Results Available,Breast Cancer,Diagnostic Test: Predictive Model|Diagnostic Test: Breast Imagers,NYU Langone Health,18-00684,"April 25, 2019","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03927768
Principal Investigator,"Laura Canovi, RT",Arcispedale S.Maria Nuova,,NCT04009278,laura canovi,laura,female,0.98,288403,687,Self-compression Mammography in Clinical Practice,"Active, not recruiting",No Results Available,Mammography|Breast Cancer,Other: Self compression arm,Arcispedale Santa Maria Nuova-IRCCS,RCT Pristina 2/TR,"July 5, 2019","Laura Canovi, Reggio Emilia, RE, Italy",https://ClinicalTrials.gov/show/NCT04009278
Principal Investigator,Robert W Mutter,Mayo Clinic Cancer Center LAO,,NCT04052555,robert w mutter,robert,male,0.99,177418,483,"Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer",Recruiting,No Results Available,Bilateral Breast Carcinoma|Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma,Drug: Berzosertib|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy,National Cancer Institute (NCI),NCI-2019-05187|10291|UM1CA186686,"August 12, 2019","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04052555
Study Director,"Robert Zachariae, DMSc","Department of Oncology, Aarhus University Hospital & Aarhus University",,NCT04137575,robert zachariae,robert,male,0.99,177418,671,ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence,Recruiting,No Results Available,Fear of Cancer Recurrence|Breast Cancer Female,Behavioral: ConquerFear-Group|Behavioral: Relaxation Training,Aarhus University Hospital|University of Aarhus,NINTAU,"October 24, 2019","Aarhus University Hospital, Aarhus, Denmark",https://ClinicalTrials.gov/show/NCT04137575
Study Director,"Robert Stagg, PharmD",Tempest Therapeutics,,NCT03829436,robert stagg,robert,male,0.99,177418,763,"TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers",Recruiting,No Results Available,Hepatocellular Carcinoma|Metastatic Castration Resistant Prostate Cancer|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma of Head and Neck|Triple-Negative Breast Cancer|Urothelial Carcinoma|Cholangiocarcinoma|GastroEsophageal Cancer|Pancreatic Cancer|Sarcoma,Drug: Part 1 TPST-1120|Drug: Part 2a TPST-1120 + nivolumab|Drug: Part 2b TPST-1120 + docetaxel|Drug: Part 2c TPST-1120 + cetuximab|Drug: Part 3 TPST-1120|Drug: Part 4a TPST-1120 + nivolumab|Drug: Part 4b TPST-1120 + docetaxel|Drug: Part 4c TPST-1120 + cetuximab,Tempest Therapeutics,TPST-1120-001,"February 4, 2019","Miami Cancer Institute, Miami, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute - TN, Nashville, Tennessee, United States|Mary Crowley Cancer Research, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT03829436
Principal Investigator,"Fiona Gilbert, FRCR",University of Cambridge,,NCT03940092,fiona gilbert,fiona,female,0.97,11154,126,Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Other: MRI|Other: PET/MRI,Cambridge University Hospitals NHS Foundation Trust,260281,"May 7, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT03940092
Principal Investigator,Fiona Gilbert,University of Cambridge,,NCT04097366,fiona gilbert,fiona,female,0.97,11154,600,Breast Screening - Risk Adaptive Imaging for Density,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: ABUS|Diagnostic Test: CESM|Diagnostic Test: ABB-MRI,University of Cambridge|Cancer Research UK|GE Healthcare|Queen Mary University of London|Public Health England,A095053,"September 20, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04097366
Principal Investigator,"Stephen Chia, MD",BCCA,,NCT03790813,stephen chia,stephen,male,0.99,36980,130,"Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers",Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Intervention 1|Diagnostic Test: Intervention 2,"British Columbia Cancer Agency|Genomic Health®, Inc.",H18-02581,"January 2, 2019",,https://ClinicalTrials.gov/show/NCT03790813
Principal Investigator,Qiao I Li,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT03923179,qiao i li,qiao,female,0.59,150,133,Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Pyrotinib|Drug: Etoposide,Chinese Academy of Medical Sciences,LQ007,"April 22, 2019","Cancer Hospital, ChineseAMS, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03923179
Principal Investigator,Qiao Li,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT03923166,qiao li,qiao,female,0.59,150,152,Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Pyrotinib|Drug: capecitabine,Chinese Academy of Medical Sciences,LQ006,"April 22, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03923166
Principal Investigator,"Paul K Marcom, MD",Duke University,,NCT04197999,paul k marcom,paul,male,0.99,148099,138,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,Recruiting,No Results Available,HR+ Metastatic Breast Cancer|Breast Cancer|Breast Cancer Metastatic,Drug: GMI-1359,GlycoMimetics Incorporated,GMI-1359-210,"December 13, 2019","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04197999
Principal Investigator,"Dorothy A Sipkins, MD, PhD",Duke University,,NCT04197999,dorothy a sipkins,dorothy,female,0.99,11523,138,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,Recruiting,No Results Available,HR+ Metastatic Breast Cancer|Breast Cancer|Breast Cancer Metastatic,Drug: GMI-1359,GlycoMimetics Incorporated,GMI-1359-210,"December 13, 2019","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04197999
Principal Investigator,"Umut Bahcacı, MSc","Florence Nightingale Hospital, Istanbul",,NCT04163692,umut bahcacı,umut,male,0.96,24982,139,Effects of Progressive Relaxation Training in Breast Cancer Survivors Receiving Aromatatase Inhibitor Therapy,"Active, not recruiting",No Results Available,Breast Cancer,Other: Progressive relaxation exercises,Hacettepe University,PREBCA,"November 15, 2019","Florence Nightingale Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04163692
Principal Investigator,"Zeynep Erdoğan İyigün, Asst. Prof.","Florence Nightingale Hospital, Istanbul",,NCT04163692,zeynep erdoğan i̇yigün,zeynep,female,0.97,31807,139,Effects of Progressive Relaxation Training in Breast Cancer Survivors Receiving Aromatatase Inhibitor Therapy,"Active, not recruiting",No Results Available,Breast Cancer,Other: Progressive relaxation exercises,Hacettepe University,PREBCA,"November 15, 2019","Florence Nightingale Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04163692
Principal Investigator,"Songul Atasavun Uysal, Asst. Prof.",Hacettepe University,,NCT04163692,songul atasavun uysal,songul,female,0.96,1252,139,Effects of Progressive Relaxation Training in Breast Cancer Survivors Receiving Aromatatase Inhibitor Therapy,"Active, not recruiting",No Results Available,Breast Cancer,Other: Progressive relaxation exercises,Hacettepe University,PREBCA,"November 15, 2019","Florence Nightingale Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04163692
Study Chair,"Vahit Özmen, Prof.","Florence Nightingale Hospital, Istanbul",,NCT04163692,vahit özmen,vahit,male,0.98,1510,139,Effects of Progressive Relaxation Training in Breast Cancer Survivors Receiving Aromatatase Inhibitor Therapy,"Active, not recruiting",No Results Available,Breast Cancer,Other: Progressive relaxation exercises,Hacettepe University,PREBCA,"November 15, 2019","Florence Nightingale Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04163692
Study Chair,"Vahit Özmen, Prof",İstanbul FN hospital,,NCT03986268,vahit özmen,vahit,male,0.98,1510,583,Vitamin D Replacement Therapy Can Affects Pathological Response in Neoadjuvant Breast Cancer Treatment,Recruiting,No Results Available,Vitamin D Deficiency|Chemotherapy Effect|Pathology,Drug: Vit D,"Florence Nightingale Hospital, Istanbul",2019-40016-06,"June 14, 2019","İstanbul Florence Nightingale Hospital Breast Health Center, Istanbul, Şişli, Turkey",https://ClinicalTrials.gov/show/NCT03986268
Study Director,"Fatma Aktepe, Prof",Gayrettepe FN Hospital,,NCT03986268,fatma aktepe,fatma,female,0.97,34628,583,Vitamin D Replacement Therapy Can Affects Pathological Response in Neoadjuvant Breast Cancer Treatment,Recruiting,No Results Available,Vitamin D Deficiency|Chemotherapy Effect|Pathology,Drug: Vit D,"Florence Nightingale Hospital, Istanbul",2019-40016-06,"June 14, 2019","İstanbul Florence Nightingale Hospital Breast Health Center, Istanbul, Şişli, Turkey",https://ClinicalTrials.gov/show/NCT03986268
Principal Investigator,"Jiabao He, PhD",University of Aberdeen,,NCT03949946,jiabao he,jiabao,male,0.8,15,141,Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?,Recruiting,No Results Available,Breast Cancer,Procedure: Magnetic resonance imaging (MRI),University of Aberdeen|NHS Grampian,2-025-19,"May 14, 2019","Aberdeen Biomedical Imaging Centre, Aberdeen, Aberdeenshire, United Kingdom",https://ClinicalTrials.gov/show/NCT03949946
Study Chair,"Jiabao He, PhD",University of Aberdeen,,NCT03944226,jiabao he,jiabao,male,0.8,15,525,Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?,Not yet recruiting,No Results Available,Malignant Breast Tissue Neoplasm,Dietary Supplement: Beetroot juice,University of Aberdeen|NHS Grampian,2-114-18|17/049,"May 9, 2019","Aberdeen Biomedical Imaging Centre, Aberdeen, United Kingdom",https://ClinicalTrials.gov/show/NCT03944226
Principal Investigator,"Vasiliki Mallikourti, MSc",University of Aberdeen,,NCT03944226,vasiliki mallikourti,vasiliki,female,0.97,962,525,Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?,Not yet recruiting,No Results Available,Malignant Breast Tissue Neoplasm,Dietary Supplement: Beetroot juice,University of Aberdeen|NHS Grampian,2-114-18|17/049,"May 9, 2019","Aberdeen Biomedical Imaging Centre, Aberdeen, United Kingdom",https://ClinicalTrials.gov/show/NCT03944226
Principal Investigator,"Olivier Rigal, MD",Centre Henri Becquerel,,NCT03946579,olivier rigal,olivier,male,0.99,76702,144,Quality of Life and Sexuality of Patients Over 65 Years Undergoing Adjuvant Treatment for Breast Cancer,Recruiting,No Results Available,Breast Cancer,Other: self questionnaires,Centre Henri Becquerel,CHB18.04,"May 10, 2019","CHU Amiens, Amiens, France|Centre François Baclesse, Caen, France|Centre Henri Becquerel, Rouen, France",https://ClinicalTrials.gov/show/NCT03946579
Principal Investigator,"Olivier Tredan, MD",Centre Leon Berard,,NCT03818685,olivier tredan,olivier,male,0.99,76702,256,Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease,"Active, not recruiting",No Results Available,Breast Cancer|Triple Negative Breast Neoplasms,Drug: Nivolumab|Drug: Ipilimumab|Drug: Capecitabine,Centre Leon Berard,ET17-093 BreastImmune03,"January 28, 2019","Institut de Cancérologie de l'Ouest, Angers, France|Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Centre Francois Baclesse, Caen, France|Hopital Prive Jean Mermoz, Lyon, France|Centre Léon Bérard, Lyon, France|Clinique de la Sauvegarde, Lyon, France|Institut Paoli Calmettes, Marseille, France|Centre Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Institut Jean Godinot, Reims, France|Institut Curie, Saint Cloud, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|Centre Paul Strauss, Strasbourg, France",https://ClinicalTrials.gov/show/NCT03818685
Principal Investigator,"Olivier Rixe, MD",Quantum Santa Fe,,NCT04064359,olivier rixe,olivier,male,0.99,76702,336,Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer,Recruiting,No Results Available,Breast Cancer|Solid Tumor,"Drug: OBT076, a CD205-directed antibody-drug conjugate",Oxford BioTherapeutics Ltd,OBT076-001,"August 21, 2019","Cedars-Sinai, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Quantum Santa Fe, Santa Fe, New Mexico, United States|Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04064359
Principal Investigator,"Gary Schwartz, MD",Columbia University,,NCT04064359,gary schwartz,gary,male,0.99,29381,336,Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer,Recruiting,No Results Available,Breast Cancer|Solid Tumor,"Drug: OBT076, a CD205-directed antibody-drug conjugate",Oxford BioTherapeutics Ltd,OBT076-001,"August 21, 2019","Cedars-Sinai, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Quantum Santa Fe, Santa Fe, New Mexico, United States|Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04064359
Principal Investigator,"Solmaz Sahebjam, MD",Moffitt Cancer Center,,NCT04064359,solmaz sahebjam,solmaz,female,0.91,714,336,Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer,Recruiting,No Results Available,Breast Cancer|Solid Tumor,"Drug: OBT076, a CD205-directed antibody-drug conjugate",Oxford BioTherapeutics Ltd,OBT076-001,"August 21, 2019","Cedars-Sinai, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Quantum Santa Fe, Santa Fe, New Mexico, United States|Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04064359
Principal Investigator,"Monica Mita, MD",Cedars-Sinai,,NCT04064359,monica mita,monica,female,0.99,81357,336,Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer,Recruiting,No Results Available,Breast Cancer|Solid Tumor,"Drug: OBT076, a CD205-directed antibody-drug conjugate",Oxford BioTherapeutics Ltd,OBT076-001,"August 21, 2019","Cedars-Sinai, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Quantum Santa Fe, Santa Fe, New Mexico, United States|Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04064359
Principal Investigator,"Lee Rosen, MD","University of California, Los Angeles",,NCT04064359,lee rosen,lee,male,0.8,38767,336,Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer,Recruiting,No Results Available,Breast Cancer|Solid Tumor,"Drug: OBT076, a CD205-directed antibody-drug conjugate",Oxford BioTherapeutics Ltd,OBT076-001,"August 21, 2019","Cedars-Sinai, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Quantum Santa Fe, Santa Fe, New Mexico, United States|Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04064359
Principal Investigator,Yali Xu,,,NCT04145960,yali xu,yali,female,0.62,191,145,Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer,Recruiting,No Results Available,Breast Cancer,,Peking Union Medical College Hospital,PUMCH-BC500,"October 31, 2019","Peking Union Medical College Hospital, Beijing, China",https://ClinicalTrials.gov/show/NCT04145960
Principal Investigator,Huiping Li,Beijing Cancer Hospital,,NCT03792529,huiping li,huiping,female,0.89,28,147,Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China,Recruiting,No Results Available,Breast Cancer,Other: detect gene mutations of ctDNA and ctRNA,"Beijing Cancer Hospital|Predicine (Shanghai) Medical Technology Co., Ltd.",2017KT40,"January 3, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03792529
Principal Investigator,"Huiping Li, PhD",Beijing Cancer Hosptial,,NCT03945604,huiping li,huiping,female,0.89,28,461,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: SHR-1210 + Apatinib +Fluzoparib,"Jiangsu HengRui Medicine Co., Ltd.",FZPL-Ib-105,"May 10, 2019","Beijing Cancer Hosptial, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03945604
Principal Investigator,"Mahmoud A Alhussini, md","faculty of medicine , univeristy of alexandria",,NCT03799757,mahmoud a alhussini,mahmoud,male,0.98,21229,688,Using Bupivacaine Locally in the Mastectomy Drains to Control Postoperative Pain,Completed,No Results Available,"Pain, Postoperative|Breast Cancer",Drug: 40ml of 0.25% bupivacaine|Drug: 40ml of 0.9% normal saline,Alexandria University,malhussini001,"January 10, 2019","Faculty of Medicine, Main Univeristy Hospital, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT03799757
Principal Investigator,"Anthony Yu, MD",Memorial Sloan Kettering Cancer Center,,NCT03983382,anthony yu,anthony,male,0.99,98251,153,A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: Left Ventricular Ejection Fraction,Memorial Sloan Kettering Cancer Center,19-045,"June 12, 2019","Memorial Sloan Kettering Cancer Center @ BaskingRidge (Consent and follow-up only), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up), Commack, New York, United States|Memoral Sloan Kettering Westchester (Consent and Follow-up), Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Consent and Follow-up), Rockville Centre, New York, United States",https://ClinicalTrials.gov/show/NCT03983382
Principal Investigator,"Peter Schmid, MD PhD FRCP",Queen Mary University of London,,NCT03841747,peter schmid,peter,male,0.99,165452,154,Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: Pembrolizumab|Drug: Paclitaxel,Queen Mary University of London|Merck Sharp & Dohme Corp.|European Institute of Oncology,012342QM|2018-000188-10,"February 15, 2019",,https://ClinicalTrials.gov/show/NCT03841747
Principal Investigator,"Peter Schmid, MD,PhD,FRCP","Centre for Experimental Cancer Medicine (CECM), Barts Cancer Institute",,NCT03997123,peter schmid,peter,male,0.99,165452,567,Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC,Recruiting,No Results Available,Triple Negative Breast Neoplasms,Drug: Capivasertib|Drug: Paclitaxel|Drug: Placebo,AstraZeneca,D3614C00001,"June 25, 2019","Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Redlands, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, East Hills, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Midlothian, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Barretos, Brazil|Research Site, Florianópolis, Brazil|Research Site, Goiania, Brazil|Research Site, Londrina, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Chomutov, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Brest Cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Villejuif, France|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Gurgaon, India|Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Fukuoka-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Estado de México, Mexico|Research Site, Guadalajara, Mexico|Research Site, Juchitan, Mexico|Research Site, Mexico Distrito Federal, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Bacolod, Philippines|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Baguio City, Philippines|Research Site, Cagayan De Oro City, Philippines|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Las Pinas, Philippines|Research Site, Legazpi City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Grudziądz, Poland|Research Site, Konin, Poland|Research Site, Ostrołęka, Poland|Research Site, Poznan, Poland|Research Site, Racibórz, Poland|Research Site, Radom, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Arkhangelsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Ar Riyāḑ, Saudi Arabia|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Makkah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet deLlobregat, Spain|Research Site, Jaén, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umeå, Sweden|Research Site, Uppsala, Sweden|Research Site, Changhua, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Songkla, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Mersin, Turkey|Research Site, Edinburgh, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, York, United Kingdom",https://ClinicalTrials.gov/show/NCT03997123
Principal Investigator,Aleix Prat,Hospital Clínic de Barcelona,,NCT03802604,aleix prat,aleix,male,0.98,1280,155,Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer,Recruiting,No Results Available,Breast Cancer,Biological: Talimogene laherparepvec|Drug: Atezolizumab,SOLTI Breast Cancer Research Group|Amgen|Roche Pharma AG,SOLTI-1503|2018-001300-10,"January 14, 2019","Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT03802604
Principal Investigator,"Jinli Ma, MD, PhD",Fudan University,,NCT03856372,jinli ma,jinli,female,0.75,12,159,Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer,Recruiting,No Results Available,Breast Cancer,Radiation: Hypofractionated|Radiation: Conventional,Fudan University,FDRT-BC008,"February 27, 2019","Suzhou Municipal hospital, Suzhou, Jiangsu, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Huangpu Branch, Shanghai ninth people's hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT03856372
Principal Investigator,"Ursa Brown-Glaberman, MD",University of New Mexico Cancer Center,,NCT03983538,ursa brown-glaberman,ursa,female,0.77,162,160,Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Other: Mathematical modeling to predict response to chemotherapy,New Mexico Cancer Care Alliance,INST 1411,"June 12, 2019","University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT03983538
Principal Investigator,Navita Somaiah,The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust,,NCT03946202,navita somaiah,navita,female,0.88,24,163,KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Drug: Hydrogen Peroxide,"Institute of Cancer Research, United Kingdom|Kortuc Inc.",CCR5119|2019-001709-25,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT03946202
Study Director,"Audrey MAILLIEZ, MD",Centre Oscar Lambret,,NCT03795246,audrey mailliez,audrey,female,0.97,54814,166,Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Consultation|Biological: Biological Test|Procedure: Pelvic Ultrasound,Centre Oscar Lambret,KSF2-1707,"January 7, 2019","Centre Oscar Lambret, Lille, France",https://ClinicalTrials.gov/show/NCT03795246
Study Director,"Christine DECANTER, MD",Centre Hopsitalier Regional Universitaire de Lille - Hôpital Jeanne de Flandre,,NCT03795246,christine decanter,christine,female,0.99,91004,166,Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Consultation|Biological: Biological Test|Procedure: Pelvic Ultrasound,Centre Oscar Lambret,KSF2-1707,"January 7, 2019","Centre Oscar Lambret, Lille, France",https://ClinicalTrials.gov/show/NCT03795246
Principal Investigator,"Kunwei Shen, MD",Ruijin Hospital,,NCT04066790,kunwei shen,kunwei,male,1.0,4,168,Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,Terminated,No Results Available,Breast Cancer,Drug: Pyrotinib|Drug: nab-Paclitaxel|Drug: Trastuzumab|Drug: EC chemotherapy|Procedure: Surgery,"Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd.",RJBC1901,"August 26, 2019","Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04066790
Principal Investigator,"Fei Ma, MD",Cancer Hospital Chinese Academy of Medical Science,,NCT03994107,fei ma,fei,male,0.54,1207,169,Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Pegylated Liposomal Doxorubicin|Drug: Albumin-bound paclitaxel|Drug: Trastuzumab,"Peking Union Medical College|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-DMS-BC-17,"June 21, 2019","Fei Ma, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03994107
Principal Investigator,"Fei Ma, MD",Cancer Hospital Chinese Academy of Medical Science,,NCT04131231,fei ma,fei,male,0.54,1207,727,Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion,Not yet recruiting,No Results Available,Lung Cancer|Breast Cancer|Malignant Pleural Effusion,Drug: microparticles packaging methotrexate (MPs-MTX)|Drug: recombinant human interleukin-2(rhIL-2),Peking Union Medical College,NCC20180327,"October 18, 2019",,https://ClinicalTrials.gov/show/NCT04131231
Principal Investigator,Wonshik Han,Seoul National University Hospital,,NCT03900637,wonshik han,wonshik,male,1.0,6,170,PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate,Recruiting,No Results Available,Breast Cancer,Drug: Leuprorelin acetate|Drug: Letrozole|Genetic: MammaPrint,Seoul National University Hospital,PLATO study,"April 3, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT03900637
Study Chair,Jia-Yi Chen,Ruijin Hospital,,NCT03829553,jia-yi chen,jia-yi,female,1.0,1,172,Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment,Recruiting,No Results Available,Breast Cancer,Radiation: Hypofractionated radiotherapy|Radiation: Conventional radiotherapy,"Ruijin Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 10th People's Hospital|RenJi Hospital|The First Affiliated Hospital of the Fourth Military Medical University|First Affiliated Hospital of Chongqing Medical University",RJBC-HFRNI,"February 4, 2019","Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT03829553
Study Director,Study Director,Hospital General Universitario Gregorio Marañón,,NCT03860740,study director,study,male,0.65,20,174,Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Luminal B,Other: Exercise|Other: Stretching,Spanish Breast Cancer Research Group|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Faculty of Physical Activity and Sport Sciences (INEF),GEICAM/2014-09,"March 4, 2019","Hospital General Universitario Gregorio Marañón, Madrid, Spain",https://ClinicalTrials.gov/show/NCT03860740
Study Director,Study Director,Fundación Jimenez Díaz,,NCT03860740,study director,study,male,0.65,20,174,Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Luminal B,Other: Exercise|Other: Stretching,Spanish Breast Cancer Research Group|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Faculty of Physical Activity and Sport Sciences (INEF),GEICAM/2014-09,"March 4, 2019","Hospital General Universitario Gregorio Marañón, Madrid, Spain",https://ClinicalTrials.gov/show/NCT03860740
Study Director,Study director,"Hospital del Mar, Barcelona, Spain",,NCT03829306,study director,study,male,0.65,20,224,Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA),Recruiting,No Results Available,Advanced Breast Cancer,,"Spanish Breast Cancer Research Group|Roche Farma, S.A",GEICAM/2017-04,"February 4, 2019","Hospital Universitario Virgen Macarena, Sevilla, Andalucía, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Clínico Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hopsital Clínico San Carlos, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT03829306
Study Director,Study director,"Fundación Jiménez-Díaz, Madrid, Spain",,NCT03829306,study director,study,male,0.65,20,224,Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA),Recruiting,No Results Available,Advanced Breast Cancer,,"Spanish Breast Cancer Research Group|Roche Farma, S.A",GEICAM/2017-04,"February 4, 2019","Hospital Universitario Virgen Macarena, Sevilla, Andalucía, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Clínico Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hopsital Clínico San Carlos, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT03829306
Study Director,Study Director,Hospital Santa Creu i Sant Pau,,NCT03847220,study director,study,male,0.65,20,399,Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis,Completed,No Results Available,Breast Carcinoma Metastatic to the Bone,Diagnostic Test: BOMET-QoL questionnaire,Spanish Breast Cancer Research Group|Novartis Pharmaceuticals,Mabomet,"February 20, 2019","Hospital Universitario Virgen Del Rocío, Sevilla, Andalucia, Spain|Hospital General de Guadalajara, Guadalajara, Castilla-La Mancha, Spain|ICO Badalona Hospital Universitari Germans Trias I Pujol, Badalona, Cataluña, Spain|Hospital Universitari Clinic I Provincial, Barcelona, Cataluña, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Cataluña, Spain|Hospital Mutua de Terrassa, Barcelona, Cataluña, Spain|ICO Girona Hospital Dr. Josep Trueta, Gerona, Cataluña, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Cataluña, Spain|Fundació Althaia, Xarxa Assistencial de Manresa, Manresa, Cataluña, Spain|Hospital General Universitario de Alicante, Alicante, Cominidad Valenciana, Spain|Hospital Clínico Universitario de Valencia, Valencia, Comunidad Valenciana, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain|Centro Oncologico de Galicia, A Coruña, Galicia, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain|Hospital de Barbastro, Barbastro, Huesca, Spain",https://ClinicalTrials.gov/show/NCT03847220
Principal Investigator,"Enoch Huang, MD",Legacy Health System,,NCT03916068,enoch huang,enoch,male,0.98,959,175,Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy,Recruiting,No Results Available,Breast Cancer,Procedure: Hyperbaric Oxygen Therapy|Drug: Trental Pill|Dietary Supplement: Vitamin E,Legacy Health System,HBO001,"April 16, 2019","Legacy Emanuel Medical Center, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT03916068
Study Chair,"Oreste D Gentilini, MD","Breast Unit, San Raffaele University and Research Hospital, Milan, Italy",,NCT04101851,oreste d gentilini,oreste,male,0.99,1413,178,Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST,Not yet recruiting,No Results Available,Breast Cancer Female|Breast Cancer,Procedure: omission of SLNB,"Toralf Reimer, MD PhD|European Breast Cancer Reseach Association of Surgical Trialists|University Medicine Rostock, Rostock, Germany (sponsor)|Else Kröner-Fresenius-Stiftung (funding)|University of Rostock",EUBREAST-01,"September 24, 2019",,https://ClinicalTrials.gov/show/NCT04101851
Study Chair,"Toralf Reimer, Prof.","Department of Obstetrics and Gynecology, University of Rostock, Germany",,NCT04101851,toralf reimer,toralf,male,1.0,109,178,Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST,Not yet recruiting,No Results Available,Breast Cancer Female|Breast Cancer,Procedure: omission of SLNB,"Toralf Reimer, MD PhD|European Breast Cancer Reseach Association of Surgical Trialists|University Medicine Rostock, Rostock, Germany (sponsor)|Else Kröner-Fresenius-Stiftung (funding)|University of Rostock",EUBREAST-01,"September 24, 2019",,https://ClinicalTrials.gov/show/NCT04101851
Principal Investigator,"Catherine E Mosher, Ph.D.",Indiana University,,NCT03998618,catherine e mosher,catherine,female,0.98,50312,179,Telephone Support for Metastatic Breast Cancer Patients,Recruiting,No Results Available,Metastatic Breast Cancer,Behavioral: Acceptance and Commitment Therapy|Behavioral: Education/Support,Indiana University|National Cancer Institute (NCI)|Eskenazi Health,1812850942|R01CA230542,"June 26, 2019","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT03998618
Principal Investigator,Catherine L Carpenter,UCLA / Jonsson Comprehensive Cancer Center,,NCT03953157,catherine l carpenter,catherine,female,0.98,50312,639,Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors,Not yet recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Arthralgia|Postmenopausal|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8,Dietary Supplement: Dietary Intervention|Behavioral: Exercise Intervention|Other: Questionnaire Administration,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),18-001926|NCI-2019-02909|P30CA016042,"May 16, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT03953157
Study Director,"Catherine BARBE, MD","University Hospital, Tours",,NCT03816904,catherine barbe,catherine,female,0.98,50312,723,Involvement of SK3 Calcium Channel in Taxane Neuropathy,Recruiting,No Results Available,Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Prostate Cancer,Other: Blood samples,"University Hospital, Tours",RIPH3-RNI18/NEUROTAX|2018-A02884-51,"January 25, 2019","Department of Oncology, Hospital, Chinon, Chinon, France|Department of Medical Oncology, University Hospital, Tours, Tours, France",https://ClinicalTrials.gov/show/NCT03816904
Principal Investigator,"Anja Welt, Dr.",Essen University Hospital,,NCT03811418,anja welt,anja,female,0.98,28930,180,A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Withdrawn,No Results Available,Advanced Breast Cancer|HER2-positive Breast Cancer,Drug: Trastuzumab|Drug: Pertuzumab|Drug: Vinorelbine|Drug: Docetaxel,iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen,iOM-110383|2017-004749-25,"January 22, 2019","iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany",https://ClinicalTrials.gov/show/NCT03811418
Principal Investigator,"Arif Awan, MD",Ottawa Hospital Research Institute,,NCT04131933,arif awan,arif,male,0.97,18031,184,Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer,Recruiting,No Results Available,Breast Cancer,,Ottawa Hospital Research Institute,REaCT-Algorithm,"October 18, 2019","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04131933
Principal Investigator,Wenjin Yin,RenJi Hospital,,NCT04126525,wenjin yin,wenjin,female,0.52,23,187,Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,Recruiting,No Results Available,Breast Cancer Female,Drug: Pyrotinib,RenJi Hospital,KY2019-023,"October 15, 2019","Renji Hospital, Shanghai, China",https://ClinicalTrials.gov/show/NCT04126525
Principal Investigator,Shi Na,Peking Union Medical College Hospital,,NCT04145986,shi na,shi,female,0.53,1339,189,Evaluation of Prognostic Monitoring for Young Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer Female,,Peking Union Medical College Hospital,PUMCH-BC503,"October 31, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04145986
Principal Investigator,"Masakazu Toi, MD,PhD","Kyoto University, Professor of Breast Surgery Department",,NCT03969121,masakazu toi,masakazu,male,1.0,352,190,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",Recruiting,No Results Available,Breast Cancer Female|Hormone Receptor Positive Malignant Neoplasm of Breast,Drug: Palbociclib|Drug: Endocrine therapy,Kyoto Breast Cancer Research Network|Pfizer,OOTR-N016/KBCRN-B-003/HT-PAB,"May 31, 2019","Monash Health, Clayton, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|UNIMED Medical Institute, Hong Kong, Hong Kong|Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kyushu Cancer Center, Fukuoka, Japan|Sagara Hospital, Kagoshima, Japan|Kobe City Medical Center General Hospital, Kobe, Japan|Kyoto University Hospital, Kyoto, Japan|Aichi Cancer Center, Nagoya, Japan|Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Toranomon Hospital, Tokyo, Japan|Tokyo Metropolitan Komagome Hospital, Tokyo, Japan|Cancer Institute Hospital Of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Kanagawa Cancer Center, Yokohama, Japan|National Cancer Center, Korea, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Seoul National University College of Medicine, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Aju University Hospital, Suwon, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Sun Yat-Sen Cancer Center, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT03969121
Principal Investigator,"Louis WC Chow, MD,PhD",Organisation for Oncology and Translational Research (OOTR),,NCT03969121,louis wc chow,louis,male,0.97,26805,190,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",Recruiting,No Results Available,Breast Cancer Female|Hormone Receptor Positive Malignant Neoplasm of Breast,Drug: Palbociclib|Drug: Endocrine therapy,Kyoto Breast Cancer Research Network|Pfizer,OOTR-N016/KBCRN-B-003/HT-PAB,"May 31, 2019","Monash Health, Clayton, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|UNIMED Medical Institute, Hong Kong, Hong Kong|Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kyushu Cancer Center, Fukuoka, Japan|Sagara Hospital, Kagoshima, Japan|Kobe City Medical Center General Hospital, Kobe, Japan|Kyoto University Hospital, Kyoto, Japan|Aichi Cancer Center, Nagoya, Japan|Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Toranomon Hospital, Tokyo, Japan|Tokyo Metropolitan Komagome Hospital, Tokyo, Japan|Cancer Institute Hospital Of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Kanagawa Cancer Center, Yokohama, Japan|National Cancer Center, Korea, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Seoul National University College of Medicine, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Aju University Hospital, Suwon, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Sun Yat-Sen Cancer Center, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT03969121
Principal Investigator,"Takayuki Ueno, MD,PhD","Cancer Institute Hospital of JFCR, Department Director, Breast Surgical Oncology Department",,NCT03969121,takayuki ueno,takayuki,male,1.0,1236,190,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",Recruiting,No Results Available,Breast Cancer Female|Hormone Receptor Positive Malignant Neoplasm of Breast,Drug: Palbociclib|Drug: Endocrine therapy,Kyoto Breast Cancer Research Network|Pfizer,OOTR-N016/KBCRN-B-003/HT-PAB,"May 31, 2019","Monash Health, Clayton, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|UNIMED Medical Institute, Hong Kong, Hong Kong|Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kyushu Cancer Center, Fukuoka, Japan|Sagara Hospital, Kagoshima, Japan|Kobe City Medical Center General Hospital, Kobe, Japan|Kyoto University Hospital, Kyoto, Japan|Aichi Cancer Center, Nagoya, Japan|Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Toranomon Hospital, Tokyo, Japan|Tokyo Metropolitan Komagome Hospital, Tokyo, Japan|Cancer Institute Hospital Of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Kanagawa Cancer Center, Yokohama, Japan|National Cancer Center, Korea, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Seoul National University College of Medicine, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Aju University Hospital, Suwon, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Sun Yat-Sen Cancer Center, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT03969121
Principal Investigator,"Louis Tassy, MD",Institut Paoli-Calmettes,,NCT03959774,louis tassy,louis,male,0.97,26805,720,Assessment of Outpatient Digital Follow-up of Patients Over 70 Years of Age Undergoing Chemotherapy Treatment,Not yet recruiting,No Results Available,Breast Cancer|Colorectal Cancer|Lung Cancer,Device: IPC NET,Institut Paoli-Calmettes,E-SN@P PROJECT-IPC 2017-029,"May 22, 2019","Institut Sainte Catherine, Avignon, France|CHI des Alpes du Sud, Gap, France|Institut Paoli-Calmettes, Marseille, France|CHU Nice, Nice, France",https://ClinicalTrials.gov/show/NCT03959774
Principal Investigator,"Kathleen Lyons, ScD, OTR",Dartmouth-Hitchcock Medical Center,,NCT03915548,kathleen lyons,kathleen,female,0.98,8685,192,Optimizing Functional Recovery of Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer Female,Behavioral: The Behavioral Activation/ Problem Solving Intervention|Behavioral: Attention Control Condition,Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI),D18167|1R01CA225792-01A1,"April 16, 2019","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",https://ClinicalTrials.gov/show/NCT03915548
Study Director,Marianne Keessen,Modra Pharmaceuticals,,NCT03890744,marianne keessen,marianne,female,0.99,37801,196,ModraDoc006/r in Patients With Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer|Recurrent Breast Cancer,Drug: ModraDoc006/r,Modra Pharmaceuticals,M18DMB,"March 26, 2019","Institut Jules Bordet, Brussels, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Odense University Hospital, Odense, Denmark",https://ClinicalTrials.gov/show/NCT03890744
Principal Investigator,Marwa M El Awadly,"National Cancer Institute, Cairo University, Egypt",,NCT04148586,marwa m el awadly,marwa,female,0.98,8624,197,Trial Comparing 3 Schedules of Hypofractionated Whole Breast Irradiation in Females With Early Stage Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer Female,Other: Whole Breast Irradiation,"National Cancer Institute, Egypt",201617090.3,"November 1, 2019","NCI. Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04148586
Study Chair,"Alex Molassiotis, PhD",The Hong Kong Polytechnic University,,NCT03836872,alex molassiotis,alex,male,0.9,411319,198,Acupuncture for Joint Symptoms in Patients With Breast Cancer,Recruiting,No Results Available,Female Breast Cancer,Device: Acupuncture,The Hong Kong Polytechnic University|The Affiliated Hospital Of Southwest Medical University,HSEARS20180509004,"February 11, 2019","Xianliang Liu, Luzhou, China",https://ClinicalTrials.gov/show/NCT03836872
Study Chair,"Alex De Caluwe, MD",Jules Bordet Institute,,NCT03875573,alex de caluwe,alex,male,0.9,411319,490,"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:","Active, not recruiting",No Results Available,Luminal B,Drug: Durvalumab|Radiation: Stereotactic Body Radiotherapy|Drug: Oleclumab,Jules Bordet Institute|Institut Curie|AstraZeneca,IJB-LBC-NEOCHECKRAY-2018,"March 14, 2019","Institut Jules Bordet, Bruxelles, Belgium",https://ClinicalTrials.gov/show/NCT03875573
Principal Investigator,"Hung-Wen Lai, MD, PhD",Changhua Christian Hospital,,NCT04049305,hung-wen lai,hung-wen,male,1.0,4,199,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy for Breast Cancer,Recruiting,No Results Available,Breast Cancer Female,Device: Robotic assisted nipple sparing mastectomy (R-NSM)|Procedure: conventional nipple sparing mastectomy (C-NSM)|Procedure: Endoscopic assisted nipple sparing mastectomy (E-NSM),"Changhua Christian Hospital|Ministry of Science and Technology, Taiwan|Intuitive Surgical",CCH-IRB-190414-R|MOST 108-2314-B-371-006-,"August 8, 2019","European Institute of Oncology, Milan, Italy|Severance Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Shuang-Ho Hospital - Taipei Medical University, Taipei county, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan",https://ClinicalTrials.gov/show/NCT04049305
Principal Investigator,"Hung-Wen Lai, MD, PhD",Changhua Christian Hospital,,NCT04037852,hung-wen lai,hung-wen,male,1.0,4,205,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study,Recruiting,No Results Available,Breast Cancer Female,Device: robotic assisted nipple sparing mastectomy|Procedure: Endoscopic assisted nipple sparing mastectomy|Procedure: Conventional nipple sparing mastectomy,"Changhua Christian Hospital|Intuitive Surgical|Ministry of Science and Technology, Taiwan",CCH-IRB-190414-P|108-2314-B-371-006-,"July 30, 2019","Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Shuang-Ho Hospital - Taipei Medical University, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Tawian, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan",https://ClinicalTrials.gov/show/NCT04037852
Principal Investigator,"Stephanie Fine, MD",University of New Mexico Comprehensive Cancer Center,,NCT03979729,stephanie fine,stephanie,female,0.98,68107,201,Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography,Recruiting,No Results Available,Breast Cancer Screening,Other: Routine Screening Mammogram (3D + 2D)|Other: Routine Screening Mammogram (2D)|Other: No Screening Mammogram,New Mexico Cancer Care Alliance,INST UNM 1525,"June 7, 2019","University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT03979729
Principal Investigator,"stephanie SERVAGI VERNAT, MD",Institut Jean-Godinot,,NCT03902964,stephanie servagi vernat,stephanie,female,0.98,68107,466,Needs Assessment After Cancer in Patients Treated for Breast Cancer,Completed,No Results Available,Breast Neoplasm Female|Quality of Life|Fear Cancer,,Institut Jean-Godinot,2018-A02191-54,"April 4, 2019","Institut Jean Godinot, Reims, France",https://ClinicalTrials.gov/show/NCT03902964
Principal Investigator,"Melinda Stolley, PhD",Principal Investigator,,NCT03824145,melinda stolley,melinda,female,0.99,11132,206,Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer,"Active, not recruiting",No Results Available,Metastatic Breast Cancer,Behavioral: Lifestyle Intervention,Medical College of Wisconsin|Loyola University Chicago,27600,"January 31, 2019","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03824145
Principal Investigator,"Norman Wolmark, MD",NSABP Foundation Inc,,NCT04024800,norman wolmark,norman,male,0.99,7666,207,Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer,Recruiting,No Results Available,Triple-negative Breast Cancer,Biological: AE37 Peptide vaccine|Biological: Pembrolizumab,"Antigen Express, Inc|Merck Sharp & Dohme Corp.|NSABP Foundation Inc",NSABP FB-14|MK3475 KN 548,"July 18, 2019","Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central Illinois-Swansea, Swansea, Illinois, United States|West Virginia University, Morgantown, West Virginia, United States",https://ClinicalTrials.gov/show/NCT04024800
Principal Investigator,Geok H Lim,KK Women's and Children's Hospital,,NCT03878017,geok h lim,geok,female,0.81,118,208,A Novel Method of Clipped Axillary Lymph Node Localization Post Neoadjuvant Chemotherapy in Breast Cancer Patients .,"Active, not recruiting",No Results Available,Breast Cancer Female,Procedure: skin marking of clip axillary lymph node for localisation,KK Women's and Children's Hospital,2017/2037,"March 18, 2019","KK Women's and Children's Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT03878017
Study Chair,"Zhiyong Yu, PhD",Shandong Cancer Hospital and Institute,,NCT04143906,zhiyong yu,zhiyong,male,0.97,76,209,Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Drug: Vinorelbine|Drug: Gemcitabine|Drug: Carboplatin,Shandong Cancer Hospital and Institute,Shandong CHI-10,"October 30, 2019",,https://ClinicalTrials.gov/show/NCT04143906
Principal Investigator,"Liang Zhang, MD",Shandong Cancer Hospital and Institute,,NCT04143906,liang zhang,liang,male,0.79,1211,209,Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Drug: Vinorelbine|Drug: Gemcitabine|Drug: Carboplatin,Shandong Cancer Hospital and Institute,Shandong CHI-10,"October 30, 2019",,https://ClinicalTrials.gov/show/NCT04143906
Principal Investigator,"Bapsi Chakravarthy, MD",Vanderbilt Medical Center,,NCT03958721,bapsi chakravarthy,bapsi,female,0.86,7,210,Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer,Suspended,No Results Available,Resistant Breast Cancer|Non-metastatic Invasive Breast Cancer,Drug: Capecitabine|Radiation: Radiotherapy,"A Bapsi Chakravarthy, MD|Vanderbilt-Ingram Cancer Center",VICC BREP 1898|NCI-2019-03276,"May 22, 2019","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03958721
Principal Investigator,"Leonel Hernandez-Aya, M.D.",Washington University School of Medicine,,NCT03982004,leonel hernandez-aya,leonel,male,0.98,3876,213,Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Device: Epicutaneous cryoimmunotherapy|Drug: Topical imiquimod|Drug: Pembrolizumab|Other: Dermatologic Quality of Life Index|Other: Functional Assessment of Cancer Therapy|Drug: Intra-lesional GM-CSF|Device: Cry-AC|Procedure: Cutaneous tumor biopsy|Procedure: Peripheral blood draw for research,Washington University School of Medicine|Merck Sharp & Dohme Corp.,201911047,"June 11, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT03982004
Principal Investigator,"Marleen Kok, MD",NKI-AvL,,NCT04159818,marleen kok,marleen,female,0.99,4046,214,Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Nivolumab|Drug: Cisplatin|Drug: Low dose doxorubicin,The Netherlands Cancer Institute|Bristol-Myers Squibb,N19TON,"November 12, 2019","Antoni van Leeuwenhoek, Amsterdam, Netherlands",https://ClinicalTrials.gov/show/NCT04159818
Principal Investigator,"Marleen KEYAERTS, MD",Universitair Ziekenhuis Brussel,,NCT03924466,marleen keyaerts,marleen,female,0.99,4046,436,Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients,Recruiting,No Results Available,Metastatic Breast Carcinoma|Locally Advanced Breast Cancer,Drug: 68GaNOTA-Anti-HER2 VHH1,"Universitair Ziekenhuis Brussel|Kom op tegen Kanker (Stand-up-to-Cancer), the Flemish cancer society|Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.",UZBRU_VHH1_3|2016-002164-13,"April 23, 2019","Uz Brussel, Brussels, Brussel, Belgium",https://ClinicalTrials.gov/show/NCT03924466
Principal Investigator,"Marleen KEYAERTS, MD",Universitair Ziekenhuis Brussel,,NCT04168528,marleen keyaerts,marleen,female,0.99,4046,756,Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT,Recruiting,No Results Available,Malignant Solid Tumor|Breast Cancer|Head and Neck Cancer|Melanoma (Skin),Drug: 68GaNOTA-Anti-MMR-VHH2,Universitair Ziekenhuis Brussel|Kom Op Tegen Kanker,UZBRU_VHH2_1|2017-001471-23,"November 19, 2019","Uz Brussel, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04168528
Principal Investigator,Xichun Hu,Department of Oncology,,NCT04001621,xichun hu,xichun,male,0.67,3,221,Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Pyrotinib combined with capecitabine,"Fudan University|Jiangsu HengRui Medicine Co., Ltd.",HR-BLTN-003,"June 28, 2019","Fudan University Shanghai Cancer Center, Shanghai, China",https://ClinicalTrials.gov/show/NCT04001621
Principal Investigator,"Jennifer M Specht, MD",Fred Hutchinson Cancer Research Center,,NCT04020575,jennifer m specht,jennifer,female,0.98,90255,222,Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*),Recruiting,No Results Available,Metastatic Breast Cancer,Biological: huMNC2-CAR44 CAR T cells|Biological: huMNC2-CAR44 CAR T cells @ RP2D,Minerva Biotechnologies Corporation|Fred Hutchinson Cancer Research Center,10038,"July 16, 2019","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04020575
Principal Investigator,"Jennifer Kue, PhD",Ohio State University,,NCT04086771,jennifer kue,jennifer,female,0.98,90255,676,Southeast Asian Women's Health Project,Not yet recruiting,No Results Available,Breast Cancer|Cervical Cancer,Behavioral: Navigation|Other: Information only,"Ohio State University|University of South Florida|American Cancer Society, Inc.",2018B0521,"September 12, 2019","The Ohio State University, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04086771
Principal Investigator,"Jennifer Johnson, MD, PhD",Sidney Kimmel Cancer Center at Thomas Jefferson University,,NCT04028479,jennifer johnson,jennifer,female,0.98,90255,812,The Master Registry of Oncology Outcomes Associated With Testing and Treatment,Not yet recruiting,No Results Available,"Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma",Diagnostic Test: Biomarker Testing (L)|Drug: Systemic Treatment (T)|Other: Patient Reported Outcomes (P),Taproot Health,ROOT,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT04028479
Principal Investigator,"Raymond Bergan, MD",OHSU Knight Cancer Institute,,NCT04028479,raymond bergan,raymond,male,0.99,21679,812,The Master Registry of Oncology Outcomes Associated With Testing and Treatment,Not yet recruiting,No Results Available,"Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma",Diagnostic Test: Biomarker Testing (L)|Drug: Systemic Treatment (T)|Other: Patient Reported Outcomes (P),Taproot Health,ROOT,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT04028479
Study Chair,"Razelle Kurzrock, MD",Moores Cancer Center at University of California at San Diego,,NCT04028479,razelle kurzrock,razelle,female,1.0,23,812,The Master Registry of Oncology Outcomes Associated With Testing and Treatment,Not yet recruiting,No Results Available,"Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma",Diagnostic Test: Biomarker Testing (L)|Drug: Systemic Treatment (T)|Other: Patient Reported Outcomes (P),Taproot Health,ROOT,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT04028479
Principal Investigator,"Vivek Subbiah, MD",M.D. Anderson Cancer Center,,NCT04028479,vivek subbiah,vivek,male,0.99,3051,812,The Master Registry of Oncology Outcomes Associated With Testing and Treatment,Not yet recruiting,No Results Available,"Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma",Diagnostic Test: Biomarker Testing (L)|Drug: Systemic Treatment (T)|Other: Patient Reported Outcomes (P),Taproot Health,ROOT,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT04028479
Principal Investigator,"Tarah Ballinger, MD",Indiana University,,NCT04170920,tarah ballinger,tarah,female,0.94,107,225,Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs,Not yet recruiting,No Results Available,Breast Cancer|DCIS,Device: LifeExtend-AI,Indiana University,CTO-IUSCC-0715,"November 20, 2019",,https://ClinicalTrials.gov/show/NCT04170920
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03955939,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,227,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,Completed,No Results Available,Metastatic Breast Cancer,Drug: LY3295668 Erbumine|Drug: Endocrine therapy|Drug: Midazolam,Eli Lilly and Company,17249|J1O-MC-JZHC|2018-004183-61,"May 20, 2019","City of Hope National Medical Center, Duarte, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium",https://ClinicalTrials.gov/show/NCT03955939
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03988114,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,233,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",Withdrawn,No Results Available,Metastatic Breast Cancer,Drug: Abemaciclib|Drug: Nonsteroidal Aromatase Inhibitor (NSAI),Eli Lilly and Company,17395|I3Y-MC-JPCX|2019-001781-16,"June 17, 2019","Southern Cancer Center, P.C., Daphne, Alabama, United States|Arizona Oncology Associates, P.C., Tempe, Arizona, United States|Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|California Cancer Associates Research and Excellence (cCARE), Fresno, California, United States|Beaver Medical Group, Highland, California, United States|Pacific Cancer Care, Monterey, California, United States|St. Joseph Hospital, Orange, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|California Cancer Associates in Research and Excellence, San Marcos, California, United States|Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States|UCLA Medical Center, Torrance, California, United States|Memorial Hospital, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Center, Lone Tree, Colorado, United States|Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States|BayCare Medical Group, Clearwater, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Woodlands Medical Specialists, Pensacola, Florida, United States|Cancer Specialists of North Florida -St Augustine, Saint Augustine, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Summit Cancer Care, Savannah, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|York Hospital, York, Maine, United States|HCA Midwest, Kansas City, Missouri, United States|Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Valley Health System, Paramus, New Jersey, United States|Broome Oncology LLC, Johnson City, New York, United States|Abington Hematology Oncology Associates, Horsham, Pennsylvania, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Texas Oncology - Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology P.A., Dallas, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Marnie McFadden Ward Cancer Center, Dallas, Texas, United States|Texas Oncology P.A., El Paso, Texas, United States|Texas Oncology Flower Mound, Flower Mound, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Renovatio Clinical, Houston, Texas, United States|Texas Oncology - McAllen, McAllen, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology- Mesquite, Mesquite, Texas, United States|Texas Oncology - Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology - Paris, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|US Oncology, The Woodlands, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Wichital Falls Texoma Cancer Center, Wichita Falls, Texas, United States|Intermountain Medical Center, Saint George, Utah, United States|Hematology Oncology Associates of Fredericksburg Inc., Fredericksburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Centro de Oncologia e Investigacion Buenos Aires, Berazategui, Buenos Aires, Argentina|CEMEDIC, Caba, Buenos Aires, Argentina|CENIT Centro de Neurociencias, Investigación y Tratamiento, Caba, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucumán, Tucuman, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Parque, Salta, Argentina|Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan, San Juan, Argentina|Centro para la Atencion Integral del Paciente Oncologico, Tucumain, Argentina|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinik Innsbruck, Innsbruck, Tirol, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|AKH, Wien, Austria|Algemeen Ziekenhuis St Jan Brugge, Brugge, Belgium|Hopital De Jolimont, Haine-St.- Paul, Belgium|VZW REgional Ziekenhuis Jan Yperman, Ieper, Belgium|Clinique Saint Pierre Ottignies, Ottignies, Belgium|Núcleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Instituto de Cancer de Londrina, Londrina, Parana, Brazil|Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Hospital São Lucas - PUCRS - ONCOLOGY, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto COI de Pesquisa Educação e Gestão, Rio de Janeiro, RJ, Brazil|Hospital Bruno Born de Lajeado, Lajeado, RS, Brazil|Fundação PIO XII, Barretos, Sao Paulo, Brazil|Hospital de Base Fac de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Hospital das Clinicas da FMRP, Ribeirao Preto, São Paulo, Brazil|INCA - Instituto Nacional Do Cancer, Rio de Janeiro, Brazil|Fundacao Antonio Prudente-Hosp. do Cancer AC Camargo, Sao Paulo, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, São Paulo, Brazil|Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária, São Paulo, Brazil|Clinica Onco Star, São Paulo, Brazil|Hämatologisch-Onkologische Praxis Augsburg, Augsburg, Bavaria, Germany|Universität Leipzig - Universitätsklinikum, Leipzig, Sachsen, Germany|St. Vincenz-Krankenhaus GmbH-Frauen- und Kinderklinik St. Louise, Paderborn, Germany|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, Italy|Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro, Candiolo, Torino, Italy|Policlinico S. Orsola Malpighi - Universita di Bologna, Bologna, Italy|Azienda Ospedaliera Universitaria Ospedale San Martino di Genova, Genova, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|Centro di Riferimento Oncologico, Udine, Italy|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|Ad-Vance Medical Research, Ponce, Puerto Rico|E-DA Cancer Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Koo Foundation Sun Yan-Sen Cancer Center, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT03988114
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04031885,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,238,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",Suspended,No Results Available,Metastatic Breast Cancer,Drug: Abemaciclib|Drug: Fulvestrant|Drug: Standard Chemotherapy,Eli Lilly and Company,17320|I3Y-MC-JPCU,"July 24, 2019","Scottsdale Healthcare Hospitals, Avondale, Arizona, United States|University of Arizona Cancer Center, Phoenix, Arizona, United States|Yuma Regional Cancer Center, Yuma, Arizona, United States|CARTI Cancer Center, Little Rock, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Compassionate Cancer Care Medical Group Inc, Corona, California, United States|Chan Soon- Shiong Institute for Medicine, Costa Mesa, California, United States|Chan Soon- Shiong Institute for Medicine, El Segundo, California, United States|Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Scripps Clinic, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|Univ of California Irvine College of Medicine, Orange, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Emad Ibrahim, MD, INC, Redlands, California, United States|Compassionate Cancer Care Medical Group Inc, Riverside, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Millennium Oncology, Hollywood, Florida, United States|Ocala Oncology, P.A., Ocala, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Candler Medical Oncology Practice, Savannah, Georgia, United States|Tift Regional Health System Anita Stewart Oncology Center, Tifton, Georgia, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Touro Infirmary, New Orleans, Louisiana, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, United States|York Hospital, York, Maine, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Baptist Cancer Center, Oxford, Mississippi, United States|St. Francis Medical Center, Grand Island, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|OptumCare Cancer Care, Las Vegas, Nevada, United States|Carol Simon Cancer Center at Overlook Medical Center, Summit, New Jersey, United States|Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY At Stony Brook, Stony Brook, New York, United States|White Plains Hospital, White Plains, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cancer Care Associates of York, York, Pennsylvania, United States|Womens and Infants, Providence, Rhode Island, United States|Baptist Cancer Center, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Centro Integrado de Cancer del Sur, PSC, Coto Laurel, Puerto Rico|Bella Vista Oncology Group, Mayaguez, Puerto Rico|Ponce Medical School, Ponce, Puerto Rico|Centro de Cancer de la Mujer, Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04031885
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04188548,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,441,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,Recruiting,No Results Available,Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Endometrial Cancer,Drug: LY3484356|Drug: Abemaciclib,Eli Lilly and Company,17502|J2J-MC-JZLA|2019-003581-41,"December 6, 2019","Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Francisco, San Francisco, California, United States|University of Miami School of Medicine, Miami, Florida, United States|Winship Cancer Center Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|US Oncology, The Woodlands, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Inova Dwight and Martha Schar Center Institute, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Linear Clinical Research Ltd, Nedlands, Western Australia, Australia|Institut Curie, Paris CEDEX 05, France|Hospital Universitari Vall d'Hebron, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04188548
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04099277,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,777,A Study of LY3435151 in Participants With Solid Tumors,Terminated,No Results Available,Solid Tumor|Triple-negative Breast Cancer|Gastric Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Cervical Carcinoma|High Grade Serous Ovarian Carcinoma|Hepatocellular Carcinoma|Undifferentiated Pleomorphic Sarcoma|Leiomyosarcoma,Drug: LY3435151|Drug: Pembrolizumab,Eli Lilly and Company,17364|J1Q-MC-JZIA,"September 23, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan",https://ClinicalTrials.gov/show/NCT04099277
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04148937,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,835,A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer,Recruiting,No Results Available,Advanced Cancer,Drug: LY3475070|Drug: Pembrolizumab,Eli Lilly and Company|Merck Sharp & Dohme Corp.,17504|J2I-MC-JZMA|2019-003270-64|Keynote A57,"November 4, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States|Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States|Florida Cancer Specialists ORLANDO/DDU, Lake Mary, Florida, United States|Washington University Medical School, Saint Louis, Missouri, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Marsden Hospital, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT04148937
Principal Investigator,"Jonathan A. Haas, MD",NYU Winthrop Hospital,,NCT03946683,jonathan a. haas,jonathan,male,0.99,87986,228,Cyberknife for Early Stage Breast Cancer,"Active, not recruiting",No Results Available,Early Stage Breast Cancer,Radiation: Cyberknife for Early Stage Breast Cancer,NYU Langone Health,18-01721,"May 13, 2019","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03946683
Principal Investigator,Dr Jonathan Krell,Imperial College London,,NCT03934827,jonathan krell,jonathan,male,0.99,87986,801,MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour,Recruiting,No Results Available,Melanoma|Breast Cancer|Uterine Cancer|Ovarian Cancer|Prostate Cancer|Urethral Cancer|Bladder Cancer|Renal Cancer|Lung Cancer|Head and Neck Cancer,Drug: MRx0518 Capsules|Drug: MRx0518/placebo Capsules,Imperial College London|4D pharma plc,C/35/2017,"May 2, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT03934827
Principal Investigator,Jose Enrique Alés-Martínez,Complejo Hospitalario de Ávila,,NCT03931551,jose enrique alés-martínez,jose,male,0.98,451671,229,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated or Homologous Recombination Deficient (HRD) Advanced Breast Cancer",Recruiting,No Results Available,Advanced Breast Cancer,Drug: Olaparib [Lynparza®] plus Trastuzumab [Herceptin®],MedSIR,MedOPP168,"April 30, 2019","Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional y Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Fundación Onkologikoa, San Sebastián, Spain|Hospital Clínico Universitario de Santiago -CHUS, Santiago De Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Complejo Asistencial de Àvila Hospital Ntra. Sra. de Sonsoles, Ávila, Spain",https://ClinicalTrials.gov/show/NCT03931551
Principal Investigator,"Jose Pablo Leone, MD",Dana-Farber Cancer Institute,,NCT03846583,jose pablo leone,jose,male,0.98,451671,302,Tucatinib + Abemaciclib + Herceptin for HER2+ MBC,Not yet recruiting,No Results Available,Breast Cancer,Drug: Tucatinib|Drug: Abemaciclib|Drug: Trastuzumab|Drug: Aromatase Inhibitor,Dana-Farber Cancer Institute|Eli Lilly and Company,18-621,"February 19, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|The Broad Institute of MIT, Cambridge, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03846583
Principal Investigator,"Jose J Jimenez-Moleon, MD, PhD",Instituto de Investigación Biosanitaria de Granada ibs.GRANADA,,NCT04174391,jose j jimenez-moleon,jose,male,0.98,451671,313,Lifestyles and Breast Cancer,Not yet recruiting,No Results Available,Malignant Tumor of Breast,Behavioral: Mediterranean diet supplemented with extra-virgin olive oil|Behavioral: Low-fat diet,University of Navarra|Instituto de Salud Carlos III,2019.046,"November 22, 2019","University of Cantabria, Santander, Cantabria, Spain|University of Navarra-Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain|Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain|University of Jaen, Jaen, Spain",https://ClinicalTrials.gov/show/NCT04174391
Principal Investigator,"Estefania A Toledo, MD, MPH, PhD",University of Navarra (IdiSNA),,NCT04174391,estefania a toledo,estefania,female,0.99,11749,313,Lifestyles and Breast Cancer,Not yet recruiting,No Results Available,Malignant Tumor of Breast,Behavioral: Mediterranean diet supplemented with extra-virgin olive oil|Behavioral: Low-fat diet,University of Navarra|Instituto de Salud Carlos III,2019.046,"November 22, 2019","University of Cantabria, Santander, Cantabria, Spain|University of Navarra-Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain|Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain|University of Jaen, Jaen, Spain",https://ClinicalTrials.gov/show/NCT04174391
Principal Investigator,"Trinidad Dierssen-Sotos, MD, PhD",University of Cantabria,,NCT04174391,trinidad dierssen-sotos,trinidad,female,0.92,1047,313,Lifestyles and Breast Cancer,Not yet recruiting,No Results Available,Malignant Tumor of Breast,Behavioral: Mediterranean diet supplemented with extra-virgin olive oil|Behavioral: Low-fat diet,University of Navarra|Instituto de Salud Carlos III,2019.046,"November 22, 2019","University of Cantabria, Santander, Cantabria, Spain|University of Navarra-Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain|Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain|University of Jaen, Jaen, Spain",https://ClinicalTrials.gov/show/NCT04174391
Principal Investigator,"Marina Pollan, Md, PhD",Instituto de Salud Carlos III,,NCT04174391,marina pollan,marina,female,0.98,109549,313,Lifestyles and Breast Cancer,Not yet recruiting,No Results Available,Malignant Tumor of Breast,Behavioral: Mediterranean diet supplemented with extra-virgin olive oil|Behavioral: Low-fat diet,University of Navarra|Instituto de Salud Carlos III,2019.046,"November 22, 2019","University of Cantabria, Santander, Cantabria, Spain|University of Navarra-Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain|Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain|University of Jaen, Jaen, Spain",https://ClinicalTrials.gov/show/NCT04174391
Study Director,"Jose M Maldonado, PhD, MSc",University of Barcelona,,NCT03985267,jose m maldonado,jose,male,0.98,451671,512,A New Mindfulness Approach Called Swinging Effect Intervention for Women With Breast Cancer,"Active, not recruiting",No Results Available,Anxiety|Stress|Self Efficacy|Depression|Breast Cancer Female|Hopefulness,Behavioral: Mindfulness based Swinging Effect Intervention,University of Barcelona,2018/14-01,"June 13, 2019","Ozel Oz Psikoloji Aile Danisma Merkezi (Oz Psychology Family Counselling Centre), Izmir, Konak, Turkey|EgeMed Hospital, Aydın, Soke, Turkey",https://ClinicalTrials.gov/show/NCT03985267
Study Chair,"Gilmar M Santos, PhD",Universidade do Estado de Santa Catarina this account disabled,,NCT04084600,gilmar m santos,gilmar,male,0.97,484,230,Effects of Manual Therapy on Chronic Pain and Functionality of Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer,Other: Kinesiotherapy Protocol|Other: Manual Therapy Protocol|Other: Traditional Massage,University of the State of Santa Catarina,Manual Therapy BCS,"September 10, 2019","Santa Catarina State University, Florianópolis, Santa Catarina, Brazil",https://ClinicalTrials.gov/show/NCT04084600
Principal Investigator,Chang Chen,Peking Union Medical College Hospital,,NCT04145973,chang chen,chang,male,0.85,3059,237,Evaluation of Prognostic Monitoring for Breast Cancer Patients With Recurrence and Metastasis After Surgery,Recruiting,No Results Available,Breast Cancer,,Peking Union Medical College Hospital,PUMCH-BC501,"October 31, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04145973
Principal Investigator,"Liv Veldeman, dr",University of Ghent,,NCT04091542,liv veldeman,liv,female,0.84,1285,239,Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment,Recruiting,No Results Available,Breast Cancer,Device: Optiflow/Ventilator,"University Hospital, Ghent",EC2019/0127,"September 16, 2019","University Hospital - Radiotherapy Department, Ghent, Belgium",https://ClinicalTrials.gov/show/NCT04091542
Principal Investigator,"Hesham Elghazaly, Professor",Ain Shams University,,NCT04012918,hesham elghazaly,hesham,male,0.97,3513,240,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study",Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Capecitabine plus aromatase inhibitor|Drug: A.I.,Ain Shams University,Combined CTH and HT in MBC,"July 9, 2019","Clinical oncology department, Faculty of medicine, Ain Shams University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04012918
Principal Investigator,"Antonio Forte, MD, PhD",Mayo Clinic,,NCT03981718,antonio forte,antonio,male,0.99,328654,243,Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Fat grafting,Mayo Clinic,19-002792,"June 11, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT03981718
Principal Investigator,"Antonio Llombart, PdH",MedSIR,,NCT03819010,antonio llombart,antonio,male,0.99,328654,404,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",Completed,No Results Available,Breast Cancer,Drug: Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Drug: Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib,MedSIR|Pfizer,MedOPP199,"January 28, 2019","Hospital da Luz, Lisboa, Portugal|Hospital Fernando Fonseca, Lisboa, Portugal|Portuguese Institute of Oncology of Oporto, Oporto, Portugal|ICO Badalona, Badalona, Barcelona, Spain|ICO l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Jaén, Jaen, Jaén, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain|H. Vall Hebrón, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Onkologikoa, Donostia, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT03819010
Principal Investigator,"Antonio Toesca, MD",European Institute of Oncology,,NCT04108117,antonio toesca,antonio,male,0.99,328654,742,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Enrolling by invitation,No Results Available,Postoperative Complications|Recurrence|Breast Neoplasms|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|Surgery|Surgery--Complications,Procedure: Robotic nipple sparing mastectomy,"Severance Hospital|European Institute of Oncology|Changhua Christian Hospital|Gustave Roussy, Cancer Campus, Grand Paris",4-2019-0834,"September 27, 2019","Yonsei University College of Medicine, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04108117
Principal Investigator,"Hyung Seok Park, MD, PhD",Severance Hospital,,NCT04108117,hyung seok park,hyung,male,0.95,821,742,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Enrolling by invitation,No Results Available,Postoperative Complications|Recurrence|Breast Neoplasms|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|Surgery|Surgery--Complications,Procedure: Robotic nipple sparing mastectomy,"Severance Hospital|European Institute of Oncology|Changhua Christian Hospital|Gustave Roussy, Cancer Campus, Grand Paris",4-2019-0834,"September 27, 2019","Yonsei University College of Medicine, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04108117
Principal Investigator,"Kathy Miller, MD",Indiana University,,NCT04134884,kathy miller,kathy,female,0.98,11449,244,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor,Drug: Talazoparib|Drug: ASTX727,"Kathy Miller|Pfizer|Astex Pharmaceuticals, Inc.|Van Andel Institute Stand Up to Cancer Team|Indiana University",CTO-IUSCC-0684,"October 22, 2019","Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT04134884
Principal Investigator,"Corrado Tinterri, MD",Istituto Clinico Humanitas,,NCT04019678,corrado tinterri,corrado,male,0.99,6857,247,Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.,Recruiting,No Results Available,Breast Cancer,Procedure: Omission of Axillary dissection|Procedure: Axillary dissection,Istituto Clinico Humanitas,651,"July 15, 2019","Istituto Clinico Humanitas, Rozzano, MI, Italy",https://ClinicalTrials.gov/show/NCT04019678
Principal Investigator,Xi Shen,Peking Union Medical College Hospital,,NCT04145947,xi shen,xi,male,0.53,406,249,Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients,Recruiting,No Results Available,Triple Negative Breast Cancer,,Peking Union Medical College Hospital,PUMCH-BC502,"October 31, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04145947
Principal Investigator,"Zeina Nahleh, MD","Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center",,NCT04205786,zeina nahleh,zeina,female,0.98,1276,252,Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer,Not yet recruiting,No Results Available,HR-positive Breast Cancer,Dietary Supplement: Vitamin B12|Other: Blood collection|Other: Brief Pain Inventory - Short Form survey|Other: FACT-ES Trial Outcome Index (Version 4)|Other: Questionnaire to Assess Adherence to Aromatase Inhibitors|Other: Demographics Questionnaire,Case Comprehensive Cancer Center,CASE5119,"December 19, 2019","Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04205786
Principal Investigator,"ICing Hou, PhD",National Yang Ming University,,NCT04174248,icing hou,icing,male,0.57,14,253,Breast Cancer Self-Management Mobile Care Application Intervention in the Quality of Life,Completed,No Results Available,Breast Cancer|Quality of Life,Other: BCSMS App,National Yang Ming University,YM107109E,"November 22, 2019","National Yang-Ming University, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04174248
Principal Investigator,"Jean Marc Bourque, MD",Ottawa Hospital Research Institute,,NCT03948568,jean marc bourque,jean,male,0.95,196185,255,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),Recruiting,No Results Available,Early-stage Breast Cancer,Combination Product: Endocrine Therapy and Radiotherapy,Ottawa Hospital Research Institute,OTT 18-02,"May 14, 2019","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03948568
Principal Investigator,"Sharon McGee, MD",Ottawa Hospital Research Institute,,NCT03948568,sharon mcgee,sharon,female,0.98,33532,255,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),Recruiting,No Results Available,Early-stage Breast Cancer,Combination Product: Endocrine Therapy and Radiotherapy,Ottawa Hospital Research Institute,OTT 18-02,"May 14, 2019","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03948568
Study Director,"Jean Olivier Arnaud, Director",Assistance Publique Hôpitaux de Marseille,,NCT03837054,jean olivier arnaud,jean,male,0.95,196185,643,Does Chemotherapy Train the Mutation of the Pig-A Gene? (PIGA),Recruiting,No Results Available,Breast Cancer Female,Biological: Blood collection and Micronuclei assay on binucleate lymphocytes in culture,Assistance Publique Hopitaux De Marseille,2018-63,"February 11, 2019",": Service de Gynécologie Obstétrique Hôpital Nord, Marseille, Marseille Cedex 20, France",https://ClinicalTrials.gov/show/NCT03837054
Principal Investigator,Rajendra Badwe,"Director, tata Memorial Centre",,NCT03797482,rajendra badwe,rajendra,male,0.99,877,257,A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer,Recruiting,No Results Available,Breast Cancer Female,Procedure: Intra-operative Tumor Tissue Biopsy,Tata Memorial Hospital,Protocol 254,"January 9, 2019","Tata Memorial Center, Mumbai, Maharashtra, India",https://ClinicalTrials.gov/show/NCT03797482
Principal Investigator,Tao Sun,Liaoning Tumor Hospital & Institute,,NCT03932526,tao sun,tao,male,0.86,1883,259,Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer,Not yet recruiting,No Results Available,Triple-negative Breast Cancer,Drug: Vinorelbine + placebo|Drug: Vinorelbine + Apatinib,Liaoning Tumor Hospital & Institute,STao-003,"April 30, 2019",,https://ClinicalTrials.gov/show/NCT03932526
Principal Investigator,"Patricia Tang, MD",Tom Baker Cancer Centre,,NCT04149444,patricia tang,patricia,female,0.98,132232,262,A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer,Withdrawn,No Results Available,Metastatic Triple Negative Breast Cancer,Drug: Trifluridine/Tipiracil,AHS Cancer Control Alberta|Tom Baker Cancer Centre,OZM-103,"November 4, 2019","Tom Baker Cancer Centre, Calgary, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04149444
Principal Investigator,Yu Jiang,West China Hospital,,NCT03953833,yu jiang,yu,male,0.54,4500,265,B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer,Recruiting,No Results Available,HER2-positive Breast Cancer,Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.,"Shanghai Pharmaceuticals Holding Co., Ltd",B003-101,"May 17, 2019","West China Hospital of Sichuan University, Chengdu, Sichuan, China",https://ClinicalTrials.gov/show/NCT03953833
Principal Investigator,Yongsheng Wang,West China Hospital,,NCT03953833,yongsheng wang,yongsheng,male,0.98,45,265,B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer,Recruiting,No Results Available,HER2-positive Breast Cancer,Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.,"Shanghai Pharmaceuticals Holding Co., Ltd",B003-101,"May 17, 2019","West China Hospital of Sichuan University, Chengdu, Sichuan, China",https://ClinicalTrials.gov/show/NCT03953833
Principal Investigator,"Yu Zhigang, DR.",The Second Hospital of Shandong University,,NCT03847818,yu zhigang,yu,male,0.54,4500,278,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer,Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin,Shandong University,495573096,"February 20, 2019",,https://ClinicalTrials.gov/show/NCT03847818
Principal Investigator,Wang Shu,Peking University People's Hospital,,NCT03978754,wang shu,wang,male,0.64,3532,266,Assessment of Breast Cancer-Related Arm Lymphedema,Recruiting,No Results Available,Breast Neoplasms,Diagnostic Test: ICG、CM、VM、BIS、self-report,Peking University People's Hospital,PUPH18050101,"June 7, 2019","Peking University People's Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03978754
Study Director,"Xiaobo Yan, MD",The Second Affiliated Hospital of Zhejiang University School of Medicidne,,NCT04158843,xiaobo yan,xiaobo,male,0.84,79,267,Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis,Recruiting,No Results Available,Breast Cancer|Oligometastasis,Procedure: Radical resection|Radiation: Radical radiotherapy|Other: Palliative treatment,"xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University",BOMB,"November 12, 2019","Institute of Cancer Research and Basic Medical Sciences, CAS Cancer Hospital, University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), Hangzhou, Zhejiang, China|Jiaxing Second Hospital, Jiaxing, Zhejiang, China|The Central Hospital of Lishui, Lishui, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04158843
Principal Investigator,"Kent Hoskins, M.D.",University of Illinois at Chicago,,NCT04083963,kent hoskins,kent,male,0.98,5262,268,Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide,University of Illinois at Chicago,2019-0550,"September 10, 2019","University of Illinois, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04083963
Principal Investigator,"Kent Hoskins, M.D.",University of Illinois at Chicago,,NCT04082117,kent hoskins,kent,male,0.98,5262,442,Uptake of Genetic Counseling Among African American Women,Recruiting,No Results Available,Breast Cancer Risk,Behavioral: Educational video,University of Illinois at Chicago,2016-1219,"September 9, 2019","University of Illinois Health System, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04082117
Study Chair,"Xuexin He, MD","Seaond Affiliated Hospital, Zhejiang University, School of Medicine",,NCT04158856,xuexin he,xuexin,male,0.6,5,270,"Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer",Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Pyrotinib|Drug: Trastuzumab,"xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University",SHERO,"November 12, 2019",,https://ClinicalTrials.gov/show/NCT04158856
Study Director,"xuexin he, MD",The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU),,NCT04158947,xuexin he,xuexin,male,0.6,5,408,A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone,Recruiting,No Results Available,HER2-positive Breast Cancer|Brain Metastases,Drug: Afatinib|Drug: T-DM1,"xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University",HER2BAT,"November 12, 2019","Peking University International Hospital, Beijing, Beijing, China|Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China|Kiang Wu Hospital, Macao, Macao, China|The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), Hangzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04158947
Principal Investigator,"Gwo Fuang Y Ho, FRCR",University of Malaya,,NCT03989089,gwo fuang y ho,gwo,male,0.83,18,274,Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation,Not yet recruiting,No Results Available,HER2-Negative Breast Cancer,Drug: Pembrolizumab,"University of Malaya|Merck Sharp & Dohme (MSD)|National University Hospital, Singapore|Cancer Research Malaysia",IIT-UM2018001,"June 18, 2019","University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",https://ClinicalTrials.gov/show/NCT03989089
Principal Investigator,"Pamela N Munster, MD","University of California, San Francisco",,NCT04190056,pamela n munster,pamela,female,0.98,31042,275,Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer,Not yet recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,Biological: Pembrolizumab|Drug: Tamoxifen|Drug: Vorinostat,"University of California, San Francisco|Merck Sharp & Dohme Corp.",197520|NCI-2019-07572,"December 9, 2019","University of California, San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04190056
Principal Investigator,"Matthias Schwab, Prof. Dr.",Margarete Fischer-Bosch Institute of Clinical Pharmacology,,NCT03931928,matthias schwab,matthias,male,1.0,26402,280,Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer|DCIS,Drug: (Z)-Endoxifen supplementation according to genotype|Drug: (Z)-Endoxifen supplementation according to plasma levels,Robert Bosch Gesellschaft für Medizinische Forschung mbH,IKP275 / GBG91|2016-000418-31,"April 30, 2019",,https://ClinicalTrials.gov/show/NCT03931928
Principal Investigator,"Matthias Wilhelm, Prof. Dr.","University Clinic for Cardiology, University Hospital Berne",,NCT03850171,matthias wilhelm,matthias,male,1.0,26402,669,Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study,Recruiting,No Results Available,Breast Neoplasm Female|Lymphoma|Cardiotoxicity|Anthracyclines|Physical Activity,Other: Exercise Training,"University Hospital Inselspital, Berne|Spital STS AG|Bürgerspital Solothurn|Lindenhofspital|University of Bern",CAPRICE,"February 21, 2019","Lindenhofgruppe, Bern, Switzerland|University Clinic for Cardiology, Bern, Switzerland|Bürgerspital Solothurn, Solothurn, Switzerland|Spital STS AG, Thun, Switzerland",https://ClinicalTrials.gov/show/NCT03850171
Principal Investigator,"Alice Ho, MD",Massachusetts General Hospital,,NCT03945721,alice ho,alice,female,0.98,68971,282,A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients,Recruiting,No Results Available,Triple Negative Breast Cancer|Residual Disease,Drug: Niraparib|Radiation: Radiation Therapy,"Massachusetts General Hospital|Tesaro, Inc.",19-055,"May 10, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03945721
Principal Investigator,"Ketki Raina, PhD, OTR/L",University of Toledo,,NCT04160182,ketki raina,ketki,female,0.95,19,283,Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer|Fatigue,Behavioral: Energy Conservation Work Simplification Education,Ketki Raina|University of Toledo Medical Center|University of Toledo Health Science Campus,UT BCS ECS Study,"November 12, 2019","University of Toledo, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT04160182
Principal Investigator,"Brent Rexer, MD, PhD",Vanderbilt Medical Center,,NCT03962647,brent rexer,brent,male,0.99,4210,284,A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer,Recruiting,No Results Available,Estrogen Receptor-positive Breast Cancer,Dietary Supplement: 2-Week Ketogenic Diet|Drug: Letrozole,Vanderbilt-Ingram Cancer Center,VICC BRE 18108|NCI-2019-03071,"May 24, 2019","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03962647
Study Director,"Evelyn Rustia, MD","Seattle Genetics, Inc.",,NCT03975647,evelyn rustia,evelyn,female,0.98,12188,285,A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer,Recruiting,No Results Available,HER2-positive Breast Cancer,Drug: tucatinib|Drug: placebo|Drug: T-DM1,"Seattle Genetics, Inc.",SGNTUC-016,"June 5, 2019","University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States|Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|California Cancer Associates for Research and Excellence Inc (cCARE), Encinitas, California, United States|UCLA Medical Center / David Geffen School of Medicine, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States|University of California Irvine - Newport, Orange, California, United States|University of California Davis, Sacramento, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States|University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States|Cancer Centers of Colorado - Denver, Denver, Colorado, United States|Poudre Valley Health System (PVHS), Fort Collins, Colorado, United States|SCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette, Colorado, United States|Helen F. Graham Cancer Center / Christiana Care Health Systems, Newark, Delaware, United States|Florida Cancer Specialists - South Region, Fort Myers, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|AdventHealth Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists - North Region, Saint Petersburg, Florida, United States|Florida Cancer Specialists - East West Palm Beach, FL (SCRI), West Palm Beach, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CHI Saint Joseph Medical Group Cancer Care Center, Lexington, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center -Weinberg Center, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders/RCCA, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|North Mississippi Medical Center Hematology Oncology - Tupelo, Tupelo, Mississippi, United States|Saint Luke's Cancer Institute LLC, Kansas City, Missouri, United States|HCA Midwest Health Kansas City, Kansas City, Missouri, United States|Washington University in St Louis, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Summit Medical Group, Florham Park, New Jersey, United States|Rutgers Cancer Institute of New Jersey / Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Brig Center for Cancer Care and Survivorship, Knoxville, Tennessee, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders: Fortworth, Fort Worth, Texas, United States|Texas Oncology - Houston Memorial City, Houston, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Saint Francis Hospital / Bon Secours - Virginia, Midlothian, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Swedish Cancer Institute - Edmonds, Edmonds, Washington, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT03975647
Study Director,"Dr. yuan, Prof","Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT03947736,yuan,yuan,male,0.56,1393,287,Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR,Recruiting,No Results Available,Recurrent or Metastatic Breast Cancer,Diagnostic Test: cfDNA was detected by dPCR,Chinese Academy of Medical Sciences|Questgenomics,NCC1824,"May 13, 2019","Chinese Academy of Medical Sciences, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03947736
Principal Investigator,Yuan Yuan,City of Hope Medical Center,,NCT03853707,yuan yuan,yuan,male,0.56,1393,379,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Atezolizumab|Drug: Capecitabine|Drug: Carboplatin|Drug: Ipatasertib|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,City of Hope Medical Center|National Cancer Institute (NCI),18496|NCI-2019-00465,"February 26, 2019","City of Hope Medical Center, Duarte, California, United States",https://ClinicalTrials.gov/show/NCT03853707
Principal Investigator,"Todd Tuttle, MD, MS","Department of Surgery, University of Minnesota",,NCT03981705,todd tuttle,todd,male,0.99,6598,291,Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer,Recruiting,No Results Available,TN ER-/PR-/HER2- Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer|ERany/PRany/HER2+ Breast Cancer,Radiation: Standard Trimodality Breast Imaging,"Masonic Cancer Center, University of Minnesota",2018NTLS176,"June 11, 2019","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03981705
Principal Investigator,"Reham A Elshafiey, PharmD",Damanhour University,,NCT03908528,reham a elshafiey,reham,female,0.96,971,292,Alpha-Lipoic Acid in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Chemotherapeutic Toxicity,Dietary Supplement: Alpha-lipoic acid|Drug: Chemotherapy,Damanhour University,Alpha-Lipoic Acid,"April 9, 2019","Ayadi AL-Mostakbal Oncology Center, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT03908528
Principal Investigator,"Neil Iyengar, MD",Memorial Sloan Kettering Cancer Center,,NCT03988595,neil iyengar,neil,male,0.99,15028,294,Exercise Treatment With Standard Therapy for Metastatic Breast Cancer,Recruiting,No Results Available,Hormone Receptor Positive Metastatic Breast Cancer,Other: Exercise Treatment,Memorial Sloan Kettering Cancer Center,19-113,"June 17, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03988595
Principal Investigator,"Kari Wisinski, MD","University of Wisconsin, Madison",,NCT03911973,kari wisinski,kari,female,0.5,5594,295,"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",Recruiting,No Results Available,TNBC - Triple-Negative Breast Cancer,Drug: Gedatolisib|Drug: Talazoparib,Kari Wisinski|Pfizer|Big Ten Cancer Research Consortium,BTCRC-BRE18-337,"April 11, 2019","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03911973
Principal Investigator,"Kari Wisinski, MD","University of Wisconsin, Madison",,NCT04174352,kari wisinski,kari,female,0.5,5594,349,FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer,Suspended,No Results Available,ERα+ Breast Cancer|ESR1 Gene Mutation,Drug: Tamoxifen|Diagnostic Test: FES PET/CT,"University of Wisconsin, Madison",UW19046|2019-0935|A534260|SMPH/MEDICINE/MEDICINE|Protocol Version 10/17/2019,"November 22, 2019","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Wisconsin Oncology Network (WONIX) sites, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04174352
Principal Investigator,"Shusen Wang, M.D.",Sun Yat-sen University,,NCT04185649,shusen wang,shusen,male,1.0,4,296,The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer,"Active, not recruiting",No Results Available,HER2-positive Advanced Breast Cancer,Biological: BAT8001 for injection|Drug: Lapatinib|Drug: Capecitabine,Bio-Thera Solutions,BAT-8001-002-CR,"December 4, 2019","The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|Beijing Hospital, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Peking union medical college hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Peking, Beijing, China|Chongqing Cancer Hospital, Chongqing, Chongqing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Foshan City No. 1 People's Hospital, Foshan, Guangdong, China|Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital. SYSU, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The First Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China|The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, Guangdong, China|Liuzhou workers hospital, Liuzhou, Guangxi, China|The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of science and technology, Luoyang, Henan, China|The First Affiliated Hospital of Xixiang Medical College, Xinxiang, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Tongji Hospital of Tongji Medical College of HUST, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Yichang Central Hospital, Yichang, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Jiangsu Cancer Hospital, Nanning, Jiangsu, China|Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China|Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, China|The Third Hospital of Nanchang, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Chang chun, Jilin, China|The First Bethune Hospital of Jilin University, Changchun, Jilin, China|Jinzhou Central Hospital, Jinzhou, Liaoning, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Shandong Cancer Hospital, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|Weifang People's Hospital, Weifang, Shandong, China|Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China|Shanghai General Hospital, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, Shanghai, China|The Second Hospital of Anhui Medical University, Shanghai, Shanghai, China|Shanxi Cancer Hospital, Xi'an, Shanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Taizhou Hispotal of Zhejiang Province, Taizhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04185649
Study Chair,"Zefei Jiang, M.D.",The fifth medical center of PLA general hospital,,NCT04138719,zefei jiang,zefei,female,1.0,1,298,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,Recruiting,No Results Available,Breast Cancer|Triple-negative Breast Cancer|Nab-paclitaxel,Drug: Nab-paclitaxel + Carboplatin|Drug: Nab-paclitaxel + Epirubicin,"Hebei Medical University Fourth Hospital|The fifth medical center of PLA general hospital|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-KAL-BC-11,"October 24, 2019","The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",https://ClinicalTrials.gov/show/NCT04138719
Study Chair,"Cuizhi Geng, M.D.",The Fourth Hospital of Hebei Medical University,,NCT04138719,cuizhi geng,cuizhi,female,0.5,2,298,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,Recruiting,No Results Available,Breast Cancer|Triple-negative Breast Cancer|Nab-paclitaxel,Drug: Nab-paclitaxel + Carboplatin|Drug: Nab-paclitaxel + Epirubicin,"Hebei Medical University Fourth Hospital|The fifth medical center of PLA general hospital|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-KAL-BC-11,"October 24, 2019","The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",https://ClinicalTrials.gov/show/NCT04138719
Study Chair,"Zefei Jiang, M.D.",The fifth medical center of PLA general hospital,,NCT04159142,zefei jiang,zefei,female,1.0,1,321,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer,Recruiting,No Results Available,Triple Negative Breast Cancer|Nab-paclitaxel,Drug: Nab-paclitaxel + Carboplatin|Drug: Nab-paclitaxel + Capecitabine,"Hebei Medical University Fourth Hospital|The fifth medical center of PLA general hospital|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-KAL-BC-16,"November 12, 2019","The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",https://ClinicalTrials.gov/show/NCT04159142
Study Chair,"Cuizhi Geng, M.D.",The Fourth Hospital of Hebei Medical University,,NCT04159142,cuizhi geng,cuizhi,female,0.5,2,321,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer,Recruiting,No Results Available,Triple Negative Breast Cancer|Nab-paclitaxel,Drug: Nab-paclitaxel + Carboplatin|Drug: Nab-paclitaxel + Capecitabine,"Hebei Medical University Fourth Hospital|The fifth medical center of PLA general hospital|CSPC Ouyi Pharmaceutical Co., Ltd.",CSPC-KAL-BC-16,"November 12, 2019","The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",https://ClinicalTrials.gov/show/NCT04159142
Principal Investigator,"Pavani Chalasani, MD",University of Arizona,,NCT03911453,pavani chalasani,pavani,female,0.9,51,300,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",Recruiting,No Results Available,Breast Cancer,Drug: Rucaparib,University of Arizona,30388|1903397220,"April 11, 2019","University of Arizona Cancer Center, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT03911453
Principal Investigator,"Jamie M. Jacobs, MD",Massachusetts General Hospital,,NCT03837496,jamie m. jacobs,jamie,male,0.81,19333,304,"Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors",Recruiting,No Results Available,"Breast Cancer|Adherence, Medication",Other: STRIDE|Other: Medication Monitoring Control,Massachusetts General Hospital|National Cancer Institute (NCI),18-603|K07CA211107,"February 12, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03837496
Principal Investigator,"Li Zhu, Prof.",Ruijin Hospital,,NCT03907800,li zhu,li,female,0.63,5785,308,Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer,Recruiting,No Results Available,Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer,Drug: Nab-paclitaxel|Drug: Carboplatin|Drug: Herceptin,Ruijin Hospital,RJBC1801,"April 9, 2019","Ruijin Hospital, Shanghai, China",https://ClinicalTrials.gov/show/NCT03907800
Study Director,"Gustav Dobos, Prof. MD",University of Duisburg Essen,,NCT03874598,gustav dobos,gustav,male,0.98,2901,309,Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast Cancer,"Active, not recruiting",No Results Available,Breast Neoplasm,Procedure: Ear acupuncture|Behavioral: Psychoeducation,Universität Duisburg-Essen|Karl and Veronica Carstens Foundation,18-8214-BO|KVC 0/100/2018,"March 14, 2019","Kliniken Essen-Mitte, Essen, NRW, Germany",https://ClinicalTrials.gov/show/NCT03874598
Principal Investigator,"Benito Chiofalo, M.D.","""Regina Elena"" National Cancer Institute of Rome",,NCT03898947,benito chiofalo,benito,male,0.98,5639,311,Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies,Completed,No Results Available,Breast Cancer|Endometrial Cancer,Procedure: Diagnostic hysteroscopy and targeted endometrial biopsy,Università degli Studi dell'Insubria,BETA-1,"April 2, 2019",,https://ClinicalTrials.gov/show/NCT03898947
Principal Investigator,"Hong-Gu HE, PhD","National University, Singapore",,NCT04172350,hong-gu he,hong-gu,male,1.0,1,314,An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery,Recruiting,No Results Available,Breast Cancer Female|Surgery,Other: iCareBreast|Other: Routine care,"HE Hong-Gu|KK Women's and Children's Hospital|Buddy Healthcare Ltd OY|National University, Singapore",2019/2632,"November 21, 2019","KK Women's and Children's Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04172350
Principal Investigator,"Katharine Yao, MD",NorthShore University HealthSystem,,NCT03880799,katharine yao,katharine,female,0.96,340,322,Mindfulness-Enhanced Decision Intervention To Aid Treatment Election - Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer|Surgery,Behavioral: Mindfulness Session,NorthShore University HealthSystem|Northwestern University,EH18-203,"March 19, 2019","NorthShore University HealthSystem, Evanston, Illinois, United States",https://ClinicalTrials.gov/show/NCT03880799
Principal Investigator,"Shu Wang, doctor",Peking University People's Hospital,,NCT04131881,shu wang,shu,female,0.57,1826,327,The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients,Completed,No Results Available,Breast Cancer|Drug Effect,,Peking University People's Hospital|Peking University,PKUPH10B002,"October 18, 2019","Peking University People'S Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04131881
Study Director,"shu wang, Doctor",Peking University People's Hospital,,NCT04137406,shu wang,shu,female,0.57,1826,346,Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis,Recruiting,No Results Available,Breast Cancer|Lymph Node Metastases,,Peking University People's Hospital,Luminal A sirt1,"October 24, 2019","Peking university people's hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04137406
Principal Investigator,"shu wang, M.D.",Peking University People's Hospital,,NCT03791853,shu wang,shu,female,0.57,1826,371,Light-CT in the Diagnosis of Breast Tumor and Lymph Node,Recruiting,No Results Available,Breast Neoplasms,Diagnostic Test: Light-CT,Peking University People's Hospital,LightCT-PKUPH,"January 3, 2019","Breast Center, Peking University People's Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03791853
Principal Investigator,"Shu Wang, MD",Peking University People's Hospital,,NCT03924609,shu wang,shu,female,0.57,1826,415,Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients,Completed,No Results Available,Breast Cancer|Bone Metastases,Diagnostic Test: Intensive screening / routine screening,Peking University People's Hospital|Fudan University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Harbin Medical University,20160504,"April 23, 2019","Peking University People's Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03924609
Principal Investigator,"Shu Wang, MD",Peking University People's Hospital,,NCT03791840,shu wang,shu,female,0.57,1826,484,The Value of High-resolution Ultrasound in the Detection of Lymph Node Metastasis: a Proposal of NI-RADS,Recruiting,No Results Available,Breast Neoplasms,Diagnostic Test: Ultrasound evaluation,Peking University People's Hospital,PKUPHUS002,"January 3, 2019","Peking University People's Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT03791840
Principal Investigator,"Hung Khong, MD",H. Lee Moffitt Cancer Center and Research Institute,,NCT03874325,hung khong,hung,male,0.93,1806,328,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,Recruiting,No Results Available,Breast Cancer|Hormone Receptor Positive Tumor,Drug: Durvalumab|Drug: Anastrozole 1mg|Drug: Letrozole 2.5mg|Drug: Exemestane 25 MG,H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca,MCC-19803|ESR-17-13182,"March 14, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT03874325
Principal Investigator,"Claudia REGIS, MD",Centre Oscar Lambret,,NCT04202640,claudia regis,claudia,female,0.98,118604,329,Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Mechanical Stimulation|Procedure: Massages,Centre Oscar Lambret,PRESSODOU-1809,"December 17, 2019","Centre Oscar Lambret, Lille, Hauts-de- France, France",https://ClinicalTrials.gov/show/NCT04202640
Study Chair,"Jong In Lee, MD PhD",Seoul St. Mary's Hospital,,NCT04152590,jong in lee,jong,male,0.94,2523,330,Real-time Interactive Digital Healthcare System in Post Operation Patients With Breast Cancer; Pilot Study,Completed,No Results Available,Breast Cancer|Rehabilitation,Device: Uincare,JongIn Lee|Seoul St. Mary's Hospital,KC19EESI0325,"November 5, 2019","Seoul St Mary's Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04152590
Principal Investigator,"Helena M Verkooijen, MD, PhD","Imaging Division, UMC Utrecht",,NCT04193722,helena m verkooijen,helena,female,0.99,40369,331,The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial,Recruiting,No Results Available,Breast Cancer|Radiation Toxicity,Drug: Hyperbaric oxygen therapy,UMC Utrecht|The Netherlands Cancer Institute,NL69081.041.19,"December 10, 2019","University Medical Center Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04193722
Principal Investigator,"Helena Romay Barrero, Prof. PhD.",University of Castilla-La Mancha,,NCT04112966,helena romay barrero,helena,female,0.99,40369,341,Lymphedema Prevention in Breast Cancer,Completed,No Results Available,Breast Cancer|Lymphedema,Procedure: 14 sessions of manual lymphatic drainage technique|Other: the health education,University of Castilla-La Mancha|Castilla-La Mancha Health Service,ECA-DLM-5,"October 2, 2019","Provincial Hospital, Toledo, Spain",https://ClinicalTrials.gov/show/NCT04112966
Principal Investigator,"Helena M Verkooijen, Prof, Dr",Universitair Medical Centre Utrecht,,NCT04075305,helena m verkooijen,helena,female,0.99,40369,780,The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study,Recruiting,No Results Available,Oncology|Breast Cancer|Prostate Cancer|Gynecologic Cancer|Brain Tumor|Brain Cancer|Gynecologic Tumor|Prostate Tumor|Prostate Neoplasm|Breast Tumor|Radiation Toxicity|Quality of Life|Rectal Cancer|Rectal Tumor|Rectal Neoplasms|Lung Cancer|Lung Tumor|Lung Neoplasm|Esophageal Cancer|Esophagus Cancer|Esophageal Tumor|Esophageal Neoplasm|Esophagus Tumor|Esophagus Neoplasm|Pancreatic Cancer|Pancreatic Tumor|Pancreatic Neoplasms|Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Tumor|Tumor|Neoplasms|Bladder Cancer|Bladder Neoplasm|Liver Cancer|Liver Neoplasms|Liver Metastases|Oligometastases,Radiation: Radiation therapy,UMC Utrecht|The Netherlands Cancer Institute|Sunnybrook Health Sciences Centre|M.D. Anderson Cancer Center|The Christie NHS Foundation Trust|Royal Marsden NHS Foundation Trust|Medical College of Wisconsin|Elekta,NL63674.041.18,"August 30, 2019","University Medical Center Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04075305
Principal Investigator,"Alessandro De Cassai, MD","Department of Medicine, DIMED - Section of Anesthesiology and Intensive Care. University of Padova",,NCT03811262,alessandro de cassai,alessandro,male,0.99,126666,332,Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery,Recruiting,No Results Available,"Breast Cancer|Anesthesia, Local",Procedure: ESP BLOCK|Procedure: PECS BLOCK,University of Padova,ESPvsPECS/AOP,"January 22, 2019","University of Padova, Padova, Veneto, Italy",https://ClinicalTrials.gov/show/NCT03811262
Principal Investigator,"Elgene Lim, MBBS FRACP PhD",Garvan Research Institute,,NCT03906669,elgene lim,elgene,female,0.57,14,334,A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.,Recruiting,No Results Available,Early-stage Breast Cancer|Hormone Receptor Positive Tumor,Drug: Letrozole|Drug: Letrozole and Prometrium|Drug: Tamoxifen and Prometrium,St. Vincent's Hospital-Manhattan,ACTRN1261000928213,"April 8, 2019","St Vincent's Hospital, Sydney, New South Wales, Australia",https://ClinicalTrials.gov/show/NCT03906669
Principal Investigator,Vesna Bjelic-Radisic,"Helios Universitiätsklinikum Wuppertal, Universität Witten/Herdecke",,NCT04018235,vesna bjelic-radisic,vesna,female,0.98,6750,335,Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer|Quality of Life,,"Helios University Hospital Wuppertal|Medical University of Graz|Université Catholique de Louvain|Hospital de Câncer de Barretos|University Hospital Rijeka|Evangelische Kliniken Gelsenkirchen, Germany|University Medical Center Freiburg|University Hospital Regensburg|Sheba Medical Center|Instituto Nazionale Tumori Fondazione Pascale|Istituto Oncologico Veneto IRCCS|Oslo University Hospital|Jagiellonian University|Oncology Department Hospital of Navarre|University of Leeds|The Netherlands Cancer Institute|Tumor- und Brust­zentrum ZeTuP St. Gallen|National Taiwan University|Taipei Veterans General Hospital, Taiwan|National Center for Global Health and Medicine, Japan|King Hussein Cancer Center",EORTC QLQ BR45,"July 12, 2019","Helios Universitiätsklinikum Wuppertal, Universität Witten/Herdecke, Wuppertal, Germany",https://ClinicalTrials.gov/show/NCT04018235
Principal Investigator,"Monica Mita, MD",Cedars-Sinai Medical Center,,NCT03822715,monica mita,monica,female,0.99,81357,615,NEOBREADS: Neoadjuvant Breast Diet Study,Recruiting,No Results Available,Breast Cancer,Other: Carbohydrate restricted dietary intervention|Drug: standard of care aromatase inhibitors,Monica Mita|Cedars-Sinai Medical Center,IIT2018-25-MITA-NEOBREADS,"January 30, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT03822715
Principal Investigator,"Shari Goldfarb, MD",Memorial Sloan Kettering Cancer Center,,NCT03817814,shari goldfarb,shari,female,0.89,1046,339,Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment,Enrolling by invitation,No Results Available,Fertility Preservation|Breast Cancer,Behavioral: web-based questionnaire,Memorial Sloan Kettering Cancer Center,18-461,"January 28, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03817814
Principal Investigator,"Shari Goldfarb, MD",Memorial Sloan Kettering Cancer Center,,NCT04180579,shari goldfarb,shari,female,0.89,1046,380,Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III,Device: PAXMAN Scalp Cooler,Memorial Sloan Kettering Cancer Center,19-277,"November 27, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04180579
Principal Investigator,"Kamran Ahmed, MD",H. Lee Moffitt Cancer Center and Research Institute,,NCT03807765,kamran ahmed,kamran,male,0.99,4648,340,Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases,Recruiting,No Results Available,Metastatic Breast Cancer|Brain Metastases,Drug: Nivolumab|Radiation: Stereotactic Radiosurgery,H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,MCC-19765|CA209-8NK,"January 17, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT03807765
Principal Investigator,"Nicole Simone, MD",Sidney Kimmel Cancer Center at Thomas Jefferson University,,NCT04074720,nicole simone,nicole,female,0.98,102075,342,Prospective Breast Cancer Biospecimen Collection,Recruiting,No Results Available,Breast Cancer|Invasive Breast Cancer|Carcinoma in Situ of the Breast,Procedure: Tissue Sample collection|Other: Blood Sample Collection|Other: Rectal Swab,Thomas Jefferson University,16D.674,"August 30, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04074720
Principal Investigator,"Suwimon Tangwiwat, MD",Mahidol University,,NCT04056676,suwimon tangwiwat,suwimon,female,0.96,49,343,Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery,Recruiting,No Results Available,"Breast Cancer Female|Pain, Postoperative",Procedure: Thoracic paravertebral block under ultrasound guidance|Procedure: Intraoperative modified PEC block|Procedure: GA with ETT,Mahidol University,SI 475/2019,"August 14, 2019","Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand",https://ClinicalTrials.gov/show/NCT04056676
Study Chair,"Paula R Pohlmann, MD, MSc, PhD",Georgetown University,,NCT03854903,paula r pohlmann,paula,female,0.98,74130,344,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",Recruiting,No Results Available,Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Hormone Receptor Positive Breast Cancer,Drug: Palbociclib|Drug: Bosutinib|Drug: Fulvestrant,Georgetown University|Pfizer,STUDY00000057,"February 26, 2019","Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States",https://ClinicalTrials.gov/show/NCT03854903
Principal Investigator,Anke Bergmann,CPQ - INCA,,NCT03796845,anke bergmann,anke,female,0.97,6368,348,Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery,Completed,No Results Available,Breast Neoplasms,Other: No limited movement after surgery,"Instituto Nacional de Cancer, Brazil",Shoulder exercise cancer,"January 8, 2019","Clarice Gomes Chagas Teodozio, Rio de Janeiro, RJ, Brazil",https://ClinicalTrials.gov/show/NCT03796845
Study Director,"Jolien Robijns, PhD",Hasselt University,,NCT03924011,jolien robijns,jolien,female,0.98,1287,351,Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy,Recruiting,No Results Available,Radiodermatitis|Breast Cancer,Device: Photobiomodulation therapy (PBMT)|Device: Sham laser,Hasselt University|Jessa Hospital|Ziekenhuis Oost-Limburg,75,"April 23, 2019","Ziekenhuis Oost-Limburg Campus St.-Jan, Genk, Limburg, Belgium|Jessa Ziekenhuis, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT03924011
Principal Investigator,Jianyi Li,Shengjing Hospital,,NCT04059003,jianyi li,jianyi,male,0.75,16,352,CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer,Recruiting,No Results Available,Breast Neoplasms,Drug: Taxanes or/and anthracycline-based therapy,Shengjing Hospital,Shengjing-LJY03,"August 16, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China",https://ClinicalTrials.gov/show/NCT04059003
Principal Investigator,"Jianyi Li, MD",Shengjing Hospital,,NCT04065321,jianyi li,jianyi,male,0.75,16,386,Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer,Recruiting,No Results Available,Breast Neoplasms,Procedure: PET-CT examination|Procedure: Peripheral blood detection,Shengjing Hospital,Shengjing-LJY04,"August 22, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China",https://ClinicalTrials.gov/show/NCT04065321
Principal Investigator,Jianyi Li,Shengjing Hospital,,NCT04052893,jianyi li,jianyi,male,0.75,16,557,DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast,Recruiting,No Results Available,Breast Neoplasms,Procedure: Expanded Mckissock surgery|Procedure: Modified radical mastectomy,Shengjing Hospital,Shengjing-LJY02,"August 12, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China",https://ClinicalTrials.gov/show/NCT04052893
Study Chair,"Caroline Lohrisch, MC",BC Cancer,,NCT03917082,caroline lohrisch,caroline,female,0.98,64753,353,Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer Female|Hormone Receptor Positive Tumor,Drug: Tamoxifen Citrate,"British Columbia Cancer Agency|Canadian Cancer Society Research Institute (CCSRI)|NanoString Technologies, Inc.",LA LEAST,"April 16, 2019",,https://ClinicalTrials.gov/show/NCT03917082
Principal Investigator,"Jianjun He, PhD",First Affiliated Hospital of Xian Jiaotong University,,NCT03881384,jianjun he,jianjun,male,0.97,88,355,Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients,Recruiting,No Results Available,Breast Neoplasms,Other: ctDNA level during neoadjuant chemotherapy,First Affiliated Hospital Xi'an Jiaotong University,XJTU1AF-CRF-2018-001,"March 19, 2019","First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT03881384
Principal Investigator,"Mette A Pedersen, MD","Department of Nuclear Medicine & PET-centre. Aarhus University Hospital, Denmark",,NCT04150731,mette a pedersen,mette,female,0.97,3117,356,16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Radiation: 16α-18F-fluor-17β-estradiol,"University of Aarhus|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|REDCap",2020FES,"November 5, 2019",,https://ClinicalTrials.gov/show/NCT04150731
Principal Investigator,"Mette Eline Brunbjerg, MD","Aarhus University Hospital, Aarhus University, Denmark",,NCT04209010,mette eline brunbjerg,mette,female,0.97,3117,679,Immediate Breast Reconstruction With Acellular Dermal Matrix,Completed,No Results Available,Breast Cancer|Breast Carcinoma in Situ|Mammaplasty|Acellular Dermis,Procedure: one-stage technique,"Aarhus University Hospital|Danish Cancer Society|The Korning foundation|Foundation of the Kjaersgaard Family|King Christian X foundation|Foundation of architect Holger Hjortenberg|LifeCell Corporation (Branchburg, NJ, USA)",VEK 1-10-72-572-12,"December 23, 2019",,https://ClinicalTrials.gov/show/NCT04209010
Principal Investigator,"DELAY Emmanuel, MD",Centre Leon Berard,,NCT03870802,delay emmanuel,delay,male,0.63,56,357,MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire),Not yet recruiting,No Results Available,Breast Cancer,Other: Characterization of breast stem & immune system cells infiltrated in the mammary gland,Centre Leon Berard,ET18-150 - MACSSI,"March 12, 2019","Centre Léon Bérard, Lyon, France",https://ClinicalTrials.gov/show/NCT03870802
Principal Investigator,"Steven J Isakoff, MD",Massachusetts General Hospital,,NCT03822312,steven j isakoff,steven,male,0.99,61542,359,A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy,Recruiting,No Results Available,Breast Cancer,Device: DBT-TOBI|Device: MRI-TOBI,Massachusetts General Hospital|National Cancer Institute (NCI),18-333|1R01CA187595,"January 30, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03822312
Principal Investigator,"Steven A Rosenberg, M.D.",National Cancer Institute (NCI),,NCT04102436,steven a rosenberg,steven,male,0.99,61542,784,Non-Viral TCR Gene Therapy,Recruiting,No Results Available,Glioblastoma|Non-Small Cell Lung Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancer|Ovarian Cancer,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Biological: Sleeping Beauty Transposed PBL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),190143|19-C-0143,"September 25, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04102436
Principal Investigator,Lori Williams,M.D. Anderson Cancer Center,,NCT04022772,lori williams,lori,female,0.86,4757,362,Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer,Recruiting,No Results Available,Breast Carcinoma,Other: Best Practice|Other: Medical Chart Review|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Supportive Care,"M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.",2018-0473|NCI-2019-03897|P30CA016672,"July 17, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04022772
Principal Investigator,"Mohab M Ibrahim, PhD., MD",University of Arizona,,NCT03847311,mohab m ibrahim,mohab,male,0.99,360,363,Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer|Chronic Pain Due to Malignancy (Finding),Drug: Sulfasalazine|Drug: Placebos,University of Arizona,1605576856,"February 20, 2019","Banner University Medical Center South, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT03847311
Principal Investigator,"Emilia Montagna, MD",European Institute of Oncology,,NCT03939156,emilia montagna,emilia,female,0.98,26372,364,Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer,Recruiting,No Results Available,Breast Cancer|Endocrine Breast Diseases,Other: Completion of questionnaires,European Institute of Oncology,IEO 0837/,"May 6, 2019","European Institute of Oncology, Milan, Italy",https://ClinicalTrials.gov/show/NCT03939156
Study Director,"Bjørn Naume, MD PhD",Oslo University Hospital,,NCT03904173,bjørn naume,bjørn,male,0.99,311,365,Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer,Recruiting,No Results Available,Breast Cancer|Breast Neoplasms|Hormone Receptor Positive Tumor,Diagnostic Test: Multi-parameter tests,Oslo University Hospital|KLINBEFORSK|Norwegian Cancer Society,Protocol EMIT-1,"April 5, 2019","Drammen Hospital - Vestre Viken, Drammen, Buskerud, Norway|Østfold Hospital, Sarpsborg, Kalnes, Norway|Telemark Hospital, Skien, Ulefossveien 55, Norway|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT03904173
Principal Investigator,Geoffrey Lindeman,"Peter MacCallum Cancer Centre, Australia",,NCT03900884,geoffrey lindeman,geoffrey,male,0.99,14049,366,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer",Recruiting,No Results Available,Breast Neoplasm Female,Drug: Venetoclax|Drug: Palbociclib|Drug: Letrozole,"Peter MacCallum Cancer Centre, Australia",18/028,"April 3, 2019","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Austin Health, Melbourne, Victoria, Australia",https://ClinicalTrials.gov/show/NCT03900884
Principal Investigator,"Theresa M Smith, PhD",Associate Professor,,NCT04027400,theresa m smith,theresa,female,0.97,8488,367,Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors,Recruiting,No Results Available,Cognitive Impairment|Breast Cancer,Behavioral: computer-assisted rehabilitation,Texas Woman's University,19959,"July 22, 2019","Texas Woman's University, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04027400
Study Chair,"Ursula Wolf, Professor",Institute for complementary and integrative medicine,,NCT04024267,ursula wolf,ursula,female,0.98,7051,368,Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients,Recruiting,No Results Available,Fatigue|Breast Cancer,Other: Eurythmy therapy|Other: CoordiFit,University of Bern|Breast Cancer Research Foundation,123123,"July 18, 2019","University Hospital Bern, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04024267
Principal Investigator,"Canan Şanal-Toprak, Asst. Prof",Marmara University,,NCT04165512,canan şanal-toprak,canan,female,0.96,13410,374,Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema,Enrolling by invitation,No Results Available,Lymphedema of Upper Limb|Breast Cancer Related Lymphedema,Combination Product: bupivacaine and triamcinolone,Marmara University,09.2019.984,"November 18, 2019","Canan Şanal-Toprak, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04165512
Study Director,"Alison Stopeck, MD",Stony Brook University,,NCT04088032,alison stopeck,alison,female,0.98,25555,375,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",Not yet recruiting,No Results Available,Breast Cancer Female|Locally Advanced Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast,"Drug: Abemaciclib, durvalumab and aromatase inhibitor",Alison Stopeck|Eli Lilly and Company|AstraZeneca|Stony Brook University,2019-00174 Neoadj Breast Pilot,"September 12, 2019","Stony Brook University Cancer Center, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04088032
Principal Investigator,"Lea Baer, MD",Stony Brook University,,NCT04088032,lea baer,lea,female,0.96,23031,375,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",Not yet recruiting,No Results Available,Breast Cancer Female|Locally Advanced Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast,"Drug: Abemaciclib, durvalumab and aromatase inhibitor",Alison Stopeck|Eli Lilly and Company|AstraZeneca|Stony Brook University,2019-00174 Neoadj Breast Pilot,"September 12, 2019","Stony Brook University Cancer Center, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04088032
Study Chair,"Thomas Ruhstaller, Prof",Kantonsspital St. Gallen - Breast Center St. Gallen,,NCT03905343,thomas ruhstaller,thomas,male,0.99,176440,377,Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC,Recruiting,No Results Available,Breast Cancer,Drug: Ribociclib|Other: Mono-chemotherapy|Other: Endocrine-Therapy,Swiss Group for Clinical Cancer Research|The Belgian Society of Medical Oncology,SAKK 21/18|2018-003648-22,"April 5, 2019","Kantonsspital Baden, Baden, Switzerland|Kantonsspital Baden, Baden, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Brustzentrum Basel - Praxis für ambulante Tumortherapie, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Clinique des Grangettes, Chêne-Bougeries, Switzerland|Hôpital neuchâtelois, La Chaux-de-Fonds, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Hirslanden Klinik St. Anna Luzern, Luzern, Switzerland|Onkologie Zentrum Spital Männedorf, Männedorf, Switzerland|Kantonsspital Olten, Olten, Switzerland|Hôpital de Sion, Sion, Switzerland|Brustzentrum Ostschweiz, St. Gallen, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Spital STS AG, Thun, Switzerland|Kantonsspital Winterthur, Brustzentrum, Winterthur, Switzerland|Onkologie Bellevue, Zurich, Switzerland|OnkoZentrum Zürich AG - Klinik im Park, Zürich, Switzerland|Universitäts Spital Zürich, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT03905343
Principal Investigator,"Thomas BACHELOT, MD",Centre Leon Berard,,NCT03872908,thomas bachelot,thomas,male,0.99,176440,635,Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies,Not yet recruiting,No Results Available,Breast Cancer|Colorectal Cancer,Device: Chilled gloves|Device: Surgical gloves,Centre Leon Berard,ET18-262 ELEGANT,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT03872908
Principal Investigator,Mariana Chavez Mac Gregor,M.D. Anderson Cancer Center,,NCT04087057,mariana chavez mac gregor,mariana,female,0.98,28214,378,Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer,Recruiting,No Results Available,Invasive Breast Carcinoma,Other: Interview|Other: Medical Chart Review|Behavioral: Questionnaire,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2018-1133|NCI-2019-05917|P30CA016672,"September 12, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04087057
Principal Investigator,"Wendie Berg, MD, PhD",University of Pittsburgh,,NCT04085510,wendie berg,wendie,female,0.96,204,382,Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania,Recruiting,No Results Available,Breast Cancer Female|Breast Cancer|Breast Neoplasms|Neoplasms,Device: Contrast-enhanced mammogram,Wendie Berg|Breast Cancer Research Foundation|University of Pittsburgh,STUDY19060359,"September 11, 2019","Magee Womancare Passavant Cranberry, Cranberry Township, Pennsylvania, United States|Magee Womancare Monroeville, Monroeville, Pennsylvania, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04085510
Principal Investigator,"Emmanuelle BOURBOULOUX, MD",ICO,,NCT03959618,emmanuelle bourbouloux,emmanuelle,female,0.97,14356,384,Intravenous Chemotherapy and Plant-based Dietary Supplements,Recruiting,No Results Available,Breast Cancer,Other: dietary supplements questionary,Institut Cancerologie de l'Ouest,ICO-N-2018-12|2018-A02460-55,"May 22, 2019","Institut de Cancerologie de L'Ouest, Saint Herblain, France",https://ClinicalTrials.gov/show/NCT03959618
Study Director,"EMMANUELLE MARTIN, MD",INSTITUT DE CANCEROLOGIE DE L'OUEST,,NCT03791736,emmanuelle martin,emmanuelle,female,0.97,14356,474,Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation,Terminated,No Results Available,Breast Cancer|Lymphocele,Procedure: Injection of sandostatine,Institut Cancerologie de l'Ouest,2015-03,"January 3, 2019",,https://ClinicalTrials.gov/show/NCT03791736
Principal Investigator,"Oskar Hemmingsson, MD, PhD",Umeå University,,NCT04079049,oskar hemmingsson,oskar,male,0.99,9693,385,BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases,Recruiting,No Results Available,Breast Cancer|Liver Metastases,Procedure: Surgical intervention|Drug: Control,Umeå University|Uppsala University|Karolinska Institutet|Linkoeping University|Lund University|Göteborg University,BreCLIM-2018-116-31M,"September 6, 2019","Umeå University Hospital, Umeå, Sweden",https://ClinicalTrials.gov/show/NCT04079049
Study Chair,Kerstin FARAVEL,Institut du Cancer de Montpellier,,NCT04001751,kerstin faravel,kerstin,female,0.97,17233,388,Feasibility Study: Yoga Educational Project,Completed,No Results Available,Breast Cancer,Behavioral: educational yoga program,Institut du Cancer de Montpellier - Val d'Aurelle,PROICM 2018-02 SKY|2018-A00208-47,"June 28, 2019","Institut du Cancer de Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04001751
Principal Investigator,"Fabrizio Brescia, MD","Centro di Riferimento Oncologico di Aviano (CRO), IRCCS",,NCT04172220,fabrizio brescia,fabrizio,male,0.99,34325,391,Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?,Recruiting,No Results Available,Breast Cancer Female,Drug: Midazolam|Procedure: PECS|Procedure: Opioid-free general anesthesia|Procedure: General anesthesia|Procedure: Postoperative analgesia,Centro di Riferimento Oncologico - Aviano,CRO-2019-26,"November 21, 2019","Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy",https://ClinicalTrials.gov/show/NCT04172220
Principal Investigator,"Stacy D'Andre, MD",Sutter Health,,NCT04092647,stacy d'andre,stacy,female,0.9,4493,392,Ashwagandha for Cognitive Dysfunction,Not yet recruiting,No Results Available,Breast Cancer,Drug: Ashwagandha|Drug: Placebo,Sutter Health,SIMR_onc19_IIS_D'Andre_Ashwaga,"September 17, 2019","Sutter Cancer Center, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT04092647
Study Director,"Carol Parise, PhD",Sutter Health,,NCT04092647,carol parise,carol,female,0.97,33721,392,Ashwagandha for Cognitive Dysfunction,Not yet recruiting,No Results Available,Breast Cancer,Drug: Ashwagandha|Drug: Placebo,Sutter Health,SIMR_onc19_IIS_D'Andre_Ashwaga,"September 17, 2019","Sutter Cancer Center, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT04092647
Principal Investigator,"Amit Goyal, MS, MD, FRCS","Royal Derby Hospital, Derby, UK",,NCT04109079,amit goyal,amit,male,0.99,8292,393,Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy,Not yet recruiting,No Results Available,"Breast Cancer|Sentinel Lymph Node|Neoplasm, Breast",Procedure: Axillary lymph node dissection|Radiation: Axillary radiotherapy|Radiation: Breast or chest wall radiotherapy,University Hospitals of Derby and Burton NHS Foundation Trust,NIHR 128311,"September 30, 2019",,https://ClinicalTrials.gov/show/NCT04109079
Principal Investigator,Severine GUIU,INSTITUT DE CANCEROLOGIE DE MONTPELLIER,,NCT04053322,severine guiu,severine,female,0.98,16545,395,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.",Recruiting,No Results Available,"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer|a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status",Drug: Durvalumab|Drug: Olaparib|Drug: Fulvestrant,UNICANCER|ARCAGY/ GINECO GROUP|SOLTI Breast Cancer Research Group,UC-0140/1812,"August 12, 2019","Institut de Cancerologie de Montpellier, Montpellier, France|Centre Henri-Becquerel, Rouen, France",https://ClinicalTrials.gov/show/NCT04053322
Principal Investigator,"Edward LW Chow, MBBS",Sunnybrook Health Sciences Centre,,NCT03910595,edward lw chow,edward,male,0.99,22248,397,Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Radiation Dermatitis,Other: Mepitel Film,Sunnybrook Health Sciences Centre,294-2018,"April 10, 2019","Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03910595
Principal Investigator,"Edward LW Chow, MBBS",Sunnybrook Health Sciences Centre,,NCT04166799,edward lw chow,edward,male,0.99,22248,526,Randomized Phase III Trial With Mepitel Film for the Prophylaxis of Radiation Dermatitis in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Radiation Dermatitis,Device: Mepitel Film,Sunnybrook Health Sciences Centre,Mepitel RCT,"November 18, 2019","Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04166799
Principal Investigator,Edward I Chang,M.D. Anderson Cancer Center,,NCT03990610,edward i chang,edward,male,0.99,22248,558,An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction,Recruiting,No Results Available,Breast Carcinoma|Mammoplasty Patient,Procedure: Mammoplasty|Procedure: Vascularized Lymph Node Transfer,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2018-0528|NCI-2019-03182|P30CA016672,"June 19, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03990610
Principal Investigator,Edward H Chang,M.D. Anderson Cancer Center,,NCT04003038,edward h chang,edward,male,0.99,22248,704,Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery,Recruiting,No Results Available,Body Mass Index Greater Than or Equal to 30|Malignant Breast Neoplasm|Mammoplasty Patient|Obesity,Procedure: Negative Pressure Wound Therapy|Procedure: Wound Care Management,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2018-0004|NCI-2019-02777|P30CA016672,"July 1, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04003038
Principal Investigator,"Emilie LE RHUN, MD",Centre Oscar Lambret,,NCT03974204,emilie le rhun,emilie,female,0.98,72741,398,Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.,Not yet recruiting,No Results Available,Breast Cancer|Leptomeningeal Metastasis,"Procedure: Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification|Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment",Centre Oscar Lambret,Exo-LCR-1807|2018-A02358-47,"June 4, 2019","Centre Oscar Lambret, Lille, Hauts-de- France, France|Centre Hospitalier Régional Universitaire de Lille, Lille, Hauts-de-France, France",https://ClinicalTrials.gov/show/NCT03974204
Principal Investigator,"Emilie KACZMAREK, MD",Medical Oncology Department - Centre Oscar Lambret,,NCT03979339,emilie kaczmarek,emilie,female,0.98,72741,767,Feasibility of a New Technology for Isolating Circulating Tumour Cells,Not yet recruiting,No Results Available,HER2-positive Metastatic Breast Cancer|Ovarian Cancer|Hormone-resistant Prostate Cancer|Circulating Tumor Cell,Procedure: Blood sample collection,Centre Oscar Lambret,CTC-SMMiL-E-1901|2019-A01187-50,"June 7, 2019","Centre Oscar Lambret, Lille, France",https://ClinicalTrials.gov/show/NCT03979339
Study Director,"Joseph O'Connell, MD","Odonate Therapeutics, Inc.",,NCT03858972,joseph o'connell,joseph,male,0.99,60259,401,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC",Recruiting,No Results Available,Breast Cancer,Drug: Tesetaxel|Drug: Capecitabine,"Odonate Therapeutics, Inc.",ODO-TE-B201,"March 1, 2019","Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Lakewood, Colorado, United States|Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|New York Cancer and Blood Specialists, East Setauket, New York, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Border Medical Oncology, Albury, New South Wales, Australia|Hopital Maisonneuve-Rosemont, Montréal, Canada|Center Hospitalier de Montreal CHUM McPeak Sirois, Montréal, Canada|CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital, Montréal, Canada|McGill University Health Center, Montréal, Canada|CHU de Quebec-University Laval, Québec, Canada|Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre, Sherbrooke, Canada|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Hospital Teresa Herrera Materno-Infantil (CHUAC), A Coruña, Spain|Fundacion Jimenez Diaz, Madrid, Spain|National Taiwan University Hospital, Taipei City, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT03858972
Study Director,"Joseph O'Connell, M.D.","Odonate Therapeutics, Inc.",,NCT03952325,joseph o'connell,joseph,male,0.99,60259,528,Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC,Recruiting,No Results Available,Breast Cancer,Drug: Tesetaxel|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab,"Odonate Therapeutics, Inc.",ODO-TE-B202,"May 16, 2019","Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists and Research Institute - Panhandle Region, Tallahassee, Florida, United States|Florida Cancer Specialists and Research Institute, West Palm Beach, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|New York Cancer and Blood Specialists, East Setauket, New York, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Asan Medical Center, Seoul, Korea, Republic of|John Hopkins Singapore International Medical Centre, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT03952325
Principal Investigator,Joseph JY Sung,Chinese University of Hong Kong,,NCT04034953,joseph jy sung,joseph,male,0.99,60259,743,Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong,Recruiting,No Results Available,Obesity|Colorectal Cancer|Prostate Cancer|Breast Cancer,Diagnostic Test: Faecal Immunochemical Test|Diagnostic Test: Prostate-Specific Antigen Test|Diagnostic Test: Mammogram,Chinese University of Hong Kong,MCP Study_Protocol_20190226,"July 29, 2019","Lek Yuen Health Centre, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04034953
Study Director,"Joseph Woolery, PharmD, BCOP",Zymeworks Inc.,,NCT03821233,joseph woolery,joseph,male,0.99,60259,831,A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers,Recruiting,No Results Available,HER2-expressing Cancers,Drug: ZW49,Zymeworks Inc.,ZWI-ZW49-101,"January 29, 2019","City of Hope, Duarte, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago Medicine, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|NEXT Oncology, San Antonio, Texas, United States|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03821233
Study Director,"Halle Zhang, PhD, RN",Medical Lead,,NCT03961698,halle zhang,halle,female,0.67,181,402,Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3),Recruiting,No Results Available,Breast Cancer|Renal Cell Carcinoma,Drug: IPI-549|Drug: Atezolizumab|Drug: nab-paclitaxel|Drug: Bevacizumab,"Infinity Pharmaceuticals, Inc.|Roche Pharma AG",IPI-549-03,"May 23, 2019","Arizona Oncology Associates, Tucson, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Pacific Cancer Care, Monterey, California, United States|Sharp Memorial Hospital, San Diego, California, United States|UCLA, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Tennessee Oncology, Nashville, Tennessee, United States|UT Health East Texas HOPE Cancer Center, Tyler, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT03961698
Principal Investigator,"Carey Lisa, MD",UNC Lineberger Comprehensive Cancer Center,,NCT04142554,carey lisa,carey,male,0.5,580,403,Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer|Breast Neoplasms|Triple Negative Breast Cancer|HER2-positive Breast Cancer,Drug: Parsaclisib,UNC Lineberger Comprehensive Cancer Center|Incyte Corporation,LCCC1820,"October 29, 2019",,https://ClinicalTrials.gov/show/NCT04142554
Principal Investigator,"Betina Yanez, PhD",Northwestern University,,NCT03849573,betina yanez,betina,female,0.98,1180,405,A Web-Based Tool to Improve Breast Cancer Survivorship,Recruiting,No Results Available,Breast Cancer|Hormone Dependent Neoplasms|Adherence to Hormone Therapy,"Behavioral: ""OncoTool"" Intervention (MBSR + HT education)|Behavioral: ""Oncotool"" Control (health +HT education)",Northwestern University,STU00206180,"February 21, 2019","Northwestern University, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT03849573
Principal Investigator,"Shirley M. Bluethmann, PhD, MPH",Milton S. Hershey Medical Center,,NCT03955627,shirley m. bluethmann,shirley,female,0.99,18371,407,REJOIN Trial for Older Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer Female,Behavioral: Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN),"Milton S. Hershey Medical Center|American Cancer Society, Inc.",STUDY00010776,"May 20, 2019","Penn State Cancer Institute, Hershey, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03955627
Study Director,"DENIS DUPOIRON, MD",Institut de Cancérologie de l'Ouest,,NCT03794388,denis dupoiron,denis,male,0.96,57303,409,Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery,Recruiting,No Results Available,Breast Cancer Patient,Drug: Capsaicin|Drug: Pregabalin,Institut Cancerologie de l'Ouest|Grünenthal GmbH,ICO-A-2018-10,"January 7, 2019","Institut de Cancerologie de L'Ouest, Angers, France|Chu Grenoble, Grenoble, France|Chd Vendee, La Roche-sur-Yon, France|Centre Oscar Lambret, Lille, France|Hopital Saitn Vincent de Paul, Lille, France|Centre Leon Berard, Lyon, France|CHU NICE, Nice, France|Institut Jean Godinot, Reims, France|Institut Curie, Saint-Cloud, France|Iuct Oncopole, Toulouse, France|Ch Valenciennes, Valenciennes, France",https://ClinicalTrials.gov/show/NCT03794388
Principal Investigator,"Ana Joaquim, MD",Centro Hospitalar de Vila Nova de Gaia/Espinho,,NCT04024280,ana joaquim,ana,female,0.98,273767,411,Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer|Quality of Life|Physical Exercise,Other: Physical exercise program,Associacao de Investigacao de Cuidados de Suporte em Oncologia|Centro Hospitalar de Vila Nova de Gaia/Espinho|Aveiro University|University Institute of Maia,MAMA_MOVE_Gaia After Treatment,"July 18, 2019","Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Oporto, Portugal",https://ClinicalTrials.gov/show/NCT04024280
Principal Investigator,"Raul Rosenthal, MD",Cleveland Clinic Florida,,NCT04170335,raul rosenthal,raul,male,0.99,64281,412,Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients,Not yet recruiting,No Results Available,Breast Cancer|Morbid Obesity|Bariatric Surgery Candidate,Procedure: Bariatric surgery,The Cleveland Clinic,FLA 18-057,"November 20, 2019",,https://ClinicalTrials.gov/show/NCT04170335
Principal Investigator,"Bethany Anderson, MD","University of Wisconsin, Madison",,NCT03936478,bethany anderson,bethany,female,0.97,1003,414,Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer,Suspended,No Results Available,Breast Cancer|DCIS|LCIS,Radiation: MRIdian Radiation Treatment Unit,"University of Wisconsin, Madison",UW18099|2019-0322|SMPH\HUMAN ONCO\HUMAN ONCO|A533300|NCI-2019-03111|Protocol Version 3/10/2020,"May 3, 2019","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03936478
Principal Investigator,"Tejas Mehta, MD",Beth Israel Deaconess Hospital,,NCT04102722,tejas mehta,tejas,male,0.99,451,416,Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening,Recruiting,No Results Available,Breast Cancer Screening,Device: MUST device,"Transonic Imaging, Inc.",MUST-02-001,"September 25, 2019","Beth Israel Deaconess Medical Center BreastCare Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04102722
Study Chair,"Zsuzsanna IK Jarmy-di Bella, PhD",Professor,,NCT04081805,zsuzsanna ik jarmy-di bella,zsuzsanna,female,0.99,7943,419,LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2),Recruiting,No Results Available,Vaginal Atrophy|Vulva; Atrophy|Breast Cancer,Procedure: LASER|Procedure: Micro Ablative Radiofrequency|Drug: Promestriene,Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo,CEP0431/2018 arm 2,"September 9, 2019","Federal University of Sao Paulo - Unifesp, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04081805
Principal Investigator,"Ting Luo, MD",West China Hospital,,NCT04152057,ting luo,ting,female,0.65,1837,420,Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer,Recruiting,No Results Available,Breast Cancer|HER2 Positive|Combination Chemotherapy,Drug: Pyrotinib Maleate Tablets|Drug: Albumin Paclitaxel|Drug: Trastuzumab,"West China Hospital|Jiangsu HengRui Medicine Co., Ltd.",BLTN-NeoBC1115,"November 5, 2019","West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China",https://ClinicalTrials.gov/show/NCT04152057
Principal Investigator,Andrei Iagaru,Stanford Cancer Institute Palo Alto,,NCT03831711,andrei iagaru,andrei,male,0.97,21506,421,68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer,Recruiting,No Results Available,Breast Carcinoma|Estrogen Receptor Positive,Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Device: Investigational software and coils in PET/MR scan,Andrei Iagaru|General Electric|Stanford University,IRB-48150|NCI-2019-00237|BRS0098,"February 6, 2019","Stanford Cancer Institute Palo Alto, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT03831711
Principal Investigator,"Nadia Harbeck, Prof. Dr.","Ludwigs-Maximilians-University Munich, Breast Cancer Centre",,NCT04055493,nadia harbeck,nadia,female,0.98,66915,422,"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC",Recruiting,No Results Available,Breast Cancer Female,Drug: Ribociclib 200Mg Oral Tablet,"West German Study Group|Novartis|Genomic Health®, Inc.",WSG-AM08,"August 13, 2019","Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, Munich, Bavaria, Germany|Universitätsklinikum Aachen, Frauenklinik - Senologie, Aachen, NRW, Germany|Kliniken Essen-Mitte, Klinik für Senologie/Interdisziplinäres Brustzentrum, Essen, NRW, Germany|Praxis für gynäkologische Onkologie am Ev. Krankenhaus Bethesda, Moenchengladbach, NRW, Germany",https://ClinicalTrials.gov/show/NCT04055493
Principal Investigator,"Roberta M. diFlorio-Alexander, MD",Dartmouth-Hitchcock Medical Center,,NCT03931655,roberta m. diflorio-alexander,roberta,female,0.99,43416,424,Photoacoustic Lymph Node Imaging,Enrolling by invitation,No Results Available,Breast Cancer,Diagnostic Test: Spectroscopic photoacoustic imaging,Geoff Luke|Dartmouth College|Dartmouth-Hitchcock Medical Center,D18155,"April 30, 2019","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",https://ClinicalTrials.gov/show/NCT03931655
Principal Investigator,"Maria Vazquez Roque, MD, MS",Mayo Clinic,,NCT04139993,maria vazquez roque,maria,female,0.98,334287,427,A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug,Not yet recruiting,No Results Available,Breast Cancer,Biological: RBX7455,Mayo Clinic|Rebiotix Inc.,19-004024,"October 25, 2019",,https://ClinicalTrials.gov/show/NCT04139993
Principal Investigator,"Maria Vernet-Tomas, MD, PhD",Parc de Salut Mar,,NCT04039893,maria vernet-tomas,maria,female,0.98,334287,456,MUltimodal Targeted Axillary Surgery,Recruiting,No Results Available,Node-positive Breast Cancer,Diagnostic Test: Systematic axillary ultrasound imaging|Diagnostic Test: Sentinel node|Procedure: Excision of suspicious lymph nodes|Procedure: Two steps axillary node clearance,Parc de Salut Mar|GEICAM,2018/8361/I,"July 31, 2019","Hospital del Mar, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04039893
Principal Investigator,"Federico bizzarri, MD",Arcispedale Santa Maria Nuova-IRCCS,,NCT03992859,federico bizzarri,federico,male,0.99,43663,428,Continuous Serrates Plane Block in Axillary Dissection,Recruiting,No Results Available,Breast Cancer,Procedure: Continuous serratus plane block,Arcispedale Santa Maria Nuova-IRCCS,CIMPAX BREAST,"June 20, 2019","Ausl-Irccs Reggio Emilia, Reggio Emilia, RE, Italy",https://ClinicalTrials.gov/show/NCT03992859
Principal Investigator,"Michaël GRYNBERG, MD, PhD",Assistance Publique - Hôpitaux de Paris,,NCT03947151,michaël grynberg,michaël,male,1.0,3,430,Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer,Recruiting,No Results Available,Invasive Ductal Breast Carcinoma,Drug: Degarelix injection(s),Assistance Publique - Hôpitaux de Paris,P170407J|2018-000049-38,"May 13, 2019","Hôpital Antoine Béclère, Clamart, France",https://ClinicalTrials.gov/show/NCT03947151
Principal Investigator,"Charlotte E Coles, MB ChB, MRCP, FRCR, PhD",University of Cambridge,,NCT03818100,charlotte e coles,charlotte,female,0.97,37761,433,Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible,Recruiting,No Results Available,Breast Cancer,Radiation: Intensity modulated radiotherapy (IMRT)|Drug: Endocrine therapy|Procedure: Breast conserving surgery,CCTU- Cancer Theme|Breast Cancer Now|CRUK Cambridge Institute|Cambridge University Hospitals NHS Foundation Trust,Neo-RT,"January 28, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT03818100
Principal Investigator,"Charlotte VAYSSE, MCU-PH","University Hospital, Toulouse",,NCT03981263,charlotte vaysse,charlotte,female,0.97,37761,609,Study of the Quality of Life in Patients With Standard External Breast Prosthesis Compared to Patients With Custom-made Breast Prosthesis.,Not yet recruiting,No Results Available,Breast Cancer,Device: MEAVANTI prothesis|Device: Standard prothesis,"University Hospital, Toulouse",RC31/17/0335,"June 10, 2019","CHU Rangueil, Toulouse, France",https://ClinicalTrials.gov/show/NCT03981263
Principal Investigator,"Olufunmilayo I Olopade, MD",University of Chicago,,NCT03879577,olufunmilayo i olopade,olufunmilayo,female,0.89,53,437,Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III,Drug: Docetaxel|Drug: Herceptin|Drug: FEC|Drug: Tamoxifen|Drug: Letrozole|Drug: LHRH agonist,University of Chicago,IRB18-1178,"March 19, 2019","University College Hospital, Ibadan, Nigeria, Ibadan, Nigeria",https://ClinicalTrials.gov/show/NCT03879577
Principal Investigator,"Delphine Hequet, MD",Institut Curie,,NCT03870919,delphine hequet,delphine,female,0.98,34395,438,"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients",Suspended,No Results Available,Breast Cancer Stage IV|Radiotherapy|Surgery,Drug: Palbociclib|Other: locoregional treatment,UNICANCER|Pfizer,UC-0140/1814|2019-A00570-57,"March 12, 2019","Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre François Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre George François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital St Joseph, Marseille, France|Institut Paoli Calmettes, Marseille, France|ICM Val d'Aurelle, Montpellier, France|Polyclinique de Gentilly, Nancy, France|Centre Antoine Lacassagne, Nice, France|Institut Curie Site Paris, Paris, France|Hôpital Saint Louis APHP, Paris, France|Hôpital St Joseph, Paris, France|Hôpital Tenon, Paris, France|Centre Hospitalier de Pau, Pau, France|Institut Jean Godinot, Reims, France|Institut Curie Hôpital René Huguenin, Saint Cloud, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France|Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT03870919
Principal Investigator,"Julia Ruiz Vozmediano, Dr",Hospital Virgen de las Nieves,,NCT04150484,julia ruiz vozmediano,julia,female,0.97,106666,439,"Influence of an Intervention on Diet, Physical Exercise and Mindfulness in the Quality of Life of Survivors With Breast Cancer",Completed,No Results Available,Breast Cancer|Nutrition Related Cancer|Physical Activity|Mindfulness,"Other: Mediterranean diet, physical exercise and mindfulness workshops",Universidad de Granada|University Hospital Virgen de las Nieves,040907,"November 4, 2019",,https://ClinicalTrials.gov/show/NCT04150484
Principal Investigator,Julia Trosman,ECOG-ACRIN Cancer Research Group,,NCT03804255,julia trosman,julia,female,0.97,106666,762,Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting,Recruiting,No Results Available,Breast Carcinoma|Colorectal Carcinoma|Community Practice|Lung Carcinoma|Melanoma|Solid Neoplasm,Other: Survey Administration,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,EAQ161CD|NCI-2018-01707|ECOG-ACRIN-EAQ161CD|UG1CA189828,"January 15, 2019","Northwestern University, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT03804255
Study Director,"Osama HA El-Sayed, Professor",Assiut University,,NCT03969524,osama ha el-sayed,osama,male,0.98,8125,443,Functional MRI in Predicting Response to Chemotherapy,Not yet recruiting,No Results Available,Breast Cancer Patients,Device: MRI,Assiut University,MRI in response assesment,"May 31, 2019",,https://ClinicalTrials.gov/show/NCT03969524
Principal Investigator,"Osama Hussein, MD,PhD.FEBS",Mansoura University,,NCT04091958,osama hussein,osama,male,0.98,8125,621,Reconstruction of Partial Mastectomy Defects With Pectoralis Myo-glandular Local Flap.,Recruiting,No Results Available,Breast Cancer,Procedure: Pectoralis myo-glandular flap reconstruction.,Mansoura University,R/19.08.578,"September 17, 2019","Mansoura University Oncology Center, Mansourah, DK, Egypt",https://ClinicalTrials.gov/show/NCT04091958
Study Chair,"Saloua El Messaoudi, PhD",Radboud University,,NCT04046315,saloua el messaoudi,saloua,female,0.98,1248,444,Early Detection of Cardiac Damage With CMR in Women With Breast Cancer,Recruiting,No Results Available,Cardiotoxicity|Breast Cancer|Chemotherapy Induced Systolic Dysfunction,Diagnostic Test: CMR,Radboud University,108818,"August 6, 2019","Radboud University Medical Center, Nijmegen, Netherlands",https://ClinicalTrials.gov/show/NCT04046315
Principal Investigator,"Angela Maas, PhD",Radboud University,,NCT04046315,angela maas,angela,female,0.99,106685,444,Early Detection of Cardiac Damage With CMR in Women With Breast Cancer,Recruiting,No Results Available,Cardiotoxicity|Breast Cancer|Chemotherapy Induced Systolic Dysfunction,Diagnostic Test: CMR,Radboud University,108818,"August 6, 2019","Radboud University Medical Center, Nijmegen, Netherlands",https://ClinicalTrials.gov/show/NCT04046315
Study Chair,"Robin Nijveldt, PhD",Radboud University,,NCT04046315,robin nijveldt,robin,male,0.93,34003,444,Early Detection of Cardiac Damage With CMR in Women With Breast Cancer,Recruiting,No Results Available,Cardiotoxicity|Breast Cancer|Chemotherapy Induced Systolic Dysfunction,Diagnostic Test: CMR,Radboud University,108818,"August 6, 2019","Radboud University Medical Center, Nijmegen, Netherlands",https://ClinicalTrials.gov/show/NCT04046315
Principal Investigator,"Angela L Gibson, MD, PhD","University of Wisconsin, Madison",,NCT04145323,angela l gibson,angela,female,0.99,106685,678,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,Completed,No Results Available,Breast Cancer|Necrosis,Diagnostic Test: ICG microangiography,"University of Wisconsin, Madison",2019-0557|SMPH/SURGERY/SURGTRAMA|A539714|UW19043,"October 30, 2019","University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04145323
Principal Investigator,"Samuel O Poore, MD, PhD","University of Wisconsin, Madison",,NCT04145323,samuel o poore,samuel,male,0.99,59464,678,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,Completed,No Results Available,Breast Cancer|Necrosis,Diagnostic Test: ICG microangiography,"University of Wisconsin, Madison",2019-0557|SMPH/SURGERY/SURGTRAMA|A539714|UW19043,"October 30, 2019","University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04145323
Principal Investigator,"Barbara Ehrlich, PhD",Yale University,,NCT03872141,barbara ehrlich,barbara,female,0.98,94709,446,Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Chemotherapy Induced Peripheral Neuropathy|Paclitaxel Induced Neuropathy,Diagnostic Test: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer,Yale University,2000020709,"March 13, 2019","Smilow Cancer Center, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT03872141
Principal Investigator,"Alexandre Chan, Pharm D","National University of Singapore, National Cancer Centre Singapore",,NCT04104113,alexandre chan,alexandre,male,0.99,61354,448,Health-related Quality of Life-intervention in Breast Cancer Survivors Experiencing Cancer-related Fatigue Using Traditional Chinese Medicine: The HERBAL Trial,Recruiting,No Results Available,Breast Cancer|Fatigue|Cognitive Impairment,Other: Modified Xiang Bei Yangrong Tang|Other: Placebo,"National University, Singapore|National Cancer Centre, Singapore|Singapore Thong Chai Medical Institute",CIRB Ref. No: 2019/2135|TCMRG-3-NUS-01,"September 26, 2019","National Cancer Centre Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04104113
Principal Investigator,"Alexandre Chan, PharmD","National University of Singapore, National Cancer Centre Singapore",,NCT04014309,alexandre chan,alexandre,male,0.99,61354,641,Accessible Cancer Care to Enable Support for Survivors Programme,Recruiting,No Results Available,Survivorship|Breast Cancer|Gynecologic Cancer,Other: Supportive and survivorship care program|Other: Usual care,"National University, Singapore|National Cancer Centre, Singapore",CIRB Ref. No: 2019/2090,"July 10, 2019","National Cancer Centre Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04014309
Principal Investigator,"Kathryn H Schmitz, PhD",Penn State University,,NCT03975621,kathryn h schmitz,kathryn,female,0.98,2307,449,Nurse AMIE: Addressing Metastatic Individuals Everyday,Recruiting,No Results Available,Metastatic Breast Cancer,Behavioral: Supportive Care,Milton S. Hershey Medical Center,STUDY00011444,"June 5, 2019","Penn State Cancer Institute, Hershey, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03975621
Principal Investigator,"Kathryn Weaver, MD",Wake Forest University Health Sciences,,NCT03935282,kathryn weaver,kathryn,female,0.98,2307,788,Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors,Enrolling by invitation,No Results Available,Breast Neoplasm|Prostatic Neoplasm|Colorectal Neoplasms|Endometrial Neoplasms|Hodgkin Disease|Non Hodgkin Lymphoma,Other: AH-HA Tool in the EPIC EHR,Wake Forest University Health Sciences|National Cancer Institute (NCI)|Washington University School of Medicine|University of Texas Southwestern Medical Center,IRB00056774|NCI-2019-01362,"May 2, 2019","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03935282
Principal Investigator,"Giovanni Corso, MD",European Institute of Oncology,,NCT04206891,giovanni corso,giovanni,male,0.99,104824,451,CDH1 Germline Mutations in Lobular Breast Cancer,Recruiting,No Results Available,Lobular Breast Carcinoma|CDH1 Gene Inactivation,,European Institute of Oncology,IEO 0834/,"December 20, 2019","European Institute of Oncology, Milan, Italy",https://ClinicalTrials.gov/show/NCT04206891
Principal Investigator,"Ricard Isaacs, MBChB FRACP",Midcentral Regional Cancer Centre Services,,NCT03948477,ricard isaacs,ricard,male,0.97,2262,452,Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy,Not yet recruiting,No Results Available,Oncology|Breast Cancer|Chemotherapy-induced Nausea and Vomiting,Drug: Pantoprazole 40mg|Drug: Placebo,"University of Auckland, New Zealand",CTNZ-2017-17,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03948477
Principal Investigator,"Navin Wewala, MBChB FRACP",Midcentral Regional Cancer Centre Services,,NCT03948477,navin wewala,navin,male,0.98,858,452,Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy,Not yet recruiting,No Results Available,Oncology|Breast Cancer|Chemotherapy-induced Nausea and Vomiting,Drug: Pantoprazole 40mg|Drug: Placebo,"University of Auckland, New Zealand",CTNZ-2017-17,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03948477
Principal Investigator,"Cynthia Aristei, MD",University Of Perugia,,NCT03997188,cynthia aristei,cynthia,female,0.99,31660,454,Zinc-L-Carnosine Prevents Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy,Completed,No Results Available,Breast Cancer Female|Dysphagia|Adjuvant Radiotherapy,Device: Hepilor,Cynthia Aristei|University Of Perugia,003 (Hepilor),"June 25, 2019","University of Perugia, Perugia, Italy",https://ClinicalTrials.gov/show/NCT03997188
Principal Investigator,Cynthia X Ma,Duke University - Duke Cancer Institute LAO,,NCT03939897,cynthia x ma,cynthia,female,0.99,31660,505,Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer - Dose-Finding Study,Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma,Drug: Abemaciclib|Drug: Copanlisib Hydrochloride|Drug: Fulvestrant,National Cancer Institute (NCI),NCI-2019-02752|10287|UM1CA186704,"May 7, 2019","University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT03939897
Study Chair,"Karina D Steffensen, Professor",Vejle Hospital,,NCT04177628,karina d steffensen,karina,female,0.98,29586,455,Shared Decision Making With Breast Cancer Patients,Recruiting,No Results Available,"Shared Decision Making|Breast Neoplasms|Radiotherapy, Adjuvant",Behavioral: Shared decision making supported by an in-consultation patient decision aid,Vejle Hospital|Danish Breast Cancer Cooperative Group|University of Southern Denmark|Danish Comprehensive Cancer Center,DBCG RT SDM,"November 26, 2019","Aalborg Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev University Hospital, Herlev, Denmark|Sjaellands University Hospital, Næstved, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark",https://ClinicalTrials.gov/show/NCT04177628
Principal Investigator,"Stine R Sondergaard, M.D.",Vejle Hospital,,NCT04177628,stine r sondergaard,stine,female,0.96,1200,455,Shared Decision Making With Breast Cancer Patients,Recruiting,No Results Available,"Shared Decision Making|Breast Neoplasms|Radiotherapy, Adjuvant",Behavioral: Shared decision making supported by an in-consultation patient decision aid,Vejle Hospital|Danish Breast Cancer Cooperative Group|University of Southern Denmark|Danish Comprehensive Cancer Center,DBCG RT SDM,"November 26, 2019","Aalborg Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev University Hospital, Herlev, Denmark|Sjaellands University Hospital, Næstved, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark",https://ClinicalTrials.gov/show/NCT04177628
Principal Investigator,"Sun Wook Cho, M.D., Ph.D.",Seoul National University Hospital,,NCT03814811,sun wook cho,sun,male,0.52,6975,457,Circulating Osteocalcin-positive Cells in Breast Cancer Bone Metastasis,Recruiting,No Results Available,Breast Neoplasms|Bone Metastases,Diagnostic Test: Circulating Osteocalcin-positive (cOC) cells,"Seoul National University Hospital|National Cancer Center, Korea",SNUH-IRB-1706069859,"January 24, 2019","Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT03814811
Principal Investigator,"Joyce A O'Shaughnessy, MD",Baylor Scott and White University Medical Center,,NCT04032080,joyce a o'shaughnessy,joyce,female,0.96,16082,459,Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Drug 1: LY3023414; Drug 2: Prexasertib,Baylor Research Institute|Eli Lilly and Company,018-745,"July 25, 2019","Baylor Scott and White University Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04032080
Principal Investigator,"Joyce O'Shaunessey, MD",US Oncology,,NCT04016935,joyce o'shaunessey,joyce,female,0.96,16082,511,EndoPredict® Extended Endocrine Trial (EXET),Recruiting,No Results Available,Breast Cancer,,"Myriad Genetic Laboratories, Inc.",ONC-010,"July 12, 2019","Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04016935
Principal Investigator,"Yunjiang Liu, MD",Hebei Medical University Fourth Hospital,,NCT04067102,yunjiang liu,yunjiang,male,1.0,1,460,Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Drug: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,Hebei Medical University Fourth Hospital,TNBC-NEO,"August 26, 2019","Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",https://ClinicalTrials.gov/show/NCT04067102
Principal Investigator,"Ze Fei Jiang, Ph.D",Affiliated Hospital of Academy of Military Medical Sciences,,NCT04170595,ze fei jiang,ze,male,0.93,3865,469,Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection,Recruiting,No Results Available,HER2-positive Breast Cancer,"Biological: GB221,2 mg/kg|Biological: GB221,6 mg/kg|Biological: Herceptin,6 mg/kg|Biological: GB221,8mg/kg|Biological: GB221:2mg/kg and Capecitabi:1000mg/kg|Biological: Herceptin:2mg/kg and Capecitabin:1000mg/kg","Genor Biopharma Co., Ltd.",GENOR GB221-002,"November 20, 2019","Affiliated Hospital of Academy of Military Medical Sciences, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04170595
Principal Investigator,"Kelli Koltyn, PhD","Professor of Kinesiology- Exercise Psychology, University of Wisconsin-Madison",,NCT04075097,kelli koltyn,kelli,female,0.93,686,470,"Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain",Completed,No Results Available,Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Neuropathic Pain,Behavioral: Aerobic exercise|Behavioral: Iyengar yoga,"University of Wisconsin, Madison|American College of Sports Medicine",2018-1518|A176000|EDUC/KINESIOLOGY/KINESIOLOG|UW18057,"August 30, 2019","University of Wisconsin-Madison Natatorium, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04075097
Principal Investigator,"Carmen Gómez Candela, Msc",Hospital Universitario La Paz,,NCT03918668,carmen gómez candela,carmen,female,0.98,103801,472,Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women,"Active, not recruiting",No Results Available,"Breast Neoplasm Female|Nutrition Related Cancer|Habits, Diet|Cancer, Breast",Behavioral: Women with recent diagnosis of breast cancer,Instituto de Investigación Hospital Universitario La Paz,PI-2842,"April 17, 2019","Institute for Health Research IdiPAZ, Madrid, Spain",https://ClinicalTrials.gov/show/NCT03918668
Principal Investigator,"gianluca cappelleri, MD","AUSL IRCCS Reggio Emilia, Italy",,NCT03941223,gianluca cappelleri,gianluca,male,0.99,41833,473,Regional Anesthesia for Breast Surgery,Recruiting,No Results Available,Breast Cancer,Procedure: PECSII and paravertebral blocks,Arcispedale Santa Maria Nuova-IRCCS,Breastblock,"May 7, 2019","AUSL IRCCS Reggio Emilia, Reggio Emilia, Italy",https://ClinicalTrials.gov/show/NCT03941223
Study Director,"Svein Skeie, PhD",Helse Stavanger HF; Stavanger University Hospital,,NCT03886389,svein skeie,svein,male,0.98,814,475,Breast Cancer Diet Intervention Study,Completed,No Results Available,Early-stage Breast Cancer|Carbohydrate Engorgement|Proliferation|Insulin Resistance|Estrogen Receptor-positive Breast Cancer,Dietary Supplement: PreOP,Helse Stavanger HF,59,"March 22, 2019",,https://ClinicalTrials.gov/show/NCT03886389
Principal Investigator,"Waseem Khaliq, MD",Johns Hopkins University,,NCT04164251,waseem khaliq,waseem,male,0.98,2479,480,Inpatient Screening Mammography for Non-adherent and High Risk Women,Completed,No Results Available,Breast Cancer,Other: Screening mammography,"Johns Hopkins University|Maryland Cigarette Restitution Research Grant|EQUIP (Excellence in Quality, Utilization of resources, Integration and Patient- centered Care)",NA_00079826,"November 15, 2019",,https://ClinicalTrials.gov/show/NCT04164251
Principal Investigator,"Saveri Bhattacharya, DO",Sidney Kimmel Cancer Center at Thomas Jefferson University,,NCT03955640,saveri bhattacharya,saveri,male,0.83,6,485,Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences,Recruiting,No Results Available,Metastatic Malignant Neoplasm in the Chest Wall|Recurrent Breast Carcinoma,Drug: Olaparib|Procedure: Hyperthermia Treatment|Other: Questionnaire Administration|Other: Quality-of-Life Assessment,Thomas Jefferson University|AstraZeneca,19P.117,"May 20, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03955640
Principal Investigator,"Ayse Cal, Asst Prof",Ankara Medipol University,,NCT04098783,ayse cal,ayse,female,0.96,16275,486,Health Belief Model Based Nursing Interventions on Lymphedema Prevention,Completed,No Results Available,Breast Cancer|Breast Cancer Lymphedema|Home Visit,"Other: Home visit, health education",Ayse Cal|The Scientific and Technological Research Council of Turkey|Dokuz Eylul University,04.04.2013 970-GOA,"September 23, 2019",,https://ClinicalTrials.gov/show/NCT04098783
Study Director,"Zuhal Bahar, Prof",Koç University,,NCT04098783,zuhal bahar,zuhal,female,0.97,3609,486,Health Belief Model Based Nursing Interventions on Lymphedema Prevention,Completed,No Results Available,Breast Cancer|Breast Cancer Lymphedema|Home Visit,"Other: Home visit, health education",Ayse Cal|The Scientific and Technological Research Council of Turkey|Dokuz Eylul University,04.04.2013 970-GOA,"September 23, 2019",,https://ClinicalTrials.gov/show/NCT04098783
Study Chair,"Ilknur Gorken, Prof",Dokuz Eylul University,,NCT04098783,ilknur gorken,ilknur,female,0.97,6914,486,Health Belief Model Based Nursing Interventions on Lymphedema Prevention,Completed,No Results Available,Breast Cancer|Breast Cancer Lymphedema|Home Visit,"Other: Home visit, health education",Ayse Cal|The Scientific and Technological Research Council of Turkey|Dokuz Eylul University,04.04.2013 970-GOA,"September 23, 2019",,https://ClinicalTrials.gov/show/NCT04098783
Principal Investigator,"Jayanthi Lea, MD",University of Texas Southwestern Medical Center,,NCT04041128,jayanthi lea,jayanthi,female,0.97,96,488,PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer,Recruiting,No Results Available,Ovarian Cancer|Breast Cancer,Drug: Lynparza,University of Texas Southwestern Medical Center,STU-2019-0769,"August 1, 2019","University of Texas Southwestern Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04041128
Principal Investigator,"Lauren Nye, MD",University of Kansas,,NCT03983577,lauren nye,lauren,female,0.9,8924,489,Efficacy of Point Of Service Testing in MBC,Recruiting,No Results Available,Metastatic Cancer|Breast Cancer,Other: Point of service delivery model,University of Kansas Medical Center,ePOST,"June 12, 2019","The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States",https://ClinicalTrials.gov/show/NCT03983577
Principal Investigator,"Alexander Lucas, Ph.D.",Massey Cancer Center,,NCT03923504,alexander lucas,alexander,male,0.99,66065,492,Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx,"Active, not recruiting",No Results Available,Hodgkin Lymphoma|Non-hodgkin Lymphoma|Lymphoma|Breast Cancer,Other: Physical Activity Intervention (PAI)|Other: Healthy Living Control,Virginia Commonwealth University,MCC-19-14621,"April 22, 2019","Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT03923504
Principal Investigator,"hazem nour, MD","assistant professor, general surgery",,NCT04137744,hazem nour,hazem,male,0.98,3411,493,"Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, Measuring Arm Size for Lymphedema, Histopathological Examination of Arm Lymph Nodes Included With Axillary Lymph Node Dissection",Completed,No Results Available,Arm Lymphedema|Lymphatic Spread of Breast Cancer|Early Breast Cancer,Procedure: AXILLARY REVERSE MAPPING,Zagazig University,hazem nour,"October 24, 2019","Zagazig Faculty of Medicine, Zagazig, Sharqya, Egypt",https://ClinicalTrials.gov/show/NCT04137744
Principal Investigator,"Su-Ying Fang, PhD",National Cheng Kung University,,NCT04190992,su-ying fang,su-ying,female,1.0,1,495,E-Based Technology to Provide Decision Aid on Breast Reconstruction for Women With Breast Cance,"Active, not recruiting",No Results Available,Decision Support Technique|Breast Cancer,Other: E-based & personalized breast reconstruction surgery decision aid|Other: Usual care,National Cheng-Kung University Hospital|National Cheng Kung University,B-ER-106-072,"December 9, 2019","National Cheng Kung University Hospital, Tainan, Taiwan",https://ClinicalTrials.gov/show/NCT04190992
Study Director,"Steve Dennis, B.Sc.",First Option Software,,NCT03829423,steve dennis,steve,male,0.99,72719,497,An Enhanced Artificial Intelligence Breast MRI Interpretation System,Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Breast MRI interpretation,Jamil Kanfoud|Brunel University London|First Option Software Ltd.|Teesside University,4901,"February 4, 2019",,https://ClinicalTrials.gov/show/NCT03829423
Principal Investigator,"Ayal Aizer, MD, MHS",Brigham and Women's Hospital,,NCT04030507,ayal aizer,ayal,male,0.85,62,498,Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Inflammatory Breast Cancer|Metastatic Breast Cancer,Device: MRI,Dana-Farber Cancer Institute|Conquer Cancer Foundation,19-066,"July 24, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04030507
Principal Investigator,"Abigail Caudle, MD, MS","MD Anderson Cancer Center, Houston, TX",,NCT03796559,abigail caudle,abigail,female,0.98,5295,500,Magseed Enabled Long-Term Localization of Axillary Lymph Nodes,Recruiting,No Results Available,Breast Cancer|Axillary Lymph Nodes,Device: Magseed Marker,Endomagnetics Inc|M.D. Anderson Cancer Center,US-003,"January 8, 2019","Cooper Health, MD Anderson Cancer Center, Camden, New Jersey, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03796559
Principal Investigator,Jyoti Malhotra,Rutgers University - Cancer Institute of New Jersey LAO,,NCT04090398,jyoti malhotra,jyoti,female,0.81,700,501,Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the Bones,Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma Metastatic in the Bone|Metastatic Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Paclitaxel|Radiation: Radium Ra 223 Dichloride,National Cancer Institute (NCI),NCI-2019-06088|10302|UM1CA186716,"September 16, 2019","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04090398
Principal Investigator,"Marc Thill, PD Dr.",Leading Principal Investigator,,NCT03975855,marc thill,marc,male,0.99,116213,502,Evaluation of NeoNavia® Biopsy System in Axillary Lymph Nodes,Recruiting,No Results Available,Breast Cancer,Device: NeoNavia® Biopsy System,NeoDynamics AB,NEODOC-2021668610-165,"June 5, 2019","Klinikum Esslingen, Esslingen, BW, Germany|Universitätsfrauenklinik Tübingen, Tübingen, BW, Germany|Agaplesion Markus Krankenhaus, Frankfurt, HE, Germany|Universitäts-Frauenklinik, Rostock, MV, Germany|HJK Erkelenz, Erkelenz, NRW, Germany|Kliniken Essen-Mitte, Essen, NRW, Germany|Uniklinik Köln, Köln, NRW, Germany",https://ClinicalTrials.gov/show/NCT03975855
Principal Investigator,"Wen Xia, MD",SunYat-sen University Cancer Center,,NCT04172259,wen xia,wen,female,0.54,2776,503,ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC,Recruiting,No Results Available,Breast Cancer|Neoadjuvant Chemotherapy,Drug: Doxorubicin liposome|Drug: Cyclophosphamide|Drug: Trastuzumab|Drug: Docetaxel|Drug: Epirubicin,"Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",METIS|SCBCG-023,"November 21, 2019","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04172259
Principal Investigator,Charles L Loprinzi,Mayo Clinic,,NCT03941743,charles l loprinzi,charles,male,0.99,49331,504,Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer,Recruiting,No Results Available,Breast Carcinoma,Drug: Fingolimod|Drug: Fingolimod Hydrochloride|Other: Questionnaire Administration,Mayo Clinic|National Cancer Institute (NCI),MC18C1|NCI-2019-02741|P30CA015083,"May 8, 2019","Mayo Clinic, Rochester, Minnesota, United States|Virginia Commonwealth University/ Massey Cancer Center, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT03941743
Principal Investigator,Malin Backman,Karolinska University Hospital,,NCT04059835,malin backman,malin,female,0.95,5619,506,"OptiBra Study, Optimal Postoperative Bra After Breastcancer Surgery",Recruiting,No Results Available,Bra|Breast Cancer Surgery|Complication|Compression|Symptoms,Other: OptiBra study,Karolinska University Hospital,KarolinskaUD,"August 16, 2019","Karolinska University Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04059835
Principal Investigator,"Gregory A Vidal, MD.,PhD",West Cancer Center,,NCT03812393,gregory a vidal,gregory,male,0.99,25701,509,Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast,Recruiting,No Results Available,Triple Negative Breast Cancer|Early-stage Breast Cancer|HER2-positive Breast Cancer,Drug: Neratinib,"West Cancer Center|Celcuity|Puma Biotechnology, Inc.",2018-002,"January 23, 2019","West Cancer Center, Germantown, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03812393
Principal Investigator,"Maysa Abu-Khaaf, MD",Sidney Kimmel Cancer Center at Thomas Jefferson University,,NCT04054557,maysa abu-khaaf,maysa,female,0.94,1395,510,Utilization of Telehealth to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients,Recruiting,No Results Available,Estrogen Receptor-positive Breast Cancer|Progesterone Receptor Positive Breast Cancer|Stage 0 Breast Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7,Other: Telemedicine|Other: Best Practice|Other: Questionnaire Administration|Other: Quality-of-Life Assessment,Thomas Jefferson University,18D.003,"August 13, 2019","Thomas Jefefrson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04054557
Study Chair,"Herui Yao, PhD",Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,NCT04004559,herui yao,herui,male,1.0,1,514,MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02),Recruiting,No Results Available,Invasive Breast Cancer|Neoadjuvant Chemotherapy|Radiomics|Axillary Lymph Node|Prognosis,Other: No interventions,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University,SYSEC-KY-KS-2019-055-001,"July 2, 2019","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04004559
Principal Investigator,"Haotian Lin, PhD","Zhongshan Ophthalmic Center, Sun Yat-sen University",,NCT04004559,haotian lin,haotian,male,1.0,18,514,MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02),Recruiting,No Results Available,Invasive Breast Cancer|Neoadjuvant Chemotherapy|Radiomics|Axillary Lymph Node|Prognosis,Other: No interventions,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University,SYSEC-KY-KS-2019-055-001,"July 2, 2019","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04004559
Study Chair,"Herui Yao, PhD",Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,NCT04003558,herui yao,herui,male,1.0,1,517,Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01),Recruiting,No Results Available,"Breast Neoplasm Female|Early-stage Breast Cancer|Radiomics|Axillary Lymph Node|Survival, Prosthesis",Other: No interventions,"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University|Shunde Hospital of Southern Medical University|Zhongshan Ophthalmic Center, Sun Yat-sen University",SYSEC-KY-KS-2019-054-001,"July 1, 2019","Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, China|Shunde hospital of southern medical university, Foshan, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04003558
Principal Investigator,"Haotian Lin, PhD","Zhongshan Ophthalmic Center, Sun Yat-sen University",,NCT04003558,haotian lin,haotian,male,1.0,18,517,Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01),Recruiting,No Results Available,"Breast Neoplasm Female|Early-stage Breast Cancer|Radiomics|Axillary Lymph Node|Survival, Prosthesis",Other: No interventions,"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University|Shunde Hospital of Southern Medical University|Zhongshan Ophthalmic Center, Sun Yat-sen University",SYSEC-KY-KS-2019-054-001,"July 1, 2019","Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, China|Shunde hospital of southern medical university, Foshan, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04003558
Principal Investigator,"Jie Ouyang, PhD",Tungwah Hospital of Sun Yat-Sen University,,NCT04003558,jie ouyang,jie,male,0.57,1619,517,Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01),Recruiting,No Results Available,"Breast Neoplasm Female|Early-stage Breast Cancer|Radiomics|Axillary Lymph Node|Survival, Prosthesis",Other: No interventions,"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University|Shunde Hospital of Southern Medical University|Zhongshan Ophthalmic Center, Sun Yat-sen University",SYSEC-KY-KS-2019-054-001,"July 1, 2019","Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, China|Shunde hospital of southern medical university, Foshan, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04003558
Principal Investigator,"Jan Lubiński, MD, PhD",Read-Gene S.A.,,NCT04014283,jan lubiński,jan,male,0.95,142869,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Cezary Cybulski, MD, PhD",Read-Gene S.A.,,NCT04014283,cezary cybulski,cezary,male,1.0,3471,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Jacek Gronwald, MD, PhD",Read-Gene S.A.,,NCT04014283,jacek gronwald,jacek,male,0.99,31243,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Tomasz Huzarski, MD, PhD",Read-Gene S.A.,,NCT04014283,tomasz huzarski,tomasz,male,1.0,61026,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Anna Jakubowska, MD, PhD",,,NCT04014283,anna jakubowska,anna,female,0.98,383713,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Antoni Morawski, PhD",,,NCT04014283,antoni morawski,antoni,male,0.97,5088,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Ewa Stachowska, PhD",Read-Gene S.A.,,NCT04014283,ewa stachowska,ewa,female,0.98,57904,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Edyta Balejko, PhD",,,NCT04014283,edyta balejko,edyta,female,0.98,20720,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Study Chair,"Karolina Ertmańska, PhD",,,NCT04014283,karolina ertmańska,karolina,female,0.98,81964,516,Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.,Recruiting,No Results Available,Breast Neoplasms,Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification,"Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.",INNOMED/I/16?NCBR/2014,"July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland",https://ClinicalTrials.gov/show/NCT04014283
Principal Investigator,Mark Schaverien,M.D. Anderson Cancer Center,,NCT03941756,mark schaverien,mark,male,0.99,119313,518,Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer,Recruiting,No Results Available,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Inflammatory Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Drug: Indocyanine Green|Procedure: Lymphangiography|Procedure: Lymphovenous Bypass,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2018-0127|NCI-2019-02320|P30CA016672,"May 8, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03941756
Principal Investigator,"Mark Trombetta, MD",AHN Research Institute,,NCT04149522,mark trombetta,mark,male,0.99,119313,563,Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer,Recruiting,No Results Available,"Breast Cancer|Radiotherapy; Adverse Effect, Dermatitis or Eczema|Radiotherapy Side Effect|Radiation Burn|Radiation Dermatitis|Radiotherapy; Complications",Device: Mepitel Film®,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),2019-185-AGH,"November 4, 2019","Allegheny Health Network, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04149522
Principal Investigator,"Teresa Paolucci, MD, PhD",University 'Sapienza' of Rome,,NCT04145739,teresa paolucci,teresa,female,0.98,51700,519,The Sequelae of Mastectomy and Quadrantectomy Respect to the Reaching Movement in Breast Cancer Survivors,Completed,No Results Available,"Breast Cancer|Pain, Chronic|Pain, Postoperative|Mastectomy; Lymphedema",Other: Rehabilitation protocol,University of Roma La Sapienza,URomLS-2019,"October 31, 2019","Umberto I Hospital, Rome, Italy",https://ClinicalTrials.gov/show/NCT04145739
Principal Investigator,"Christian Kurzeder, PD Dr. med","Breast Cancer Center, University Hospital Basel",,NCT03928210,christian kurzeder,christian,male,0.99,156233,520,Digoxin Induced Dissolution of CTC Clusters,Not yet recruiting,No Results Available,Breast Cancer|Circulating Tumor Cells (CTCs),Drug: Digoxin,"University Hospital, Basel, Switzerland",2019-00673; sp19Kurzeder,"April 26, 2019","Breast Cancer Center, University Hospital Basel, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT03928210
Study Chair,"Christian Marth, Prof Dr",Medical University Innsbruck,,NCT04117815,christian marth,christian,male,0.99,156233,693,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Recruiting,No Results Available,Breast Cancer Female|Alopecia,Device: Paxman Scalp Cooling System|Other: Alopecia Assessments,Medical University Innsbruck,1049/2018,"October 7, 2019","Medical University Innsbruck, Department of Gynaecology and Obstetrics, Innsbruck, Tyrol, Austria",https://ClinicalTrials.gov/show/NCT04117815
Principal Investigator,"Gabrielle B Rocque, MD",University of Alabama at Birmingham,,NCT03806738,gabrielle b rocque,gabrielle,female,0.95,4965,521,Enhancing Shared Decision-Making in Breast Cancer,Recruiting,No Results Available,Shared Decision Making,Other: Intervention-specific Carevive questionnaire|Other: Standard of Care questionnaire,"University of Alabama at Birmingham|American Cancer Society, Inc.|Carevive Systems, Inc.",427 BC SDM,"January 16, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT03806738
Principal Investigator,"Darpan I Patel, PhD",UT Health San Antonio,,NCT04207359,darpan i patel,darpan,male,1.0,76,522,Effects of Creatine Supplementation in Breast Cancer Survivors,Not yet recruiting,No Results Available,Breast Cancer|Chemotherapy Effect|Muscle Weakness|Muscle Loss|Exercise,Dietary Supplement: Creatine,The University of Texas Health Science Center at San Antonio,CTMS# 19-0028,"December 20, 2019",,https://ClinicalTrials.gov/show/NCT04207359
Study Director,"Andreas Ströhle, Prof.",Charite Universitätsmedizin Berlin,,NCT04193644,andreas ströhle,andreas,male,0.99,71365,524,Mindfulness and Self-compassion Focussed Walking,Recruiting,No Results Available,Breast Cancer|Fatigue,Behavioral: Mindfulness and Self-Compassion focussed exercises during walking training|Behavioral: Walking training,"Charite University, Berlin, Germany|Sana-Klinikum Lichtenberg|Park-Klinik Berlin Weißensee|Vivantes Klinikum am Urban|Steffen Lohrer Stiftung",MSCW2019,"December 10, 2019","Charite Universitätsmedizin Berlin, Berlin, Germany|Sana-Klinikum Lichtenberg, Berlin, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04193644
Study Director,"ANDREAS CHARALAMBOUS, PhD",Cyprus University of Technology,,NCT03992664,andreas charalambous,andreas,male,0.99,71365,796,Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.,"Active, not recruiting",No Results Available,Consent Form|Lung Cancer|Colon Cancer|Pancreas Cancer|Head and Neck Cancer|Breast Cancer,Other: EDUCATION,Cyprus University of Technology,0000-0001-5580-7256,"June 20, 2019","Eleni Papoui, Larnaca, Athienou, Cyprus",https://ClinicalTrials.gov/show/NCT03992664
Principal Investigator,José Perez,MedSIR,,NCT03809988,josé perez,josé,male,0.97,2086,529,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),Recruiting,No Results Available,Breast Cancer|Advanced Breast Cancer|Hormone Receptor Positive Tumor|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Drug: Palbociclib|Drug: Endocrine therapy,MedSIR|Pfizer,MedOPP068,"January 18, 2019","Hôpital Jean Minjoz, Besançon, France|Centre Georges François Leclerc, Dijon, France|Chd-Vendee, La Roche-sur-Yon, France|APHP Tenon, Paris, France|George Pompidou European Hospital, Paris, France|Centre Paul Strauss, Strasbourg, France|ICO Badalona, Badalona, Barcelona, Spain|Hospital Provincial de Castellón, Castello, Castelló, Spain|Consorci Sanitari de Terrassa, Terrassa, Terrasa, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Institut Català d'Oncologia Bellvitge, Barcelona, Spain|H. Vall Hebrón, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Institut Català d'Oncologia, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Sanchinarro, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Spain|Hospital Sant Joan, Reus, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valenciano de Oncología IVO, Valencia, Spain|Hospital General Universitari de Valencia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Hospital Álvaro Cunqueiro, Vigo, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Beatson West of Scotland Cancer Center, Glasgow, United Kingdom|Barts Cancer Institute, London, United Kingdom|Kent Oncology Department, Maidstone, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Royal Cornwall Hospital NHS Trust, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT03809988
Principal Investigator,"Zahi Mitri, MD",OHSU Knight Cancer Institute,,NCT03801369,zahi mitri,zahi,male,0.9,489,530,Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer,Recruiting,No Results Available,Metastatic Triple Negative Breast Cancer|Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Neoplasms|Triple-Negative Breast Cancer|Triple Negative Breast Cancer|Triple-Negative Breast Neoplasm,Drug: Olaparib|Biological: Durvalumib,OHSU Knight Cancer Institute|Oregon Health and Science University,STUDY00018504,"January 11, 2019","OHSU Knight Cancer Institute, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT03801369
Study Chair,"Glauco Baiocchi, MD, PhD",AC Camargo Cancer Center,,NCT04059809,glauco baiocchi,glauco,male,0.99,542,532,Photobiomodulation for Breast Cancer Radiodermatitis,Recruiting,No Results Available,Breast Cancer|Radiodermatitis|Radiotherapy Side Effect|Radiation Dermatitis|Radiation Toxicity|Radiation Injuries|Quality of Life|Breast Neoplasms,Device: Photobiomodulation,AC Camargo Cancer Center,2.777.676,"August 16, 2019","Universidade do Vale do Itajai - UNIVALI, Itajai, Santa Catarina, Brazil",https://ClinicalTrials.gov/show/NCT04059809
Principal Investigator,"Maryam B Lustberg, MD",Ohio State University Comprehensive Cancer Center,,NCT04205903,maryam b lustberg,maryam,female,0.98,9767,535,Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Drug: Nilotinib|Drug: Nilotinib Hydrochloride Monohydrate|Drug: Paclitaxel|Other: Placebo|Other: Questionnaire Administration,Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),OSU-18317|NCI-2019-03146|P30CA016058|R01CA238946,"December 20, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04205903
Principal Investigator,"Maryam B Lustberg, MD",Ohio State University Comprehensive Cancer Center,,NCT04205071,maryam b lustberg,maryam,female,0.98,9767,636,Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer,Not yet recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Chemotherapy-Induced Peripheral Neuropathy|Digestive System Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Lorcaserin|Drug: Lorcaserin Hydrochloride|Other: Questionnaire Administration,Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),OSU-19085|NCI-2019-03368|P30CA016058,"December 19, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04205071
Principal Investigator,Banu Arun,M.D. Anderson Cancer Center,,NCT04090567,banu arun,banu,female,0.93,6694,536,Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer,Not yet recruiting,No Results Available,Advanced Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Germline BRCA1 Gene Mutation|Germline BRCA2 Gene Mutation|HER2/Neu Negative|Metastatic Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Cediranib|Drug: Ceralasertib|Drug: Olaparib,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2018-0062|NCI-2019-04148|P30CA016672,"September 16, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04090567
Study Director,Banu Dilek,Dokuz Eylul University,,NCT04213001,banu dilek,banu,female,0.93,6694,566,Diagnostic Contribution of Ultrasonography in Breast Cancer-Related Lymphedema,Completed,No Results Available,Lymphedema of Upper Arm,Diagnostic Test: ultrasonographic measurement,Dokuz Eylul University,DokuzEUBanuNihan,"December 30, 2019","Dokuz eylul university, İzmir, Inciralti, Turkey",https://ClinicalTrials.gov/show/NCT04213001
Principal Investigator,"Hope Rugo, MD","University of California, San Francisco",,NCT03971409,hope rugo,hope,female,0.69,3238,537,"Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer",Recruiting,No Results Available,Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma,Biological: Anti-OX40 Antibody PF-04518600|Drug: Avelumab|Drug: Binimetinib|Biological: Utomilumab,"Hope Rugo, MD|Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|University of California, San Francisco",187519|NCI-2019-01531|TBCRC 047|BRE16-279,"June 3, 2019","University of California, San Francisco, San Francisco, California, United States|Mayo Clinic, Rochester, Minnesota, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03971409
Study Chair,"Chen Xi, PhD",Fuzhou General Hospital,,NCT04088110,chen xi,chen,male,0.62,5003,538,Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor,Drug: Pyrotinib|Drug: Trastuzumab|Drug: Aromatase Inhibitors,Fuzhou General Hospital,Arise-FJ-B102,"September 12, 2019","Fuzhou general hospital, Fuzhou, Fujian, China",https://ClinicalTrials.gov/show/NCT04088110
Principal Investigator,Rashmi Murthy,University of Texas MD Anderson Cancer Center LAO,,NCT04108858,rashmi murthy,rashmi,female,0.94,551,540,"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",Not yet recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|ERBB2 Gene Amplification|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|PIK3CA Gene Mutation|PTEN Gene Mutation,Drug: Copanlisib|Biological: Pertuzumab|Biological: Trastuzumab,National Cancer Institute (NCI),NCI-2019-06461|10296|UM1CA186688,"September 30, 2019",,https://ClinicalTrials.gov/show/NCT04108858
Principal Investigator,"Diane K Ehlers, PhD",University of Nebraska,,NCT03980626,diane k ehlers,diane,female,0.97,15367,541,Study on Physical Activity's Relationship With Cancer and Cognition,Recruiting,No Results Available,Breast Cancer|Breast Neoplasm Female,Behavioral: Walking,University of Nebraska,IRB091-19,"June 10, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States",https://ClinicalTrials.gov/show/NCT03980626
Principal Investigator,Aleksandr Obukhov,"A. Tsyb Medical Radiological Research Centre, (A. Tsyb MRRC), Obninsk, Russia",,NCT03970967,aleksandr obukhov,aleksandr,male,0.99,7354,542,Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases,Recruiting,No Results Available,Breast Carcinoma|Metastatic Breast Cancer|Invasive Breast Cancer|Distant Metastases.Pathology,Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT),Alpha Tau Medical LTD.,CTP-BRST-01,"June 3, 2019","A. Tsyb Medical Radiological Research Center, Obninsk, Kaluga Region, Russian Federation",https://ClinicalTrials.gov/show/NCT03970967
Study Chair,Rob Crombie,Que Oncology,,NCT04080297,rob crombie,rob,male,0.98,32016,543,Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen,Completed,Has Results,Vasomotor Symptoms (VMS),Drug: oral capsule of Q-122,Que Oncology,Q-1001,"September 6, 2019",,https://ClinicalTrials.gov/show/NCT04080297
Study Chair,"Gulseren Akyuz, Prof",Marmara University,,NCT04138667,gulseren akyuz,gulseren,female,0.96,248,544,Responsiveness of Outcome Scales in Breast Cancer Related Lymphedema,Recruiting,No Results Available,Lymphedema of Upper Arm,Other: complex decongestive therapy,Marmara University,09.2019.865,"October 24, 2019","Marmara University School of Medicine Department of Physical Medicine and Rehabilitation, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04138667
Principal Investigator,"Nele Adriaenssens, Prof. Dr.",Universitair Ziekenhuis Brussel,,NCT04125953,nele adriaenssens,nele,female,0.89,2771,545,Stochastic Modulated Vibrations on Autonomic Nervous System of Breast Cancer Patients During Radiotherapy,Recruiting,No Results Available,Autonomic Nervous System Imbalance|Psychological Distress|Cancer-related Pain|Breast Cancer Lymphedema|Quality of Life,Device: Andullation|Other: Placebo,Universitair Ziekenhuis Brussel,2018/455,"October 14, 2019","Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04125953
Principal Investigator,"Muriel Brackstone, PhD, MD",Lawson Health Research Institute,,NCT03868475,muriel brackstone,muriel,female,0.98,14732,790,Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions,Not yet recruiting,No Results Available,Breast Fibroadenoma|Atypical Ductal Hyperplasia|Atypical Lobular Hyperplasia|Lobular Carcinoma in Situ|Flat Epithelial Atypia|Phyllodes; Fibroadenoma|Phyllodes Breast Tumor|Radial Scar|Breast Papilloma|Complex Sclerosing Papillary Lesion of the Breast,Procedure: Vacuum-assisted percutaneous excision|Procedure: Open surgical excision,Lawson Health Research Institute,1,"March 11, 2019",,https://ClinicalTrials.gov/show/NCT03868475
Principal Investigator,Saranya Chumsri,Mayo Clinic,,NCT04197687,saranya chumsri,saranya,female,0.98,446,547,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",Recruiting,No Results Available,Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7,Biological: Pertuzumab|Other: Placebo Administration|Biological: Sargramostim|Biological: Trastuzumab|Biological: Trastuzumab Emtansine|Biological: Vaccine Therapy,Mayo Clinic|National Cancer Institute (NCI),MC1835|NCI-2019-08038|P30CA015083,"December 13, 2019","Mayo Clinic Arizona, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04197687
Principal Investigator,Elizabeth C Dees,Duke University - Duke Cancer Institute LAO,,NCT03803761,elizabeth c dees,elizabeth,female,0.99,31288,549,"Study of a New Drug Combination, Copanlisib and Fulvestrant, in Postmenopausal Women With Advanced Breast Cancer",Not yet recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Postmenopausal|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Copanlisib|Drug: Fulvestrant,National Cancer Institute (NCI),NCI-2019-00048|NCI10195|10195|UM1CA186704,"January 15, 2019",,https://ClinicalTrials.gov/show/NCT03803761
Study Director,"Elizabeth Olek, DO, MPH",Loxo Oncology,,NCT03899792,elizabeth olek,elizabeth,female,0.99,31288,824,A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors,Recruiting,No Results Available,Medullary Thyroid Cancer|Infantile Myofibromatosis|Infantile Fibrosarcoma|Papillary Thyroid Cancer|Soft Tissue Sarcoma,Drug: LOXO-292,"Loxo Oncology, Inc.",LOXO-RET-18036|2019‐000212‐28,"April 2, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT03899792
Study Director,Jutta Hänninen,"Orion Corporation, Orion Pharma",,NCT03878823,jutta hänninen,jutta,female,0.97,3872,551,Safety and Pharmacokinetics of ODM-209,Recruiting,No Results Available,Prostate Cancer Metastatic|Advanced Breast Cancer|Castration-resistant Prostate Cancer|Metastatic Breast Cancer,Drug: ODM-209,"Orion Corporation, Orion Pharma",3125001,"March 18, 2019","Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Institut Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT03878823
Principal Investigator,"Alejandra Hurtado de Mendoza, PhD",Georgetown University,,NCT03959267,alejandra hurtado de mendoza,alejandra,female,0.98,16369,552,Testing a Culturally Adapted Telephone Genetic Counseling Intervention,Recruiting,No Results Available,Breast Cancer|Hereditary Breast Cancer,Behavioral: Telephone Genetic Counseling,Georgetown University|Hackensack Meridian Health,KL2TR001432,"May 22, 2019","Capital Breast Care Center, Washington, District of Columbia, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Nueva Vida, Alexandria, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT03959267
Principal Investigator,Ermelinda Bonaccio,Roswell Park Cancer Institute,,NCT03897270,ermelinda bonaccio,ermelinda,female,0.99,668,553,Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects,Recruiting,No Results Available,Breast Carcinoma|Healthy Subject,Procedure: Photoacoustic Imaging,Roswell Park Cancer Institute|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation,I 60217|NCI-2019-01356|P30CA016056,"April 1, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT03897270
Principal Investigator,"Hanae Tokita, MD",Memorial Sloan Kettering Cancer Center,,NCT04016376,hanae tokita,hanae,female,0.98,2215,555,Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction,Recruiting,No Results Available,Breast Cancer|Breast Cancer Female,Drug: PVB Protocol|Drug: PECS-1|Drug: Serratus,Memorial Sloan Kettering Cancer Center,19-238,"July 11, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04016376
Principal Investigator,Shipra Gandhi,Roswell Park Cancer Institute,,NCT04081389,shipra gandhi,shipra,female,0.99,88,559,Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer,Recruiting,No Results Available,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,Drug: Celecoxib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Doxorubicin Hydrochloride|Drug: Paclitaxel|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod,Roswell Park Cancer Institute|National Cancer Institute (NCI),I 73718|NCI-2019-05299|P30CA016056,"September 9, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT04081389
Principal Investigator,"Bonnie Ky, MD, MSCE",Perelman School of Medicine at the University of Pennsylvania,,NCT04023110,bonnie ky,bonnie,female,0.9,3712,565,Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab,Recruiting,No Results Available,"Cardiotoxicity|Risk Factor, Cardiovascular|Toxicity Due to Chemotherapy|Breast Cancer|Cardiomyopathies|Heart Failure",Drug: Carvedilol,Abramson Cancer Center of the University of Pennsylvania,UPCC12118,"July 17, 2019","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04023110
Study Director,"Bonnie Mills, PhD","Tanvex BioPharma USA, Inc.",,NCT04109391,bonnie mills,bonnie,female,0.9,3712,582,Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03,Enrolling by invitation,No Results Available,HER2-positive Breast Cancer|Early-stage Breast Cancer|Breast Cancer|Breast Neoplasms|Stage II Breast Cancer|Stage IIIA Breast Cancer,Biological: TX05 (trastuzumab)|Biological: Herceptin (trastuzumab),"Tanvex BioPharma USA, Inc.",TX05-03E,"September 30, 2019","Tanvex Investigational Site 1003E, Gomel, Belarus|Tanvex Investigational Site 1006E, Grodno, Belarus|Tanvex Investigational Site 1008E, Lesnoy, Belarus|Tanvex Investigational Site 1002E, Minsk, Belarus|Tanvex Investigational Site 1001E, Vitebsk, Belarus|Tanvex Investigational Site 4001E, Temuco, Chile|Tanvex Investigational Site 4002E, Vina del Mar, Chile|Tanvex Investigational Site 5006E, Batumi, Georgia|Tanvex Investigational Site 5002E, Batumi, Georgia|Tanvex Investigational Site 5001E, Tbilisi, Georgia|Tanvex Investigational Site 5005E, Tbilisi, Georgia|Tanvex Investigational Site 5010E, Tbilisi, Georgia|Tanvex Investigational Site 6003E, Budapest, Hungary|Tanvex Investigational Site 7031E, Nashik, Maharashtra, India|Tanvex Investigational Site 7019E, Bangalore, India|Tanvex Investigational Site 7001E, Nashik, India|Tanvex Investigational Site 7015E, Pune, India|Tanvex Investigational Site 7017E, Vijayawada, India|Tanvex Investigational Site 2109E, Aguascalientes, Mexico|Tanvex Investigational Site 2103E, Monterrey, Mexico|Tanvex Investigational Site 2106E, Oaxaca, Mexico|Tanvex Investigational Site 2110E, Tequisquiapan, Mexico|Tanvex Investigational Site 2108E, Zapopan, Mexico|Tanvex Investigational Site 1101E, Arequipa, Peru|Tanvex Investigational Site 1107E, Arequipa, Peru|Tanvex Investigational Site 1104E, Chiclayo, Peru|Tanvex Investigational Site 1112E, Lima Cercado, Peru|Tanvex Investigational Site 1108E, San Borja, Peru|Tanvex Investigational Site 1102E, San Isidro, Peru|Tanvex Investigational Site 1109E, Surquillo, Peru|Tanvex Investigational Site 1103E, Trujillo, Peru|Tanvex Investigational Site 1211E, Cebu city, Philippines|Tanvex Investigational Site 1209E, Quezon City, Philippines|Tanvex Investigational Site 1213E, Quezon City, Philippines|Tanvex Invesitgational Site 1210E, Santo Tomas, Philippines|Tanvex Investigational Site 1513E, Sochi, Krasnodar Region, Russian Federation|Tanvex Investigational Site 1535E, Arkhangelsk, Russian Federation|Tanvex Investigational Site 1502E, Kaluga, Russian Federation|Tanvex Investigational Site 1505E, Kislino, Russian Federation|Tanvex Investigational Site 1529E, Krasnodar, Russian Federation|Tanvex Investigational Site 1512E, Krasnoyarsk, Russian Federation|Tanvex Investigational Site 1507E, Moscow, Russian Federation|Tanvex Investigational Site 1511E, Novosibirsk, Russian Federation|Tanvex Investigational Site 1503E, Omsk, Russian Federation|Tanvex Investigational Site 1509E, Omsk, Russian Federation|Tanvex Investigational Site 1537E, Orenburg, Russian Federation|Tanvex Investigational Site 1526E, Pesochnyy, Russian Federation|Tanvex Investigational Site 1510E, Pushkin, Russian Federation|Tanvex Investigational Site 1521E, Rostov-Na-Donu, Russian Federation|Tanvex Investigational Site 1516E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1524E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1525E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1506E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1501E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1523E, Sankt-peterburg, Russian Federation|Tanvex Investigational Site 1508E, Saransk, Russian Federation|Tanvex Investigational Site 1534E, Yaroslavl, Russian Federation|Tanvex Investigational Site 1820E, Antonivka, Ukraine|Tanvex Investigational Site 1803E, Chernihiv, Ukraine|Tanvex Investigational Site 1808E, Chernihiv, Ukraine|Tanvex Investigational Site 1821E, Chernivtsi, Ukraine|Tanvex Investigational Site 1811E, Kiev, Ukraine|Tanvex Investigational Site 1802E, Kiev, Ukraine|Tanvex Investigational Site 1819E, Kropyvnytskyi, Ukraine|Tanvex Investigational Site 1804E, Kryvyi Rih, Ukraine|Tanvex Investigational Site 1815E, Kyiv, Ukraine|Tanvex Investigational Site, Kyiv, Ukraine|Tanvex Investigational Site 1810E, Odesa, Ukraine|Tanvex Investigational Site 1806E, Sumy, Ukraine|Tanvex Investigational Site 1822E, Ternopil, Ukraine|Tanvex Investigational Site 1818E, Vinnytsia, Ukraine|Tanvex Investigational Site 1813E, Zaporizhzhya, Ukraine",https://ClinicalTrials.gov/show/NCT04109391
Principal Investigator,"Matt Brown, MBBS",Royal Marsden NHS Foundation Trust,,NCT04007861,matt brown,matt,male,0.99,38275,570,Exploring the Link Between Cancer Genetics and PPSP,Not yet recruiting,No Results Available,Cancer-related Pain|Chronic Post Cancer Surgery Pain|Breast Cancer,,"Institute of Cancer Research, United Kingdom",CCR 5006,"July 5, 2019",,https://ClinicalTrials.gov/show/NCT04007861
Principal Investigator,"Gabriel Oliveira B Gil, MD",Baleia Hospital,,NCT04015531,gabriel oliveira b gil,gabriel,male,0.98,52559,571,Hypofractionated Versus Conventional Fractionation Radiotherapy,Not yet recruiting,No Results Available,Breast Cancer|Radiation Toxicity,Radiation: Conventional radiotherapy|Radiation: Hypofractionated radiotherapy,Hospital da Baleia,RT 1901,"July 11, 2019",,https://ClinicalTrials.gov/show/NCT04015531
Principal Investigator,Roy Strowd,Wake Forest University Health Sciences,,NCT03796273,roy strowd,roy,male,0.98,21602,572,Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases,Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Astrocytoma|Breast Carcinoma Metastatic in the Brain|Glioma|Invasive Breast Carcinoma|Oligodendroglioma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Glioma,Other: Best Practice|Drug: Ketoconazole,Wake Forest University Health Sciences|National Cancer Institute (NCI),IRB00054587|NCI-2018-03087|CCCWFU 91118|P30CA012197,"January 8, 2019","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03796273
Principal Investigator,"Roy Strowd, MD",Wake Forest University Health Sciences,,NCT03987555,roy strowd,roy,male,0.98,21602,772,Paclitaxel Therapeutic Drug Monitoring in Cancer Patients,Recruiting,No Results Available,"Solid Tumor, Adult|Metastatic Nonsmall Cell Lung Cancer|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Cervical Carcinoma|Metastatic Ovarian Carcinoma|Malignant Uterine Neoplasm|Vulvar Cancer|Invasive Breast Cancer|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Vulvar Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Vulvar Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Vulvar Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Vulvar Cancer AJCC v8|Vulva Squamous Cell Carcinoma",Other: Blood draws|Other: QLQ-CIPN20 Survey|Other: PR-CTCAE Survey,Wake Forest University Health Sciences|National Cancer Institute (NCI),IRB00058758|WFBCCC 01319|P30CA012197|NCI-2019-05616,"June 17, 2019","Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03987555
Principal Investigator,"Katarzya J Jerzak, MD MSc FRCPC",University of Toronto,,NCT03881605,katarzya j jerzak,katarzya,female,1.0,4,579,MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC,Recruiting,No Results Available,Breast Neoplasm|Brain Metastases|Triple Negative Breast Cancer|HER2-positive Breast Cancer,Diagnostic Test: MRI screening,Sunnybrook Health Sciences Centre|Harvard University,211-2018,"March 19, 2019","Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03881605
Principal Investigator,Seema A Khan,Northwestern University,,NCT04009044,seema a khan,seema,female,0.95,665,581,Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast,Not yet recruiting,No Results Available,Cancer Survivor|Ductal Breast Carcinoma In Situ|Invasive Breast Carcinoma,Drug: Afimoxifene|Procedure: Core Biopsy|Other: Questionnaire Administration,Northwestern University|National Cancer Institute (NCI),NU 18B05|NCI-2019-03771|P30CA060553,"July 5, 2019","Northwestern University, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04009044
Principal Investigator,Lydia Liao,Sidney Kimmel Cancer Center at Thomas Jefferson University,,NCT03929783,lydia liao,lydia,female,0.98,21382,586,Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings,Not yet recruiting,No Results Available,Breast Neoplasms,Procedure: Contrast Enhanced Digital Mammography,Thomas Jefferson University,19D.203,"April 29, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03929783
Principal Investigator,"Abida K. Sattar, MD",The Aga Khan University,,NCT03939598,abida k. sattar,abida,female,0.7,162,587,Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study,Recruiting,No Results Available,Breast Neoplasm,,Aga Khan University,2018-0345-1105,"May 7, 2019","Aga Khan University, Karachi, Sindh, Pakistan",https://ClinicalTrials.gov/show/NCT03939598
Study Chair,"Pierre FUMOLEAU, MD",Institut Curie,,NCT04145817,pierre fumoleau,pierre,male,0.99,91174,588,Breast Cancer Risk After Diagnostic Gene Sequencing,Recruiting,No Results Available,Genetic Predisposition to Disease,Genetic: BRIDGES gene panel testing|Genetic: Breast cancer risk polygenic risk score (PRS)|Behavioral: Questionnaires,Institut Curie,IC 2018-08,"October 31, 2019","Institut Curie, Paris, France|University Hospital of Cologne, Cologne, Germany",https://ClinicalTrials.gov/show/NCT04145817
Principal Investigator,Arzu Karaveli,Antalya TRH,,NCT04036370,arzu karaveli,arzu,female,0.97,17457,589,Continuous Pectoral Nerve Block in Breast Cancer Surgery,Completed,No Results Available,Nerve Blocks|Breast Surgery|Postoperative Pain,Procedure: PECS group|Other: Control group,Antalya Training and Research Hospital,13/21,"July 29, 2019","Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation, Antalya, Turkey",https://ClinicalTrials.gov/show/NCT04036370
Principal Investigator,"Atif J Khan, MD",Memorial Sloan Kettering Cancer Center,,NCT04084730,atif j khan,atif,male,0.98,2643,591,Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer,Recruiting,No Results Available,"Invasive Ductal Breast Carcinoma|Invasive Ductal Carcinoma, Breast|DCIS|DCIS Grade 1|DCIS Grade 2|Breast Cancer",Radiation: Accelerated Partial Breast Irradiation,Memorial Sloan Kettering Cancer Center,19-300,"September 10, 2019","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",https://ClinicalTrials.gov/show/NCT04084730
Principal Investigator,"Michelino De Laurentiis, MD, PhD","National Cancer Institute ""Fondazione Pascale"", Naples",,NCT03862144,michelino de laurentiis,michelino,male,0.98,291,592,NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer,Completed,No Results Available,Chemotherapy-induced Nausea and Vomiting,Drug: Netupitant/Palonosetron,Consorzio Oncotech,GIM15-NEPA,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03862144
Principal Investigator,"Tamara J Somers, Ph.D.",Duke University,,NCT04175639,tamara j somers,tamara,female,0.98,42613,593,mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients,Not yet recruiting,No Results Available,Breast Cancer,Behavioral: Mobile Health Pain Coping Skills Training (mPCST),Duke University,Pro00103527,"November 25, 2019",,https://ClinicalTrials.gov/show/NCT04175639
Principal Investigator,"Serdar Yeşiltaş, MD",Bezmialem Vakif University,,NCT03899545,serdar yeşiltaş,serdar,male,0.97,44174,594,Serratus Plane Plus Pectoral I Block Versus Serratus Plane Block for Perioperative Analgesia in Breast Cancer Surgery,Completed,No Results Available,Postoperative Pain|Postoperative Nausea|Patient Satisfaction|Narcotic Use,Other: Serratus Plane Block|Other: Serratus Plane Block plus Pectoral I Block,Bezmialem Vakif University,71306642-5/24,"April 2, 2019","Bezmialem Vakıf University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT03899545
Principal Investigator,"Xiaoli Yu, MD, PhD",Fudan University,,NCT04025164,xiaoli yu,xiaoli,female,0.86,129,597,Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery,Recruiting,No Results Available,Breast Cancer,Radiation: Hypofractionated Radiotherapy|Radiation: Conventional fractionated Radiotherapy,Fudan University,FDRT-BC007,"July 18, 2019","Guizhou Provincial People's Hospital, Guiyang, Guizhou, China|Suzhou Municipal hospital, Suzhou, Jiangsu, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, China|Shanghai Huangpu District Central Hospital, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04025164
Principal Investigator,"René van der Hulst, MD, PhD",Maastricht University Medical Center,,NCT04093999,rené van der hulst,rené,male,1.0,4,598,Sensory Nerve Coaptation in DIEP Flap Breast Reconstruction,Completed,No Results Available,Breast Cancer,Procedure: Sensory nerve coaptation,Maastricht University Medical Center,METC 16 - 4 - 147,"September 18, 2019","Maastricht University Medical Center, Maastricht, Limburg, Netherlands",https://ClinicalTrials.gov/show/NCT04093999
Principal Investigator,"René van der Hulst, MD, PhD",Maastricht University Medical Center,,NCT03959943,rené van der hulst,rené,male,1.0,4,605,Nerve Coaptation in LTP Flap Breast Reconstruction,Completed,No Results Available,Breast Cancer,Procedure: Sensory nerve coaptation,Maastricht University Medical Center,METC16-4-147,"May 22, 2019","Maastricht University Medical Center, Maastricht, Limburg, Netherlands",https://ClinicalTrials.gov/show/NCT03959943
Principal Investigator,"Farin Amersi, MD",Cedars-Sinai Medical Center,,NCT04189263,farin amersi,farin,female,0.5,72,599,BREADS: Breast Adjuvant Diet Study,Recruiting,No Results Available,Breast Cancer,Other: Carbohydrate restricted dietary intervention|Drug: standard of care aromatase inhibitors,Farin Amersi|Cedars-Sinai Medical Center,IIT2018-21-AMERSI-BREADS,"December 6, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04189263
Study Director,"Evangelos Konstantinou, RN, PhD",National and Kapodistrian University of Athens,,NCT04077827,evangelos konstantinou,evangelos,male,1.0,507,601,TIVA Admnistration and Autologous Fat Transfer in Breast Reconstruction,Recruiting,No Results Available,Breast Cancer,Drug: Propofol,National and Kapodistrian University of Athens|Saint Savvas Anticancer Hospital,2834,"September 4, 2019","""Saint Savvas"" Hospital, Athens, Greece",https://ClinicalTrials.gov/show/NCT04077827
Study Chair,"You-Bin Deng, PhD,MD",Tongji Hospital,,NCT03887598,you-bin deng,you-bin,female,1.0,1,602,Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules,Recruiting,No Results Available,Breast Cancer,Device: Ultrasound diagnosis,"Xin-Wu Cui|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Taizhou Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Macheng People's Hospital|Huangshi Central Hospital|Affiliated Hospital of Jiangsu University|The First People's Hospital of Yichang|The Second People's Hospital of Yichang|Xiangyang Central Hospital|the Second Affiliated Hospital of Anhui Medical University|Anqing People's Hospital|Huainan People's Hospital|Wenzhou Central Hospital|Xuzhou First People's Hospital|The Central Hospital of Lishui City|Huai'an First People's Hospital|WISCO General Hospital|First People's Hospital of Jiangxia District, Wuhan City|Enshi State Central Hospital|Lianyungang Third People's Hospital|Xiangyang First People's Hospital|Tongji Hospital",2019(S073),"March 25, 2019","Xin-Wu Cui, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT03887598
Principal Investigator,Wendy B DeMartini,Stanford University,,NCT04016818,wendy b demartini,wendy,female,0.97,25729,608,Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution,Not yet recruiting,No Results Available,Breast Cancer,Drug: 18F-FDG|Device: Breast-dedicated PET camera,Stanford University,IRB-50877|BRS0102,"July 12, 2019","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04016818
Principal Investigator,"Wendy Demark-Wahnefried, PhD, RD",University of Alabama at Birmingham,,NCT04000880,wendy demark-wahnefried,wendy,female,0.97,25729,798,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,Not yet recruiting,No Results Available,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Ovary Cancer|Prostate Cancer,Behavioral: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|Other: Diet-Exercise|Other: Exercise-Diet|Other: Wait-list Control- Combined Diet and Exercise,University of Alabama at Birmingham|University of Tennessee Health Science Center|National Cancer Institute (NCI),IRB-300002068|1P01CA229997,"June 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04000880
Principal Investigator,"Dr. Tabassum Wadasadawala, MBBS,MD,DNB","Associate Professor, Breast Services",,NCT03962595,tabassum wadasadawala,tabassum,female,0.56,96,610,Patient Satisfaction Survey (PSS) In Breast Clinic,Recruiting,No Results Available,Breast Cancer,,Tata Memorial Centre,1835,"May 24, 2019","Tata Memorial Centre, Mumbai, Maharashtra, India",https://ClinicalTrials.gov/show/NCT03962595
Principal Investigator,"Eveline MA Bleiker, Professor",The Netherlands Cancer Institute,,NCT03791138,eveline ma bleiker,eveline,female,0.99,4331,613,The Impact of a Web-based Patient Decision Aid for Women Considering Breast Reconstruction,Recruiting,No Results Available,Breast Cancer,Other: online patient decision aid,The Netherlands Cancer Institute|Dutch Cancer Society|UMC Utrecht,NKI 2014-7031|A6C/NKI 2014-7031,"January 2, 2019","Meander Medical Center, Amersfoort, Netherlands|Medical Center Slotervaart, Amsterdam, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Medical Center Leeuwarden, Leeuwarden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT03791138
Principal Investigator,Sina Grape,Hopital du Valais,,NCT04116021,sina grape,sina,female,0.69,9158,624,The Analgesic Efficacy of the Pectoral Nerves Block Versus Local Anesthetic Infiltration After Mastectomy,Not yet recruiting,No Results Available,Breast Cancer,Other: PECS block|Other: Local infiltration,Hôpital du Valais|University of Lausanne Hospitals,PECS 2019,"October 4, 2019",,https://ClinicalTrials.gov/show/NCT04116021
Study Director,Shaan Schaeffer,Seno Medical,,NCT04030104,shaan schaeffer,shaan,male,0.92,655,626,Optoacoustic Images Versus Imagio® Ultrasound,Completed,No Results Available,Breast Cancer,Device: Reader Study - Imagio Ultrasound|Device: Reader Study Imagio Ultrasound + Optoacoustic Imaging|Device: Mammography,Seno Medical Instruments Inc.,Reader-02 Study,"July 23, 2019","American College of Radiology Center for Research and Innovation, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04030104
Principal Investigator,"Manuel Algara Lopez, Medicine",Grupo de Investigación Clínica en Oncología Radioterápica (GICOR),,NCT03972696,manuel algara lopez,manuel,male,0.99,166605,627,OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment,Recruiting,No Results Available,Breast Cancer,Radiation: Irradiation,Grupo de Investigación Clínica en Oncología Radioterapia,GIC-RAD-2016-01,"June 4, 2019","Hospital Universitario de Cruces, Barakaldo, Bilbao, Spain|Hospital Universitario de Araba, Vitoria, Pais Vasco, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital Infanta Cristina, Badajoz, Spain|ICO Badalona, Badalona, Spain|Hospital Universitario Santa Lucía, Cartagena, Spain|Hospital Universitario de Donostia, Donostia, Spain|ICO Girona, Girona, Spain|Hospital Universitari Arnau de Vilanova, Lerida, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Gregrorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT03972696
Principal Investigator,Chirag Shah,The Cleveland Clinic,,NCT03918317,chirag shah,chirag,male,1.0,809,628,A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy,Withdrawn,No Results Available,Breast Cancer,Device: AirXpanders AeroFormtissue expander,Case Comprehensive Cancer Center,CASE2119,"April 17, 2019",,https://ClinicalTrials.gov/show/NCT03918317
Principal Investigator,Joerg Herrmann,Mayo Clinic,,NCT03879629,joerg herrmann,joerg,male,0.99,2016,629,TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol,Recruiting,No Results Available,Breast Cancer,Drug: Carvedilol,Mayo Clinic|National Cancer Institute (NCI),18-006090|R01CA233610,"March 19, 2019","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03879629
Study Chair,"Margarita Pérez Ruiz, MD, PhD",Universidad Europea,,NCT03873519,margarita pérez ruiz,margarita,female,0.98,12994,630,Acute Effect of Chromatic Environment During Chemotherapy,Recruiting,No Results Available,Breast Cancer,Other: Chromatic Environment|Other: Room Orientation,Universidad Europea de Madrid|Instituto Oncológico Balselga,R-2017/UEM11,"March 13, 2019","Hospital Ruber Internacional, Madrid, Spain",https://ClinicalTrials.gov/show/NCT03873519
Principal Investigator,"Bhavika Patel, MD",Mayo Clinic,,NCT03859492,bhavika patel,bhavika,female,0.96,49,631,Screening CEDM in Intermediate and High-Risk Patient Populations,Recruiting,No Results Available,Breast Cancer,Device: Contrast Enhanced Digital Mammography,Mayo Clinic,18-010602,"March 1, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States",https://ClinicalTrials.gov/show/NCT03859492
Principal Investigator,"RAFT JULIEN, MD",Institut de Cancérologie de Lorraine (ICL),,NCT03832920,raft julien,raft,male,0.94,50,633,Analgesia Nociception Index (ANI) After Unilateral Radical Mastectomy as an Evaluation of Paravertebral Block Failure,Recruiting,No Results Available,Breast Cancer,Other: Analgesia Nociception Index,Institut de Cancérologie de Lorraine,2019-A00121-56,"February 6, 2019","Institut de Cancérologie de Lorraine (ICL), Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT03832920
Study Director,"Abeer, PhD",Assiut University,,NCT03870659,abeer,abeer,female,0.92,1623,637,Abbreviated Breast MRI in Cancer Detection,Recruiting,No Results Available,Breast Cancer Female,Radiation: Breast MRI,Assiut University,Abbreviated Breast MRI,"March 12, 2019","Zahraa, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT03870659
Principal Investigator,Bryan P Schneider,ECOG-ACRIN Cancer Research Group,,NCT04001829,bryan p schneider,bryan,male,0.99,22678,638,Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Drug: Docetaxel|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,EAZ171|NCI-2019-00266|ECOG-ACRIN-EAZ171|UG1CA189828,"June 28, 2019","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|IU Health West Hospital, Avon, Indiana, United States|IU Health North Hospital, Carmel, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Center, Indianapolis, Indiana, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lexington Medical Center, West Columbia, South Carolina, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States",https://ClinicalTrials.gov/show/NCT04001829
Principal Investigator,"Janice Y Tsoh, PhD","University of California, San Francisco",,NCT04079556,janice y tsoh,janice,female,0.98,6277,640,Reducing Breast Cancer Risk in Korean American Women,Completed,No Results Available,Secondhand Tobacco Smoke Exposure Reduction,Behavioral: Tobacco LHW,"University of California, San Francisco|Korean Community Center of the East Bay",CBCRP 23AB-1400,"September 6, 2019","Korean Community Center of the East Bay, San Leandro, California, United States",https://ClinicalTrials.gov/show/NCT04079556
Principal Investigator,"Matteo Moretti, PhD",IRCCS Istituto Ortopedico Galeazzi,,NCT04047459,matteo moretti,matteo,male,0.99,69199,642,Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics,Completed,No Results Available,Breast Cancer Metastatic,Other: Tissue samples collection and cells isolation,Istituto Ortopedico Galeazzi,BRCP USA,"August 6, 2019","IRCCS Galeazzi Orthopedic Hospital, Milan, Italy",https://ClinicalTrials.gov/show/NCT04047459
Principal Investigator,Esra Giray,Marmara University,,NCT04139291,esra giray,esra,female,0.96,34071,645,Ultrasonographic Evaluation of Changes After Complex Decongestive Therapy,Not yet recruiting,No Results Available,Lymphedema of Upper Arm,Other: Complex decongestive therapy phase 1,Marmara University,09.2019.866,"October 25, 2019","Esra Giray, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04139291
Principal Investigator,"Graciela Caire Juvera, PhD",CIAD,,NCT04096469,graciela caire juvera,graciela,female,0.98,3285,646,"Impact of Diet and Physical Activity Changes on Body Weight, Biomarkers and Quality of Life in Breast Cancer Survivors",Completed,No Results Available,Body Weight Changes|Mammographic Density|Quality of Life,Behavioral: Motivational Interviewing|Behavioral: Traditional Education,"Centro de Investigación en Alimentación y Desarrollo A.C.|National Council of Science and Technology, Mexico",60252|262211,"September 19, 2019","Centro de Investigación en Alimentación y Desarrollo, Hermosillo, Sonora, Mexico",https://ClinicalTrials.gov/show/NCT04096469
Principal Investigator,"Andrewn Redfer, PhD; MBBS",Linear Clinical Research Limited,,NCT04175171,andrewn redfer,andrewn,male,1.0,2,648,Clinical Trial of Comparative Study of GB221 Pharmacokinetics,Completed,No Results Available,Metastatic Breast Cancer,Drug: Coprelotamab Injection|Drug: Trastuzumab Injection,"Genor Biopharma Co., Ltd.",GB221-001,"November 22, 2019","Linear Clinical Research Limited, Nedlands, Western Australia, Australia",https://ClinicalTrials.gov/show/NCT04175171
Principal Investigator,"Katrina N. Glazebrook, M.B., Ch.B.",Mayo Clinic,,NCT03954015,katrina n. glazebrook,katrina,female,0.98,6088,653,Comparison of Three Methods for Early Detection of Breast Cancer,Enrolling by invitation,No Results Available,Proliferative Breast Disease,Diagnostic Test: Contrast Enhanced imaging|Drug: Lumason,Mayo Clinic,18-003544,"May 17, 2019","Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03954015
Principal Investigator,"Zev M Nakamura, MD",Univesity of North Carolina at Chapel Hill,,NCT04033419,zev m nakamura,zev,male,0.94,69,655,Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer,"Active, not recruiting",No Results Available,Cognitive Decline|Chemo-brain,Drug: Memantine,UNC Lineberger Comprehensive Cancer Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),LCCC1921|5K12HD001441,"July 26, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04033419
Principal Investigator,"Ralph Weissleder, MD, PhD",Massachusetts General Hospital,,NCT04119154,ralph weissleder,ralph,male,0.99,10130,656,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),Recruiting,No Results Available,Breast Neoplasms|Lymphoma,Diagnostic Test: Contrast Microhalography (CEM),Harvard School of Public Health|National Cancer Institute (NCI)|Botswana Harvard Aids Institute|Massachusetts General Hospital|Brigham and Women's Hospital,BHP0111|UH3CA202637,"October 8, 2019","Botswana Harvard AIDS Institute, Gaborone, Botswana",https://ClinicalTrials.gov/show/NCT04119154
Principal Investigator,"Scott Dryden-Peterson, MD, MSc","Botswana Harvard AIDS Institute, Harvard TH Chan School of Public Health, Brigham and Women's Hospital",,NCT04119154,scott dryden-peterson,scott,male,0.99,31815,656,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),Recruiting,No Results Available,Breast Neoplasms|Lymphoma,Diagnostic Test: Contrast Microhalography (CEM),Harvard School of Public Health|National Cancer Institute (NCI)|Botswana Harvard Aids Institute|Massachusetts General Hospital|Brigham and Women's Hospital,BHP0111|UH3CA202637,"October 8, 2019","Botswana Harvard AIDS Institute, Gaborone, Botswana",https://ClinicalTrials.gov/show/NCT04119154
Principal Investigator,"Zhaoxiang Ye, M.D. & Ph.D.",Tianjin Medical University Cancer Institute and Hospital,,NCT03861221,zhaoxiang ye,zhaoxiang,male,1.0,2,658,The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer,Unknown status,No Results Available,The Clinical Application Guide of Conebeam Breast CT,Device: CBBCT,Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Chinese PLA General Hospital|The First Affiliated Hospital of Zhengzhou University|Guangxi Medical University|Koning Corporation,CBBCT2018CIH,"March 4, 2019","Tianjin Medical University Cancer Institute And Hospital, Tianjin, Tianjin, China",https://ClinicalTrials.gov/show/NCT03861221
Principal Investigator,"Natalie Mills, MD",Univeristy of Ottawa,,NCT04080934,natalie mills,natalie,female,0.98,22384,659,"Breaststroke Swimming After Breast Cancer Treatment/Surgery as a Means of Treatment for Seroma, Lymphedema, and Chronic Arm and Chest Pain",Not yet recruiting,No Results Available,"Lymphedema|Seroma|Pain, Postoperative|Pain, Chest",Behavioral: Swimming,Ottawa Hospital Research Institute|University of Ottawa|Bruyere Research Institute,20190304-01H,"September 6, 2019",,https://ClinicalTrials.gov/show/NCT04080934
Principal Investigator,"Julie Fisher, MD",Atrium Health,,NCT04174742,julie fisher,julie,female,0.98,116926,660,Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer,"Active, not recruiting",No Results Available,Breast,Drug: pegfilgrastim,"Julie Fisher, MD|Atrium Health",LCI-BRE-GCSF-001|00037721,"November 22, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04174742
Principal Investigator,"Irene Wapnir, MD",Stanford University,,NCT03909282,irene wapnir,irene,female,0.99,50462,661,Phase II Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma,Recruiting,No Results Available,Ductal Breast Carcinoma in Situ,Procedure: Lumpectomy|Radiation: Partial breast irradiation prior to surgery,Stanford University,IRB-46373|BRS0096,"April 10, 2019","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT03909282
Study Director,"Ofer S Dubinsky, Ph.D.",Ferring Holding Ltd.,,NCT03941665,ofer s dubinsky,ofer,male,0.98,242,663,Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients,"Active, not recruiting",No Results Available,Radiation Dermatitis,Device: Gelronate|Other: Aloevera,Sheba Medical Center|Ferring Pharmaceuticals,5652-18-SMC,"May 8, 2019","Sheba Medical Center, Ramat Gan, Israel",https://ClinicalTrials.gov/show/NCT03941665
Study Director,"Bill Paxton, MD PhD","Spectrum Pharmaceuticals, Inc",,NCT04172597,bill paxton,bill,male,0.97,15510,664,A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies,Recruiting,No Results Available,Breast Cancer|Colorectal Cancer|Solid Tumor|High Grade Glioma,Drug: Poziotinib Hydrochloride,"Spectrum Pharmaceuticals, Inc",SPI-POZ-203,"November 21, 2019","Pacific Shores Medical Group, Long Beach, California, United States",https://ClinicalTrials.gov/show/NCT04172597
Study Director,"Niels Hannibal, PhD",Aalborg University,,NCT03936075,niels hannibal,niels,male,0.99,7479,667,Guided Imagery & Music in Cancer,Recruiting,No Results Available,"Cancer, Breast|Cancer, Metastatic|Cancer Ovaries|Cancer Uterus Cervix",Behavioral: the Guided Imagery and Music method|Behavioral: standard care and verbal counselling,Aalborg University|Aretaieion University Hospital|SONORA Organisation for Music Therapy and Research,62/19-06-18,"May 3, 2019","Aretaieion University Hospital, Athens, Attiki, Greece",https://ClinicalTrials.gov/show/NCT03936075
Study Director,Global Clinical Leader,"Daiichi Sankyo, Inc.",,NCT04042701,global clinical leader,global,male,0.88,120,672,DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer,Recruiting,No Results Available,Breast Cancer|Non-small Cell Lung Carcinoma,Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Pembrolizumab,"Daiichi Sankyo, Inc.|AstraZeneca UK Limited|Merck Sharp & Dohme Corp.",DS8201-A-U106|2018-002489-38,"August 2, 2019","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University du Cancer de Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04042701
Study Chair,"Guillaume GRANIER, MD",Centre Hospitalier Henri Duffaut,,NCT04104633,guillaume granier,guillaume,male,0.99,58261,673,"Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the ""Massive Parallel Sequencing"" on Circulating Tumor DNA",Recruiting,No Results Available,Breast Cancer|Colo-rectal Cancer,Procedure: Blood samples,Centre Hospitalier Henri Duffaut - Avignon,DEGENCA,"September 26, 2019","Centre Hospitalier Henri Duffaut, Avignon, France",https://ClinicalTrials.gov/show/NCT04104633
Principal Investigator,"Yueh Lee, MD, PhD","University of North Carolina, Chapel Hill",,NCT04136912,yueh lee,yueh,female,0.58,52,674,3-D Super Resolution Ultrasound Microvascular Imaging,Not yet recruiting,No Results Available,Breast Cancer|Thyroid Cancer,Drug: Definity|Device: Acoustic Angiography,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),LCCC1915|R01CA220681,"October 23, 2019","Univeristy of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04136912
Principal Investigator,"Arash Asher, MD",Cedars-Sinai Medical Center,,NCT03824132,arash asher,arash,male,0.98,6033,675,LOL: It's All Improv After Cancer!™,Recruiting,No Results Available,Breast Cancer|Psychological Distress,Behavioral: Improvisational comedy classes|Behavioral: Waitlist control,"Arash Asher, MD|Tower Cancer Research Foundation|Cedars-Sinai Medical Center",IIT2018-05-ASHER-IMPROV2,"January 31, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT03824132
Study Chair,"Jibba AMRAOUI, MD",Institut régional du cancer de Montpellier,,NCT03981731,jibba amraoui,jibba,male,0.78,9,677,Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session,Recruiting,No Results Available,Breast Cancer|Gynecologic Cancer,Other: Cardiac coherence,Institut du Cancer de Montpellier - Val d'Aurelle,PROICM 2019-06 COH,"June 11, 2019","Institut régional du cancer de Montpellier, Montpellier, Hérault, France",https://ClinicalTrials.gov/show/NCT03981731
Principal Investigator,"Per Hall, MD, PhD",Karolinska Institutet,,NCT04079517,per hall,per,male,0.97,8746,681,Karolinska Interventional Study of Mammograhic Density (Karisma-1),Completed,No Results Available,Breast Cancer|Mammographic Density,Drug: Tamoxifen,Karolinska Institutet,2015-000345|2014-005005-20,"September 6, 2019",,https://ClinicalTrials.gov/show/NCT04079517
Principal Investigator,"Mei Fu, PhD, RN, FAAN",New York Langone Medical Center,,NCT03999177,mei fu,mei,female,0.94,3347,682,Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises,Recruiting,No Results Available,Breast Cancer|Lymphedema,Behavioral: Kinect-TOLF Training System,NYU Langone Health|National Cancer Institute (NCI),19-00222|1R01CA214085,"June 26, 2019","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03999177
Principal Investigator,Noemi Weisenberg,Meir Medical Center,,NCT03914911,noemi weisenberg,noemi,female,0.99,21284,683,In Vivo Smart Biopsy Device Protocol In Radiology,"Active, not recruiting",No Results Available,Breast Cancer|Image Guided Biopsy,Device: Smart Biopsy Device,Dune Medical Devices,CP-10-001,"April 16, 2019","Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center Campus Beilinson, Petah Tikva, Israel",https://ClinicalTrials.gov/show/NCT03914911
Principal Investigator,"Jing Zhang, MD",Ottawa Hospital Research Institute,,NCT03959709,jing zhang,jing,female,0.75,2653,685,Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction,Recruiting,No Results Available,Mastectomy|Breast Cancer,Procedure: immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|Procedure: Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement,Ottawa Hospital Research Institute,1449,"May 22, 2019","The Ottawa Hospital, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT03959709
Principal Investigator,"Georges NOEL, MD PhD",Centre Paul Strauss,,NCT03801850,georges noel,georges,male,0.98,18119,690,Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D,Recruiting,No Results Available,Breast Cancer Female|Adjuvant Radiotherapy,Device: 3D surface scan,Centre Paul Strauss,2018-01|2017-A02489-44,"January 14, 2019","Centre paul Strauss, Strasbourg, France",https://ClinicalTrials.gov/show/NCT03801850
Principal Investigator,"Raymond Bergan, MD",OHSU Knight Cancer Institute,,NCT03878524,raymond bergan,raymond,male,0.99,21679,692,"A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia",Recruiting,No Results Available,Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia,Procedure: Biopsy|Drug: ABIRATERONE|Drug: ENZALUTAMIDE|Drug: VENETOCLAX|Drug: PALBOCICLIB|Drug: All-trans Retinoic Acid|Drug: BORTEZOMIB|Drug: CABAZITAXEL|Drug: OXALIPLATIN|Drug: FLUOROURACIL|Drug: FOLINIC ACID|Drug: CARBOPLATIN|Drug: PANOBINOSTAT|Drug: VORINOSTAT|Drug: PEMBROLIZUMAB|Drug: BEVACIZUMAB|Drug: IPILIMUMAB|Drug: NIVOLUMAB|Drug: EVEROLIMUS|Drug: SIROLIMUS|Drug: CELECOXIB|Drug: OLAPARIB|Drug: AFATINIB|Drug: CABOZANTINIB|Drug: SORAFENIB|Drug: DASATINIB|Drug: ERLOTINIB|Drug: IDELALISIB|Drug: IMATINIB|Drug: LENVATINIB|Drug: PERTUZUMAB|Drug: PONATINIB|Drug: RUXOLITINIB|Drug: SUNITINIB|Drug: TRAMETINIB|Drug: VEMURAFENIB,OHSU Knight Cancer Institute|Oregon Health and Science University,STUDY00015588,"March 18, 2019","OHSU Knight Cancer Institute, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT03878524
Principal Investigator,"Eliza M Park, MD",University of North Carolina,,NCT04092816,eliza m park,eliza,female,0.99,21564,694,Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention,Recruiting,No Results Available,Metastatic Breast Cancer|Parenting,Behavioral: FAMILY Intervention,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),LCCC1920|5K07CA218167-02,"September 17, 2019","Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04092816
Principal Investigator,Colleen Jernigan,M.D. Anderson Cancer Center,,NCT03964896,colleen jernigan,colleen,female,0.97,1577,698,Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy,Completed,No Results Available,Breast Carcinoma|Head and Neck Carcinoma|Sarcoma,Other: Survey|Other: Survey Administration|Behavioral: Telephone-Based Intervention,M.D. Anderson Cancer Center|National Cancer Institute (NCI),2016-0300|NCI-2019-02651|P30CA016672,"May 28, 2019","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03964896
Principal Investigator,LAD Williams,"University of the West Indies, Mona",,NCT04113096,lad williams,lad,male,0.72,367,699,Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer,Recruiting,No Results Available,Stage IV Prostate Cancer|Stage IV Colon Cancer|Stage IV Breast Cancer|Stage IV Cancer of the Cervix,Drug: Dibenzyl trisulphide capsules|Drug: Stage IV Breast Cancer Placebo|Drug: Stage IV: Colon Cancer Placebo|Drug: Cervical Cancer Stage IV Placebo|Drug: Cancer of the Prostate Placebo,The University of The West Indies,ECP 250 - 15/16,"October 2, 2019","Faculty of Medial Sciences, Kingston, Jamaica",https://ClinicalTrials.gov/show/NCT04113096
Principal Investigator,"James L Thorne, PhD",University of Leeds,,NCT04147767,james l thorne,james,male,0.99,117309,700,Plant Sterol INtervention for Cancer Prevention (PINC),Recruiting,No Results Available,Hypercholesterolemia|Breast Cancer|Obesity,Dietary Supplement: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|Dietary Supplement: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd),University of Leeds|The Leeds Teaching Hospitals NHS Trust|University of Oslo,RD19/123502,"November 1, 2019","University of Leeds, Leeds, West Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04147767
Principal Investigator,"James Flory, MD",Memorial Sloan Kettering Cancer Center,,NCT04210128,james flory,james,male,0.99,117309,724,Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment,Recruiting,No Results Available,Breast Cancer|Pre Diabetes|Diabetes,,Memorial Sloan Kettering Cancer Center,19-315,"December 24, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04210128
Study Chair,Johanna Bendell,Tennessee Oncology,,NCT04180371,johanna bendell,johanna,female,0.97,25767,703,Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression,Recruiting,No Results Available,Non Small Cell Lung Cancer|Ovarian Cancer|Triple Negative Breast Cancer|Gastric Cancer|Pancreatic Cancer|Urothelial Cancer,Drug: BT5528|Drug: Nivolumab,Bicycle Tx Limited,BT5528-100,"November 27, 2019","Florida Cancer Specialists, Sarasota, Florida, United States|Stephenson Cancer Center (Oklahoma University), Oklahoma City, Oklahoma, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04180371
Principal Investigator,"Ronald E Gress, M.D.",National Cancer Institute (NCI),,NCT04054752,ronald e gress,ronald,male,0.99,23684,707,Vaccine Response With NT-I7,Not yet recruiting,No Results Available,Breast Carcinoma|Colorectal Adenocarcinoma|Bladder Carcinoma,Biological: Recombinant human IL-7-hyFc (NT-I7)|Biological: Vaccine sequence 1|Biological: Vaccine sequence 2,"National Cancer Institute (NCI)|NeoImmuneTech, Inc.|National Institutes of Health Clinical Center (CC)",190134|19-C-0134,"August 13, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04054752
Principal Investigator,Linda Ko,Fred Hutch/University of Washington Cancer Consortium,,NCT04208724,linda ko,linda,female,0.98,99198,709,Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization,Not yet recruiting,No Results Available,Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma,Other: Training|Other: Cancer Screening intervention,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),RG1006143|NCI-2019-08033|P30CA015704,"December 23, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04208724
Principal Investigator,"Jun Mao, MD, MSCE",Memorial Sloan Kettering Cancer Center,,NCT04007770,jun mao,jun,male,0.9,8911,710,The Effect of Acupuncture on Cancer-Related Cognitive Difficulties,Recruiting,No Results Available,Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Stage I Colorectal Cancer|Stage II Colorectal Cancer|Stage III Colorectal Cancer|Gynecologic Cancer|Stage I Gynecologic Cancer|Stage II Gynecologic Cancer|Stage III Gynecologic Cancer,Other: Acupuncture|Other: Sham Acupuncture|Other: 8 week waiting period + optional Acupuncture,Memorial Sloan Kettering Cancer Center,19-179,"July 5, 2019","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",https://ClinicalTrials.gov/show/NCT04007770
Principal Investigator,Amy C Degnim,Mayo Clinic,,NCT04144023,amy c degnim,amy,female,0.97,31233,712,A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ,Recruiting,No Results Available,Ductal Breast Carcinoma In Situ|HER2/Neu Positive,Biological: Granulocyte-Macrophage Colony-Stimulating Factor|Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC|Procedure: Therapeutic Conventional Surgery,Mayo Clinic|National Cancer Institute (NCI),MC1713|NCI-2019-07002|P30CA015083,"October 30, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04144023
Study Director,Sinette Heys,Proteus Digital Health,,NCT04088955,sinette heys,sinette,female,0.9,10,721,A Digimed Oncology PharmacoTherapy Registry,"Active, not recruiting",No Results Available,Colon Cancer|Breast Cancer|Rectal Cancer,Other: DigiMeds,"Proteus Digital Health, Inc.",PRO 1676,"September 13, 2019","Carolina Blood and Cancer Care, Rock Hill, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04088955
Principal Investigator,"Jeroen Mebis, prof. dr.",Jessa Hospital,,NCT04036994,jeroen mebis,jeroen,male,0.99,11552,722,PBMT for the Management of CIA ( HAIRLASER ),Not yet recruiting,No Results Available,Breast Cancer|Chemotherapy-induced Alopecia|Alopecia,Device: Photobiomodulation therapy|Device: Sham photobiomodulation therapy,Hasselt University|Jessa Hospital,19.58/ONCO19.08,"July 30, 2019","Jessa Ziekenhuis, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04036994
Study Chair,"Joy Lodewijckx, drs.",Hasselt University,,NCT04036994,joy lodewijckx,joy,female,0.84,20740,722,PBMT for the Management of CIA ( HAIRLASER ),Not yet recruiting,No Results Available,Breast Cancer|Chemotherapy-induced Alopecia|Alopecia,Device: Photobiomodulation therapy|Device: Sham photobiomodulation therapy,Hasselt University|Jessa Hospital,19.58/ONCO19.08,"July 30, 2019","Jessa Ziekenhuis, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04036994
Principal Investigator,"Nadine McCleary, MD, MPH",Dana-Farber Cancer Institute,,NCT03858712,nadine mccleary,nadine,female,0.98,55786,728,EHR-embedded OCDT in Breast or GI Cancer,Recruiting,No Results Available,Oral Cancer Directed Therapy|Breast Cancer|Gastrointestinal Cancer|Oral Chemotherapy,Other: Active Care Team Alert|Other: Passive Care Team Alert,Dana-Farber Cancer Institute,18-571,"March 1, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03858712
Principal Investigator,In Gyu Hwang,"Chung-Ang University Hosptial, Chung-Ang University College of Medicine",,NCT03838406,in gyu hwang,in,female,0.73,3007,729,BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer,Recruiting,No Results Available,BRCA Gene Rearrangement,Genetic: BRCA 1|Drug: Chemotherapy,Chung-Ang University,1771-001-287,"February 12, 2019","Chung-Ang University College of Medicine, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT03838406
Principal Investigator,"Roland SCHOTT, Md",Centre Paul Strauss,,NCT03956641,roland schott,roland,male,0.99,30706,730,Evolution of the Physical Condition in Treated Cancer Patients,Recruiting,No Results Available,Non-small Cell Lung Cancer Metastatic|Breast Cancer Female|Colon Cancer,Other: Adaptated Physical Activity,Centre Paul Strauss,2019-001|2019-A00848-49,"May 21, 2019","Centre Paul Strauss, Strasbourg, France",https://ClinicalTrials.gov/show/NCT03956641
Principal Investigator,"Cyrille CONFAVREUX, PR",Service de Rhumatologie,,NCT04170634,cyrille confavreux,cyrille,male,0.95,9192,734,Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study,Recruiting,No Results Available,Metastases to Bone|Metastatic Breast Cancer|Metastatic NSCLC,Other: Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation,Hospices Civils de Lyon,69HCL17_0642,"November 20, 2019","Service de rhumatologie, CHU d'Angers, Angers, France|Service de radiothérapie, Institut Jean-Perrin, Clermont-Ferrand, France|Service de rhumatologie, CH Annemasse, Contamine-sur-Arve, France|Service de rhumatologie, CHU de Grenoble, La Tronche, France|Service d'onco-rhumatologie, Centre Oscar Lombret, Lille, France|Service de Radiothérapie, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon, France|Service d'oncologie médicale, Institut Curie, 26 rue d'Ulm, Paris, France|Service de Radiologie, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France|Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud, Pierre-Bénite, France|Service de rhumatologie, CHU de Poitiers, Poitiers, France|Service de rhumatologie, CHU de Saint Etienne, Saint-Priest-en-Jarez, France",https://ClinicalTrials.gov/show/NCT04170634
Principal Investigator,"Anne-Marie Heegaard, PhD",University of Copenhagen,,NCT03908853,anne-marie heegaard,anne-marie,female,0.98,5857,735,Pain Phenotyping of Patients With Bone Cancer Pain,Recruiting,No Results Available,Pain|Bone Metastases|Metastatic Breast Cancer,,University of Copenhagen|The Novo Nordic Foundation,H-18041465,"April 9, 2019","Department of Oncology, Rigshospitalet, Copenhagen, Denmark|The Department of Oncology, Herlev Hospital, Herlev, Denmark",https://ClinicalTrials.gov/show/NCT03908853
Study Director,"Christer Svedman, M.D. Ph.D.",Cadex Genomics,,NCT03892096,christer svedman,christer,male,0.98,2672,736,Development and Validation of a qPCR Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer,"Active, not recruiting",No Results Available,Metastatic Non-Small Cell Lung Carcinoma|Metastatic Colorectal Cancer|Metastatic Breast Cancer,Diagnostic Test: Blood-based cell-free cfDNA qPCR assay,Cadex Genomics,CADEX-0001,"March 27, 2019","CARTI Cancer Center, Little Rock, Arkansas, United States|Sutter Health - Palo Alto Medical Foundation, Sunnyvale, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|IACT Health, Columbus, Georgia, United States|University Medical Center, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, United States|Nebraska Cancer Center, Omaha, Nebraska, United States|National Translational Research Group LLC, Port Jefferson Station, New York, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|Advent Health, Hendersonville, North Carolina, United States|Greenville Health System - Prisma Health, Greenville, South Carolina, United States|West Cancer Center and Research Institute, Germantown, Tennessee, United States|McGill University, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT03892096
Study Chair,"Jordi Rodon Ahnert, MD, PhD",M.D. Anderson Cancer Center,,NCT04152499,jordi rodon ahnert,jordi,male,0.99,31600,737,"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies",Recruiting,No Results Available,Ovarian Epithelial Cancer|Gastric Adenocarcinoma|Pancreas Adenocarcinoma|Triple Negative Breast Cancer|Bladder Cancer,Drug: SKB264,Klus Pharma Inc.,KL264-01,"November 5, 2019","University of California Los Angeles, Los Angeles, California, United States|Georgetown University, Washington, District of Columbia, United States|Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|START MidWest, Grand Rapids, Michigan, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",https://ClinicalTrials.gov/show/NCT04152499
Study Director,"Sam Whiting, MD, PhD","Calithera Biosciences, Inc",,NCT03875313,sam whiting,sam,male,0.81,96261,740,Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors,Recruiting,No Results Available,Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC,Drug: CB-839|Drug: Talazoparib,"Calithera Biosciences, Inc",CX-839-011,"March 14, 2019","University of Alabama, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University, New York, New York, United States|MD Anderson, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03875313
Study Director,"Phillip Garfin, MD, PhD","Seattle Genetics, Inc.",,NCT04042480,phillip garfin,phillip,male,0.99,7618,741,A Study of SGN-CD228A in Advanced Solid Tumors,Recruiting,No Results Available,Cutaneous Melanoma|Pleural Mesothelioma|Breast Cancer|Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Adenocarcinoma,Drug: SGN-CD228A,"Seattle Genetics, Inc.",SGN228-001,"August 2, 2019","Angeles Clinic and Research Institute, The, Santa Monica, California, United States|Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04042480
Study Chair,"Marco Klinger, MD",Istituto Clinico Humanitas,,NCT04130373,marco klinger,marco,male,0.99,357670,744,Multicentric Risk Evaluation of Autologous Fat Grafting Procedure,"Active, not recruiting",No Results Available,"Pain, Postoperative",Procedure: Autologous fat grafting procedure|Procedure: Breast reconstruction,Humanitas Clinical and Research Center,1955K,"October 17, 2019","Istituto Clinico Humanitas, Rozzano, Milan, Italy",https://ClinicalTrials.gov/show/NCT04130373
Principal Investigator,"Melissa Accordino, MD",Columbia University,,NCT03873272,melissa accordino,melissa,female,0.99,63975,747,The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL,Recruiting,No Results Available,CIPN - Chemotherapy-Induced Peripheral Neuropathy,Device: Cryotherapy|Device: Compression Therapy|Device: Loose glove/sock,Columbia University,AAAR9515,"March 13, 2019","Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03873272
Principal Investigator,"Huma Q Rana, MD",Dana-Farber Cancer Institute,,NCT04066361,huma q rana,huma,female,0.85,496,752,OPTimizing Treatment Focused Genetic Testing IN Cancer,Recruiting,No Results Available,Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer,Other: Chatbot|Other: Video Education,Dana-Farber Cancer Institute,19-068,"August 26, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04066361
Principal Investigator,"Ralf Bargou, Prof. Dr.","Universitätsklinikum Würzburg, CCC Mainfranken",,NCT03927573,ralf bargou,ralf,male,0.99,16387,754,"Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker",Recruiting,No Results Available,Non-small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer|Urogenital Cancer,Drug: GEM3PSCA,GEMoaB Monoclonals GmbH|GCP-Service International Ltd. & Co. KG,GEM3PSCA-01,"April 25, 2019","Klinikum rechts der Isar der TU München, Munich, Bayern, Germany|Universitätsklinikum Würzburg, Würzburg, Bayern, Germany|Universitätsklinikum Dresden, Dresden, Sachsen, Germany",https://ClinicalTrials.gov/show/NCT03927573
Principal Investigator,"Rachael B Lancaster, MD",University of Alabama at Birmingham,,NCT04019834,rachael b lancaster,rachael,female,0.97,3161,758,Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy,Not yet recruiting,No Results Available,"Breast Cancer|Mastectomy|Anesthesia, Local|Narcotic Use",Drug: regional nerve block with local anesthesia of bupivacaine with steroid|Other: Placebo regional nerveblock with normal saline,University of Alabama at Birmingham,IRB-300003680,"July 15, 2019",,https://ClinicalTrials.gov/show/NCT04019834
Principal Investigator,"Filippo De Braud, Professor","Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy",,NCT04001725,filippo de braud,filippo,male,0.99,27899,759,Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases,Recruiting,No Results Available,Brain Metastases|Melanoma|Lung Cancer|Breast Cancer,Drug: Dexamethasone|Drug: Metformin,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|University of Milan",INT31/19|B43C17000350001|2019-000105-73,"June 28, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy",https://ClinicalTrials.gov/show/NCT04001725
Principal Investigator,"Megha Ramaswamy, PhD, MPH",University of Kansas School of Medicine,,NCT03984695,megha ramaswamy,megha,female,0.93,383,760,Sexual Health Empowerment for Women's Health,Recruiting,No Results Available,Cervical Cancer|Breast Cancer|Contraceptive Usage|Sexually Transmitted Diseases,Behavioral: SHE-WOMEN,University of Kansas Medical Center,STUDY00143316,"June 13, 2019","Jackson County Correctional Facility, Kansas City, Missouri, United States",https://ClinicalTrials.gov/show/NCT03984695
Principal Investigator,"doaa AA abd-el-wahed, A.lecturer","assistant lecturer at faculty of physical therapy, Cairo university",,NCT04185181,doaa aa abd-el-wahed,doaa,female,0.98,725,761,Virtual Reality Versus Proprioceptive Neuromuscular Facilitation on Postmastectomy Lymphedema,Completed,No Results Available,Postmastectomy Lymphedema,Other: virtual reality|Other: proprioceptive neuromuscular facilitation|Other: complete decogestive therapy,doaa atef|Cairo University,Doaa Atef,"December 4, 2019","faculty of physical therapy, Cairo university, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04185181
Principal Investigator,Eric Chow,Fred Hutch/University of Washington Cancer Consortium,,NCT04081779,eric chow,eric,male,0.99,135071,764,"Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study",Enrolling by invitation,No Results Available,Breast Carcinoma|Colorectal Carcinoma|Lung Carcinoma|Lymphoma|Prostate Carcinoma,Other: Survivorship Care Plan|Other: Educational Intervention|Other: Questionnaire Administration,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),RG1005815|NCI-2019-05726|P30CA015704,"September 9, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04081779
Principal Investigator,"Hu Liu, MD",Anhui Provincial Cancer Hospital,,NCT03958812,hu liu,hu,male,0.71,849,765,Diagnostic Power Comparison Between VOCs and CTCs,Not yet recruiting,No Results Available,Circulating Tumor Cell|Volatile Organic Chemicals|Breast Cancer|Gastric Cancer|Diagnoses Disease,"Diagnostic Test: Circulating tumor cells, Volatile organic compounds","Anhui Medical University|Technion, Israel Institute of Technology",DPCVC,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03958812
Study Director,"Benjamin Thompson, MD, PhD","Xencor, Inc.",,NCT03849469,benjamin thompson,benjamin,male,0.99,62465,768,A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors,Recruiting,No Results Available,Melanoma|Cervical Carcinoma|Pancreatic Carcinoma|Triple Negative Breast Cancer|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced or Metastatic Solid Tumors|Prostate Carcinoma|MSI-H|Mismatch Repair Deficiency|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Intrahepatic Cholangiocarcinoma,Biological: XmAb®22841|Biological: Pembrolizumab (Keytruda®),"Xencor, Inc.|ICON Clinical Research",XmAb22841-01|DUET-4,"February 21, 2019","UCLA Hematology & Oncology Clinic, Los Angeles, California, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Health Care Center, Chestnut Hill, Chestnut Hill, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - North County, Saint Louis, Missouri, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Hospital of the University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research - Medical City, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT03849469
Principal Investigator,Meghna S Trivedi,Southwest Oncology Group,,NCT03939481,meghna s trivedi,meghna,female,0.93,102,769,Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Lung Non-Small Cell Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage I Lung Cancer AJCC v8|Stage I Ovarian Cancer AJCC v8|Stage IA Ovarian Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage IB Ovarian Cancer AJCC v8|Stage IC Ovarian Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage II Ovarian Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIA Ovarian Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIB Ovarian Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8,Drug: Chemotherapy|Other: Functional Assessment|Other: Questionnaire Administration,Southwest Oncology Group|National Cancer Institute (NCI),S1714|NCI-2018-01568|SWOG-S1714|UG1CA189974,"May 6, 2019","Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Little Company of Mary Hospital, Evergreen Park, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Salina Regional Health Center, Salina, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Saint Joseph Hospital, Nashua, New Hampshire, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Texas Tech University Health Sciences Center-Lubbock, Lubbock, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States",https://ClinicalTrials.gov/show/NCT03939481
Principal Investigator,Niloy J Samadder,Mayo Clinic,,NCT04067960,niloy j samadder,niloy,male,0.98,53,773,Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer,Recruiting,No Results Available,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Health Care Provider|Malignant Brain Neoplasm|Malignant Genitourinary System Neoplasm|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Pancreatic Cancer|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Pancreatic Cancer|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Procedure: Biospecimen Collection|Other: Genetic Testing|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,Mayo Clinic|National Cancer Institute (NCI),19-002006|NCI-2019-04725|P30CA015083,"August 28, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States",https://ClinicalTrials.gov/show/NCT04067960
Principal Investigator,"Yulei Jiang, Ph.D",University of Chicago,,NCT03972605,yulei jiang,yulei,female,0.7,20,774,Delphinus SoftVue™ ROC Reader Study,Completed,No Results Available,Breast Cancer Detection|Dense Breast Parenchyma|Benign Breast Findings|Normal Breast Screening|Abnormal Breast Screening,Device: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography,"Delphinus Medical Technologies, Inc.|University of Chicago|Boston Biomedical Associates LLC|Reed Technical Associates, LLC",DMT-2019.001,"June 3, 2019","Cobo Center, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT03972605
Principal Investigator,"Mary Ellen Giger, Ph.D",Univeristy of Chicago,,NCT03972605,mary ellen giger,mary,female,0.99,142684,774,Delphinus SoftVue™ ROC Reader Study,Completed,No Results Available,Breast Cancer Detection|Dense Breast Parenchyma|Benign Breast Findings|Normal Breast Screening|Abnormal Breast Screening,Device: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography,"Delphinus Medical Technologies, Inc.|University of Chicago|Boston Biomedical Associates LLC|Reed Technical Associates, LLC",DMT-2019.001,"June 3, 2019","Cobo Center, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT03972605
Study Director,"Albert Yu, MD",Petra Pharma,,NCT04073680,albert yu,albert,male,0.98,41504,778,A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors,Not yet recruiting,No Results Available,Breast Cancer|Endometrial Cancer|Lung Cancer|Colo-rectal Cancer|Head and Neck Cancer,Drug: Serabelisib|Drug: Canagliflozin 300mg,Petra Pharma,PT06-01,"August 29, 2019",,https://ClinicalTrials.gov/show/NCT04073680
Principal Investigator,"Alain FOURQUET, MD",Institut Curie,,NCT03878342,alain fourquet,alain,male,0.99,76390,779,Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast,Suspended,No Results Available,DCIS|Breast Cancer|Low Risk DCIS|Breast Conserving Surgery|Radiotherapy Omission,Radiation: Radiotherapy|Other: No Radiotherapy,"UNICANCER|National Cancer Institute, France",UC-0107/1803,"March 18, 2019","Institut de Cancérologie de l'Ouest -Site Paul Papin, Angers, France|Institut Sainte Catherine, Avignon, France|Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges Francois Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Hospitalier Bretagne Sud, Lorient, France|Centre Léon Berard, Lyon, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Institut CURIE, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut De Cancerologie De Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT03878342
Principal Investigator,"Hardeep Singh, MD MPH","Michael E. DeBakey VA Medical Center, Houston, TX",,NCT04166240,hardeep singh,hardeep,male,0.87,309,782,Measuring and Improving the Safety of Test Result Follow-Up,"Active, not recruiting",No Results Available,Lung Cancer|Breast Cancer|Colon Cancer|Bladder Cancer|Hepatocellular Cancer,Behavioral: SAFER TRACKS Intervention,VA Office of Research and Development|White River Junction Veterans Affairs Medical Center|Michael Debakey Veterans Affairs Medical Center|Baylor College of Medicine,IIR 17-127|H-45450,"November 18, 2019","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States",https://ClinicalTrials.gov/show/NCT04166240
Study Director,JEAN-PIERRE BLEUSE,DRCI ICM VAL D'AURELLE,,NCT03975959,jean-pierre bleuse,jean-pierre,male,0.99,12826,783,Memory Perception Assessment in Central/Non-central Nervous System Cancers and HIV,Recruiting,No Results Available,Glioblastoma|Glioma|Breast Cancer|Hiv|Healthy,Other: QMRP questionnaire,Institut du Cancer de Montpellier - Val d'Aurelle,PROICM 2018-07 BPR,"June 5, 2019","Icm Val D'Aurelle, Montpellier, Herault, France",https://ClinicalTrials.gov/show/NCT03975959
Principal Investigator,"Tulin D Cil, MD, MEd","University Health Network, Toronto",,NCT04151368,tulin d cil,tulin,female,0.94,387,786,Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy,Recruiting,No Results Available,Breast Cancer|Surgery--Complications|Genetic Predisposition to Disease|Surgery|BRCA1 Mutation|BRCA2 Mutation|Breast Diseases,Procedure: Robotic Nipple-Sparing Mastectomy (RNSM),"University Health Network, Toronto",19-5250.0,"November 5, 2019","University Health Network, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04151368
Principal Investigator,"Sofia F Garcia, Ph.D.",Northwestern University,,NCT03996031,sofia f garcia,sofia,female,0.98,59571,789,Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic,Recruiting,No Results Available,"Cancer, Breast|Cancer of Colon|Cancer of Rectum|Cancer",Device: Plan to Thrive smartphone application,"Northwestern University|Vignet, Inc.",STU00209558,"June 24, 2019","Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT03996031
Principal Investigator,"Rebecca Shelby, Ph.D.",Duke Psychiatry and Behavioral Sciences,,NCT03877146,rebecca shelby,rebecca,female,0.98,36835,791,Calming Alternatives Learned During MRI-Guided Breast Biopsy,Completed,No Results Available,"Breast Cancer|Breast Pain|Pain, Acute|Anxiety|Coping Skills|Self Efficacy",Behavioral: Controlled Breathing Intervention,Duke University,Pro00100029,"March 15, 2019","Duke Cancer Institute, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03877146
Principal Investigator,"Douglas Corley, MD, PhD","Division of Research, Kaiser Permanente Northern California",,NCT04145388,douglas corley,douglas,male,0.99,9529,793,Family History Study on Cancer Risk,Not yet recruiting,No Results Available,Lynch Syndrome|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Family Characteristics|Genetic Predisposition,Other: online cancer risk assessment|Other: Usual care,Kaiser Permanente|Patient-Centered Outcomes Research Institute,1407426,"October 30, 2019","Division of Research, Kaiser Permanente Northern California, Oakland, California, United States",https://ClinicalTrials.gov/show/NCT04145388
Study Director,"Wayne Chu, MD",Fate Therapeutics,,NCT03841110,wayne chu,wayne,male,0.98,12470,794,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,Recruiting,No Results Available,Advanced Solid Tumors|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma,Drug: FT500|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine,Fate Therapeutics,FT500-101,"February 15, 2019","UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03841110
Study Director,"Wayne Chu, MD",Fate Therapeutics,,NCT04106167,wayne chu,wayne,male,0.98,12470,815,"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",Recruiting,No Results Available,Advanced Solid Tumor|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small-cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma,Genetic: Allogeneic natural killer (NK) cell,Fate Therapeutics,FT-003,"September 26, 2019","UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04106167
Principal Investigator,"Jeremie Calais, MD",UCLA / Jonsson Comprehensive Cancer Center,,NCT04147494,jeremie calais,jeremie,male,0.98,5231,795,Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues,Recruiting,No Results Available,Breast Carcinoma|Colon Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Head and Neck Carcinoma|Kidney Carcinoma|Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Solid Neoplasm|Uterine Corpus Cancer,Procedure: Computed Tomography|Radiation: Gallium Ga 68 FAPi-46|Radiation: Gallium Ga 68-labeled PSMA-11|Procedure: Positron Emission Tomography,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),19-000756|NCI-2019-07265|P30CA016042,"November 1, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04147494
Study Director,"Ilana Lorber, MD",NeoTX Therapeutics Ltd.,,NCT03983954,ilana lorber,ilana,female,0.99,621,799,Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors,Recruiting,No Results Available,Breast Cancer|Epithelial Ovarian Cancer|Cervical Cancer|Pancreatic Cancer|Endometrial Cancer|Renal Cancer|Urothelial Cancer|Head and Neck Cancer|Mesothelioma|Melanoma|Hepatic Carcinoma|Prostate Cancer|NSCLC,Combination Product: Naptumomab estafenatox (ABR-217620; Nap) with durvalumab (IMFINZI; MEDI4736),NeoTX Therapeutics Ltd.|AstraZeneca Pharmaceuticals PLC,127-CL-01,"June 12, 2019","Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",https://ClinicalTrials.gov/show/NCT03983954
Principal Investigator,"Francisco V Munoz, Ph.D.",Arizona State University,,NCT04213872,francisco v munoz,francisco,male,0.99,98797,800,"Gene Expression, Meditative Movement, and Emotional Distress (GME)","Active, not recruiting",No Results Available,Cognitive Impairment,Behavioral: Meditative Movement,Arizona State University|Pomona Valley Hospital Medical Center|Children's Hospital Los Angeles,GME Study,"December 30, 2019","Robert and Beverly Lewis Family Cancer Care Center, Pomona, California, United States",https://ClinicalTrials.gov/show/NCT04213872
Principal Investigator,"Lynn Dengel, MD, MSc",University of Virginia,,NCT04116320,lynn dengel,lynn,female,0.93,7857,802,Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors,Recruiting,No Results Available,Melanoma|Breast Cancer|Merkel Cell Carcinoma|Squamous Cell Cancer|Non Small Cell Lung Cancer|Cervical Cancer|Urothelial Carcinoma|Ovarian Cancer|Hepatocellular Carcinoma|Small-cell Lung Cancer|Microsatellite Instability High|Gastric Cancer|Esophageal Cancer,Device: Echopulse|Drug: Imiquimod|Drug: Standard of Care PD-1 Therapy,"Craig L Slingluff, Jr|Theraclion|University of Virginia",21850,"October 4, 2019","University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT04116320
Study Director,"JongSeok Kim, MD",Eli Lilly and Company,,NCT03906331,jongseok kim,jongseok,male,1.0,58,805,Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation,Available,No Results Available,Non Small Cell Lung Cancer|Medullary Thyroid Cancer|Colon Cancer|Breast Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Other Solid Tumors With Evidence of Activating RET Alteration,Drug: Selpercatinib,"Loxo Oncology, Inc.|Eli Lilly and Company",Selpercatinib EAP,"April 8, 2019","Cancer Treatment Centers of America, Goodyear, Arizona, United States|Mayo Clinic Hospital, Scottsdale, Arizona, United States|City of Hope, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Emory University, Atlanta, Georgia, United States|Cancer Treatment Centers of America, Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|START Midwest, Grand Rapids, Michigan, United States|Mayo Clinic Hospital, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|JamesCare at Martha Morehouse Medical Plaza, Columbus, Ohio, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, United States|University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of American, Philadelphia, Philadelphia, Pennsylvania, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Oncology Consultants, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Linear Clinical Research, Nedlands, Western Australia, Australia|Universitatsklinikum Würzburg, Würzburg, Germany|Prince of Wales Hospital, Shatin, Hong Kong|Soroka University Medical Center, Be'er Sheva, Israel|Sheba Medical Center, Ramat Gan, Israel|University of Pisa, Pisa, Italy|Osaka City General Hospital, Miyakojima-Ku, Osaka, Japan|National Cancer Centre, Singapore, Singapore|Hospital Universitari de la Vall d'Hebron, Barcelona, Spain|START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain|Luzerner Kantonsspital, Spitalstrasse, Switzerland",https://ClinicalTrials.gov/show/NCT03906331
Study Director,"Markus Renschler, MD",Cyteir Therapeutics,,NCT03997968,markus renschler,markus,male,1.0,47703,807,"A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors",Recruiting,No Results Available,Malignancy|Non-hodgkin Lymphoma|Multiple Myeloma|Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Squamous Cell Carcinoma|Head and Neck Cancer|DLBCL|Mantle Cell Lymphoma|Follicular Lymphoma|Leiomyosarcoma|Pancreatic Cancer|Sarcoma|CLL,Drug: CYT-0851,"Cyteir Therapeutics, Inc.",CYT-0851-01,"June 25, 2019","Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States|John Theurer Cancer Center at HUMC, Hackensack, New Jersey, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Washington Seattle Cancer Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03997968
Principal Investigator,"Yuankai Shi, MD","Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,NCT04121286,yuankai shi,yuankai,male,1.0,3,809,A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China,Not yet recruiting,No Results Available,Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer|Other Solid Tumors,Drug: JAB-3312,"Jacobio Pharmaceuticals Co., Ltd.",JAB-3312-1002,"October 9, 2019","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04121286
Study Chair,"Fredrik Vannberg, DPhil",SpeciCare,,NCT03896958,fredrik vannberg,fredrik,male,0.99,9106,813,The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology),Recruiting,No Results Available,"Cancer, All Types|Cancer of Liver|Cancer of Stomach|Cancer of Head and Neck|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Colon|Cancer Skin|Cancer of Cervix|Cancer, Metastatic|Cancer of Larynx|Cancer of Neck|Cancer of Lung|Cancer of Brain and Nervous System|Cancer of Vulva, Disseminated|Cancer of Pancreas|Sarcoma|GIST|Small-cell Lung Cancer|Adenocarcinoma Lung|Cancer of Prostate|Cancer, Advanced|Adrenal Cancer|Testicular Cancer|Uterine Cancer|Bronchoalveolar Cell Lung Cancer|Cancer Unknown Primary|Glioblastoma Multiforme|Oligodendroglioma|Breast Cancer|Renal Cell Carcinoma|Hepatocellular Carcinoma|Cholangiocarcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Cancer, Other|Cancer, Anal|Melanoma|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancers Cell Neuroendocrine|Cancer Differentiated Poorly|Cancer, Anaplastic Thyroid",,SpeciCare|Dana-Farber Cancer Institute|Kalispell Regional Medical Center|Georgia Institute of Technology|Ontario Institute for Cancer Research|SEngine Precision Medicine|Helomics,MYCT001,"April 1, 2019","Specicare, Gainesville, Georgia, United States",https://ClinicalTrials.gov/show/NCT03896958
Principal Investigator,"Mohamed Hassan, MD",Ass Prof- Anesthesia Dept- National Cancer Institute - Cairo University,,NCT04111848,mohamed hassan,mohamed,male,0.98,175927,817,Magnesium and Ketamine in Postoperative Analgesia,Recruiting,No Results Available,Postoperative Analgesia,Drug: Ketamine|Drug: ketamine and magnesium,"National Cancer Institute, Egypt",AP1904-50102,"October 1, 2019","National Cancer Institute, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04111848
Principal Investigator,"Bhavana Pothuri, MD",New York Langone Medical Center,,NCT04009148,bhavana pothuri,bhavana,female,0.96,83,819,Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome,Recruiting,No Results Available,BRCA-Mutated Ovarian Carcinoma|BRIP1 Gene Mutation|MSH2 A636P|MLH1 Gene Mutation|MSH6 Gene Mutation|PMS2 Gene Mutation|EPCAM|RAD51C Gene Mutation,Other: CASCADE genetic screening,NYU Langone Health,17-01135,"July 5, 2019","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04009148
Principal Investigator,"Adetunji T Toriola, M.D., Ph.D.",Washington University School of Medicine,,NCT04067726,adetunji t toriola,adetunji,male,0.93,511,825,RANKL Inhibition and Mammographic Breast Density,Recruiting,No Results Available,Dense Breasts,Drug: Denosumab|Drug: Placebo|Drug: Calcium|Drug: Vitamin D3|Procedure: Core needle biopsy|Procedure: Blood draw,Washington University School of Medicine|National Institutes of Health (NIH),201907039,"August 26, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04067726
Principal Investigator,"Rodrigo Alcántara, MD",RAlcantara@parcdesalutmar.cat,,NCT03928886,rodrigo alcántara,rodrigo,male,0.99,22355,826,Discomfort Assessment of Senographe Pristina Patient-assisted Versus Standard Compression Mode and Quality Assessment of Screening Mammograms,Recruiting,No Results Available,Mammography Related Discomfort,Device: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Device: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode,Parc de Salut Mar|GE Healthcare,2017-7631,"April 26, 2019","Hospital del Mar - Parc de Salut Mar, Barcelona, Catalonia, Spain",https://ClinicalTrials.gov/show/NCT03928886
Principal Investigator,"PierFranco Conte, MD",Istituto Oncologico Veneto IRCCS,,NCT04182516,pierfranco conte,pierfranco,male,0.99,160,828,Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors,Recruiting,No Results Available,Advanced/Metastatic Solid Tumors,Drug: NMS-03305293,Nerviano Medical Sciences,PARPA-293-001|2018-003918-40,"December 2, 2019","MD Anderson Cancer Center, Houston, Texas, United States|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Centro Ricerche Cliniche di Verona Srl, Verona, Italy",https://ClinicalTrials.gov/show/NCT04182516
Principal Investigator,"Kim Reiss-Binder, MD",University of Pennsylvania,,NCT04171700,kim reiss-binder,kim,female,0.56,51609,830,A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes,Recruiting,No Results Available,Solid Tumor,Drug: Rucaparib,"Clovis Oncology, Inc.",CO-338-100,"November 21, 2019","Innovative Clinical Research Institute, Glendale, California, United States|UCLA Medicine Hematology and Oncology, Los Angeles, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|New York Cancer And Blood Specialists, Bronx, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States|Mayo Clinic, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|Stephenson Cancer Center - The University of Oklahoma, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|SCRI/Tennessee Oncology - Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas Health Center at Tyler, Tyler, Texas, United States|Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04171700
Study Director,Carl Cook,"Black Diamond Therapeutics, Inc.",,NCT04209465,carl cook,carl,male,0.98,17561,832,"A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",Recruiting,No Results Available,Solid Tumor,Drug: BDTX-189,"Black Diamond Therapeutics, Inc.",BDTX-189-01,"December 24, 2019","Florida Cancer Specialists, Lake Mary, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04209465
Principal Investigator,"María L Garmendia, PhD",Instituto de Nutrición y Tecnología de Alimentos,,NCT03920098,maría l garmendia,maría,female,0.99,232436,838,Association Between Maternal Metabolic Disturbances During the First Pregnancy and Breast Density,Recruiting,No Results Available,Breast Density,Other: Altered metabolic milieu during first full term pregnancy,Instituto de Nutrición y Tecnología de los Alimentos|Pontificia Universidad Catolica de Chile|Servicio de Salud Metropolitano Sur Oriente,1190532,"April 18, 2019","Corporación de Salud Municipal de Puente Alto, Santiago de Chile, Puente Alto, Chile",https://ClinicalTrials.gov/show/NCT03920098
Principal Investigator,"Carmina Valle, PhD","University of North Carolina, Chapel Hill",,NCT04188002,carmina valle,carmina,female,0.98,1674,839,A Web-based Tailored Health Behavior Intervention for Breast and Colon Cancer Survivors (eWellness),Completed,No Results Available,Nutrition|Physical Activity,Behavioral: Intervention Physical Activity|Other: Usual Care,"University of North Carolina, Chapel Hill|University of Texas",16-1897,"December 5, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04188002
